Versenyképesség iparágak szintjén - a globalizáció tükrében = Competitiveness at Industry Level - In the Light of Globalization by Czakó, Erzsébet
Budapest University of Economic Sciences and Public Administration 
Business and Management PhD Program 
 
 
 
 
 
 
 
 
Erzsébet Czakó 
 
 
 
Competitiveness at Industry Level 
  
In the Light of Globalization 
 
 
 
 
 
PhD Thesis 
 
 
 
 
 
 
 
 
Supervisor: 
Attila Chikán, Department of Business Economics, BUESPA 
 
Budapest, September 2000
 2
Table of Contents 
 
ACKNOWLEDGEMENTS............................................................................................................ 4 
1. EXAMINED PROBLEMS AND THE STRUCTURE OF THE THESIS.............................. 6 
REFERENCES...................................................................................................................... 8 
2. CHARACTERISTICS OF COMPETITIVENESS RESEARCH........................................... 9 
2.1. ECONOMICS AND BUSINESS AND MANAGEMENT STUDIES.......................................... 12 
2.2. COMPETITIVENESS RESEARCH AND COMPETITIVENESS ............................................ 16 
2.2.1. Competitiveness Research................................................................................ 17 
2.2.2. The Questions and Theories of Economics ...................................................... 21 
2.2.3 The Business and Management Studies Approach............................................ 24 
2.3 AN INTERPRETATION OF COMPETITIVENESS............................................................... 27 
BIBLIOGRAPHY ................................................................................................................ 30 
3. THE EU AND COMPETITIVENESS..................................................................................... 38 
3.1. EUROPEAN UNION OBJECTIVES AND COMPETITIVENESS............................................ 38 
3.2. POLICIES AND PROGRAMS SUPPORTING COMPETITIVENESS ....................................... 41 
3.2.1. The Single Market ............................................................................................ 41 
3.2.3. Trade policy...................................................................................................... 44 
3.3.3. Industrial policy ............................................................................................... 45 
3.3. THE EU’S APPROACH TO COMPETITIVENESS ............................................................. 47 
3.4. SUMMARY ................................................................................................................ 52 
BIBLIOGRAPHY ................................................................................................................ 53 
4. SOME RESEARCH FINDINGS ABOUT THE HUNGARIAN COMPETITIVENESS ... 55 
4.1 THE WORLD ECONOMY, FOREIGN TRADE AND INDUSTRIAL ADJUSTMENT AT THE END 
OF 1980S ......................................................................................................................... 55 
4.1.1. World economy adjustment .............................................................................. 56 
4.1.2. Foreign trade adjustment ................................................................................. 59 
4.1.3. Industrial adjustment........................................................................................ 61 
4.2. SPECIFIC PROBLEMS OF TRANSITION AND QUESTIONS OF MARKET ECONOMY IN THE 
1990S .............................................................................................................................. 62 
4.2.1. Questions of transition ..................................................................................... 63 
4.2.2 Problems of market economy ............................................................................ 63 
4.3. SUMMARY ................................................................................................................ 64 
BIBLIOGRAPHY ................................................................................................................ 65 
5. MAJOR LESSONS OF THE INDUSTRY COMPETITIVENESS RESEARCH PROJECT 
OF THE “IN GLOBAL COMPETITION” RESEARCH PROGRAM ................................... 70 
5.1 AN INTERPRETATION OF INDUSTRY AND COMPETITIVENESS IN THE RESEARCH PROJECT
........................................................................................................................................ 70 
5.2 METHODOLOGY OF THE RESEARCH............................................................................ 77 
5.3 LESSONS OF THE CASE STUDIES.................................................................................. 81 
5.3.1 Factors influencing the competitiveness of industries ...................................... 83 
5.3.2 Interpretation of competitiveness ...................................................................... 86 
5.4 RESEARCH QUESTIONS............................................................................................... 91 
BIBLIOGRAPHY ................................................................................................................ 92 
 3
6. INDUSTRIAL GLOBALIZATION AND ITS INFLUENCE ON ENTERPRISES IN 
GLOBAL INDUSTRIES IN HUNGARY.................................................................................... 98 
6.1. GLOBALIZATION OF INDUSTRIES AND ENTERPRISE STRATEGIES.............................. 102 
6.1.1. Global industries ............................................................................................ 102 
6.1.2. Strategic opportunities in the global industries ............................................. 104 
6.1.2.1 Alternative strategies for parent companies ............................................. 105 
6.1.2.2 Global parents and their subsidiaries ....................................................... 108 
6.1.3. Globalization in the pharmaceutical industry................................................ 110 
6.1.3.1 Global companies ..................................................................................... 110 
6.1.3.2. The European Union and the pharmaceutical industry ........................... 117 
6.1.3.3. Pharmaceutical firms of the Central and Eastern Europe and the Hungarian 
pharmaceutical industry ....................................................................................... 121 
BIOGRAPHY FOR CHAPTERS 6 AND 6.1 .......................................................................... 123 
6.2. FACTORS INFLUENCING THE COMPETITIVENESS OF THE HUNGARIAN 
PHARMACEUTICAL INDUSTRY IN THE 1990S .................................................................. 129 
6.2.1 Position of the pharmaceutical industry in the Hungarian economy.............. 130 
6.2.2 Characteristics of the medicines as products.................................................. 137 
6.2.3 Role of the government in the pharmaceutical industry ................................. 140 
6.2.4.Transition of the pharmaceutical industry ...................................................... 145 
6.2.4.1 Drug consumption .................................................................................... 145 
6.2.4.2. Distribution: wholesaling and retailing of pharmaceuticals.................... 153 
6.2.4.3 Competition in the pharmaceutical industry ............................................ 158 
6.2.4.4 Competitiveness of three domestic pharmaceutical producers ................ 165 
BIBLIOGRAPHY FOR CHAPTER 6.2 ................................................................................. 176 
6.3. MODIFICATIONS OF COMPETITIVENESS OF THE PHARMACEUTICAL INDUSTRY......... 181 
6.3.1. Competitiveness of the pharmaceutical industry on the basis of Porter’s 
diamond .................................................................................................................... 181 
6.3.2 Competitiveness of pharmaceutical industry by a multilevel approach ......... 185 
6.3.3 Is the Hungarian pharmaceutical industry competitive? ................................ 187 
References ................................................................................................................ 188 
SELECTED LIST OF PUBLICATIONS ON THE TOPIC OF THE PHD THESIS ........... 190 
 
 4
Acknowledgements 
 
A PhD thesis is a completion of a longer research process and starting point of a new one. 
It is an opportunity to assess so far results and to give an overview of the road led there. In 
this section I would like to say thanks for those persons who contributed the completion of 
this work over the past years. With my acknowledgements I would like to express my 
gratitude for those whom I learnt most in the past ten years. 
 
The empirical part of my thesis deals with the Hungarian economy, more precisely with 
the pharmaceutical industry in the period of 1989-1998. From certain respect my thesis 
can be considered as result of this period. This period can be characterising as a very 
intensive learning process in education and research from both my own respect and that of 
my working place, the Department of Business Economics. This learning process touched 
upon my thesis, as well. I would like to assess briefly who were those persons who 
contributed most to preparation of my thesis by mentioning them by their names. 
 
Fellows of Department of Business Economics among them persons not belonging to the 
Department any more contributed to the greatest extant to preparation of my thesis. The 
activity of my Department was influenced by curriculum development until the launching 
the In Global Competition research program. Curriculum development activity was also 
about research. In developing and introducing two core subjects ‘Business Economics’ 
and ‘Strategic Management’ I especially learnt a lot from my colleagues. Professor József 
Kindler has influenced my view by emphasising importance of disclosing assumptions. 
Ms. Erzsébet Könczöl got me acquainted with strategic management and she made my 
Department familiar with Porter’s book on competitive strategy at the end of the 1980s. 
Based on her practice with enterprises she reminded continuously on the balance of theory 
and practice. I owe a lot of thanks to Professor László Reszegi and Professor József Bayer 
who have contributed to the development of my business orientation. Prof. Reszegi has 
done that by his courses on performance evaluation and Prof. Bayer by his lectures and 
our joint projects. 
 
I am thankful to Professor Herman Daems of Catholic University of Leuven for deepening 
my knowledge on formulating strategy and Michael Porter’s works. I met him during my 
Soros scholarship in the academic year of 1992-1993. He also commented my so far 
results of industry competitiveness in the spring of 1999 and he suggested analysing the 
pharmaceutical industry in my thesis. Thanks to Professor Jean-Paul Larçon to give me 
an opportunity for discussing the methodological issues of the research project on 
competitiveness of industries with his fellows of his department in a research seminar at 
HEC (Jouy-en-Josas, France). The company of scholars of natural and liberal art sciences 
was influential in the Collegium Hungaricum in Leuven in the academic year of 1992-
1993 and in the spring of 1999.  
 
Workshops In Global Competition research program in 1995-1997 induced me to broaden 
the approach of industry competitiveness. This is due to the discussions with the seven 
other project leaders and workshops on working papers. I am grateful to the members of 
the consultative committee of my research project and the authors of case studies on 
industry competitiveness. I also appreciated the contribution of research fellows, business 
and governmental people for participating in the workshops on case studies. Ms. Erzsébet 
 5
Könczöl and Professor Ádám Török refereed the final report on my research project the 
opinions of whom I am grateful. 
 
I learnt a lot from my MBA students who selected me as a supervisor of their 
dissertations. Most of them chose topics, which represented a new challenge in both 
national and international practice and theory. I am thankful for the business leaders gave 
lectures in my full time Strategic Management course. 
 
Thanks for József Berács Director of and József Temesi Academic Director of 
International Studies Centre of BUESPA for having involved me into the work of the 
multidisciplinary Curriculum Development Committee in 1997. In this job I was made 
study several text books on different subjects and I could learn a lot from other members 
of the Committee. 
 
There were several written and oral comments on my thesis proposal. Thanks to the 
examiners, Professors Zoltán Antal-Mokos and János Vecsenyi for their valuable written 
and oral reports. Thanks to Professors András Bauer, András Blahó and Gábor Papanek 
for expressing their opinions on my thesis proposal in written form. 
 
Professors Károly Balaton, György Boda, Mária Kovács and László Reszegi made 
invaluable comments and suggestions in completion my PhD thesis. I am grateful to my 
Head of Department, Professor Mihály Gálik for releasing from my administrative jobs. 
Ms. Zsuzsa Takó and Ms. Rita Ruschel helped with word processing. 
 
Last but not least I am obliged to Professor Attila Chikán who was my supervisor and first 
boss for the longest period in my academic carrier. I am grateful for the opportunities he 
offered in working with the Research Group of Business Economics and the Department 
of Business Economics. I am thankful for involving me in the In Global Competition 
research program. I appreciated his trust, respecting my initiatives, and his critical but 
supporting opinions on my works. 
 
Naturally all the professional and technical mistakes and misunderstandings might be 
found in this work remain the responsibility of the author of the PhD thesis. 
 
 
 
 6
1. Examined problems and the structure of the thesis 
 
The PhD thesis is the result of a research work lasted several years. It is closely related to 
the In Global Competition – Microeconomic Factors of Competitiveness of the Hungarian 
Economy research program led by Attila Chikán in 1995-1997. In this program I led the 
research project on industry competitiveness. The most important findings of the research 
program on the Hungarian economy were that the Hungarian economy is a market 
economy and the most important challenge of the economy is that of the globalisation. 
The thesis proposal (Czakó, 1999) presented the theoretical frameworks and my so far 
research findings based on the program. 
 
Based on findings of international research projects and that of the In Global Competition 
research program I came across the problem of how globalisation influences the 
competitiveness of national industries. Meanwhile it was an unexposed issue what 
competitiveness means at national, industry and company level and how one can examine 
them. These two complex problems resulted in three discussed themes in my thesis: 
1. How can competitiveness be defined and examined? 
2. What kinds of competitiveness criteria are brought about and what opportunities 
are created in global industries, especially in the Hungarian economy? 
3. How did local companies in the competitive pharmaceutical industry adapt to the 
evolving market economy and globalisation in the 1990s? 
 
As In Global Competition research program examined the transformation of the 
Hungarian economic system at micro level (Chikán, 1996) the applied methods were 
mainly qualitative, especially case study method. In consequence of my topic selection the 
thesis does not want to verify model or analyse the relationships among various factors 
within a model. From now on instead of hypothesis I use research questions. My main 
research questions are the following  
 
1. How can competitiveness be defined and examined? 
1.1 Can research projects on competitiveness be explained in the traditional 
frameworks of economics and business studies? Has competitiveness approach 
brought a paradigm shift? 
1.2 Can we talk about system paradigm1 change as result of globalisation? 
Globalisation means spreading global (transnational) corporations. 
1.3 Intention of the Hungarian economy for joining the European Union (EU) 
raise the question what competitiveness means for the EU and how it comes to 
light in its policy and operations.  
 
2. What kinds of competitiveness criteria are brought about and what opportunities 
are created in global industries especially in the Hungarian economy? 
2.1 How can global industries be analysed? How does globalisation change our so 
far knowledge in this field? 
                                                 
1 Based on Kornai (1999) system paradigm is defined as a system of thoughts, based on which one deals 
with social or human relationships. In examining these relationships the circumstances influencing the 
activity of a defined group of people are of importance. 
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2.2. Traditional export oriented industries in Hungary (like chemical, 
pharmaceutical or textile industries) are global industries. What are the most 
important pressures for adjustment of the industry leader companies in a small 
open economy like the Hungary. 
 
3. How did local companies in the competitive pharmaceutical industry adapt to the 
evolving market economy and globalisation? 
Research project on competitiveness of selected Hungarian industries pointed out that the 
flagship industries of the socialist regime have remained competitive, as they have 
preserved their position in the Hungarian exports in the 1990s (see Czakó, 1997). Based 
on this statement I wanted to examine the following questions in the pharmaceutical 
industry. 
3.1. What kinds of environmental changes made the pharmaceutical industry adapt 
in the second half of the 1990s? 
3.2. In a global industry context how does the definition of ‘Hungarian 
pharmaceutical industry’ modify? 
3.3. How can one assess the international competitiveness of a small national 
industry on a global scale especially when the small national industry is 
important in its small home economy? 
 
 
Analysis of the above listed questions are presented in the thesis in the following 
structure: 
 
The Chapter 2 summarises the main features of the competitiveness research projects. The 
benchmarks of the review are those that were carried out in the United States and 
especially one that was led by M. E. Porter (1990). This chapter examines research 
questions 1.1 and 1.2. 
 
The Chapter 3 gives an overview on the approach to the competitiveness of he EU. I 
emphasize those issues that are likely to be instructive for the Hungarian economy. This 
chapter is to give answers to the question 1.3. 
 
The Chapter 4 is about the Hungarian findings and researches. I focus on themes which 
resulted in similar conclusions as the competitiveness research and that were published in 
Hungarian language papers at the end of 80s and in the 90s. 
 
The Chapter 5 gives an overview on the methodology and the most important statements 
of the Competitiveness of Selected Hungarian Industries research project. This chapter 
sets hypotheses that will be examined in chapter 6. 
 
The Chapter 6 consists of three subchapters. Chapter 6.1 is about the global industries 
where main features of global corporations are also discussed. This chapter is to deal with 
the questions 2.1 and 2.2. Chapter 6.2 is a case study on the competitiveness of the 
Hungarian pharmaceutical industry that belongs to a global industry. Based on chapter 5, 
and Chapters 6.1 and 6.2 Chapter 6.3 sums up the main conclusions on the 
competitiveness of the Hungarian pharmaceutical industry in the 1990s.  
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2. Characteristics of competitiveness research 
 
One of the greatest challenges to competitiveness research is the need to synthesize the 
theoretical and conceptual backgrounds. Two facts indicated that during my research. I 
found scientific and non-scientific works with different approaches under the heading 
of competitiveness and I also found works on subjects other than competitiveness 
dealing with it. In my opinion, it can be explained by that the Harvard school of 
competitiveness that I follow appeared in the middle of the 1980s. Since then there 
have been several loosely defined schools examining the same phenomena in the works 
published in this field. 
 
These statements were particularly true when the In Global Competition research 
program was launched.2 There were heated debates about the relevance of 
competitiveness research (see e. g. in Krugman, 1996). It seems that the authors of 
those times agreed in what the phenomenon to analyze was, since the starting point of 
each work was the deteriorating position of the USA in the world economy. It was 
indicated by the country’s market share loss its export markets and the growth of the 
imports and inward foreign direct investment in the US economy. The debates about 
competitiveness mainly covered the following issues: which scientific field was 
competent to examine the phenomenon and on what kind of theoretical bases and with 
what kind of scientific methods should it be examined? 
 
I found that the debates in the United States can also be traced back to the following 
factors: 
• The investigated phenomenon (deteriorating position of the American economy in 
the world economy) was the subject of research at several levels, that is, it was a 
subject of international, macro- (dealing with national economies), micro- (dealing 
with industries), and company-level investigations. 
• Research projects applied mainly qualitative methods like descriptive statistics, 
case studies and field research. 
• The research was defined as applied research, and the pragmatic objective of their 
conclusions was to support both economic policy and the executives of the largest 
corporations in improving competitiveness. 
• The competitiveness concept used but not defined precisely by the research projects 
altered from the competitiveness concept of economics, because it strongly 
emphasized the non-price-based components of competition. 
 
The theoretical and practical developments in the 1990s attest that competitiveness 
research has been focusing on the American economy’s conversion into an open 
economy, and has intended to define how this phenomenon should be treated in 
                                                 
2Chapters 1 and 2 of my thesis proposal discussed the characteristics of competitiveness research on the 
basis of works of e.g. Scott-Lodge, 1984; Dertouzous et al., 1989; Francis, 1989; and Porter, 1990. These 
works were considered to be the point of reference when starting the In Global Competition research 
program. Chapter 1 summarized the theoretical background of competitiveness research, discussing the 
approaches of economics and business studies, of competitiveness and economics, and of competitiveness 
and business studies. Chapter 2 of the thesis proposal described three major competitiveness research 
projects carried out in the US on the basis of the results published in the 1980s (Scott-Lodge, 1985; 
Dertouzous et al., 1989; and Porter, 1990).  
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economic policy and at business level. In parallel with that globalization emerged and 
required both academic and practical treatment. 
 
Since the end of World War I the Hungarian economy has been regarded as an open 
economy. However, at the beginning of the 1990’s its international economic position 
diminished and the economy faced a significant recession due to collapse of 
COMECON and its transition into a market economy. The competitiveness research 
started in 1995 aimed at formulating suggestions to the business community and 
government in the transition economy, on the findings of the research on enterprises 
and industries. The debates about the competitiveness in the In Global Competition 
research program raised additional issues besides the factors in international debates, 
which can be summarized as follows: 
• The lack of clarification of and changes in the interpretations, the body of 
knowledge, and the scopes of economics and business studies; 
• The issue of proper research methods matching the peculiar economic, political, 
and social conditions of the transition economy. It raised the question of whether it 
is fruitful to apply the approach of competitiveness school developed in the United 
States when its theoretical roots are unexplored (Török, 1996). 
 
Completing my thesis proposal, I concluded that competitiveness research modified the 
paradigms of economics and business studies. Since this thesis investigates the 
Hungarian economy in the 1990s, I have to take into account the changes of the 
Hungarian economy, society, and legal system as well, which, according to Kornai’s 
(1999) interpretation, makes us focus on the system paradigm. Kornai does not give a 
notion for system paradigm. He introduces the concept in connection with the transition 
economies of several former socialist countries. He refers to Khun’s work (Khun, 
1984) when reviewing the history of his concept. Khun introduced the notion of 
paradigm and paradigm shift in science without defining it. According to Khun (Khun, 
1984), a paradigm can be observed in the works of scientists employing the same or 
closely related concepts and methodology. Kornai traces back the system paradigm to 
Mises’, Hayek’s, Polányi’s, and Schumpeter’s works (Mises, 1981; Hayek, 1991; 
Polányi, 1997; Schumpeter, 1942) who investigate social conditions and human 
interactions, and consider the circumstances to be of significant in making certain 
groups of people behave in a certain way (Kornai, 1999, pp. 585-89). According to 
Kornai, the main features of the system paradigm can be summarized as follows 
(Kornai, 1999, pp. 590-91): 
• The whole system or the relationship between the whole and a certain part of it is in 
the center of the investigation, and narrow partial analysis does not fall into the area 
covered. 
• The investigated problem cannot be squeezed into the framework of any traditional 
branch of science. 
• Institutions existing for a long term, in the frameworks of which the economic, 
political, and cultural events and processes take place, hold researchers' attention. 
• The system paradigm requires the understanding that there is a strong relation 
between an organization and the historical process that created it. 
• In the system’s approach the preferences of the individuals are mainly the outcomes 
of the system. If the system changes, the preferences will change as well. 
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• The system paradigm deals with the issue of great changes and large-scale 
transformations: what kind of disintegrative processes are going on in a system as a 
result of that the system ceases to exist and it is transformed into another system? 
• Researchers working in the framework of the system paradigm realize that systems 
have system-specific drawbacks. 
• One of the most typical research methods of the system paradigm is comparison 
that is usually qualitative. The system paradigm does not use mathematical models; 
however, it is ready to face mysteries avoided by economics for instance. 
 
János Kornai points out in respect of the Hungarian economy that the system paradigm 
“has been proven to be indispensable for investigating the issue of transition. The 
conceptual framework of the analyses has been put together by the following concepts 
and concepts similar to them: socialism and capitalism, state property and private 
property, command economy and market economy, bureaucracy and entrepreneurship, 
redistribution and the consumer’s freedom of choice. Just like Moliere’s “Le Malade 
Imaginaire” who did not know he had been speaking in prose until his philosopher-
adviser informed him about it, a significant part of researchers dealing with post-
communist countries are unaware of the fact that they do not speak the language of 
their own discipline, but rather that of the system paradigm” (Kornai, 1999, p. 592). 
Continuing his argumentation, he claims that now when the post-socialist 
transformation is over, the system paradigm can be used in the investigation of several 
issues. Some of them are interesting for this thesis as well. For example (pp. 594-96): 
• Analyzing the alternatives within the capitalist system, 
• Microcosms having a number of problems like those of big systems, such as 
healthcare for instance, and 
• The global historical transformation of the large-scale capitalist system. 
 
The topic of this thesis coincides at two points with the approach of János Kornai 
(Kornai, 1999): 
• Competitiveness research has brought a change of paradigms the essence of which 
introduced here in advance is the gaining of ground of macroeconomic and 
economic-policy aspects of open economies in the mainstream literature of 
economics, mainly due to the fact that the economy of the United States has 
become an open economy. 
• The phenomenon of globalization, its complexity, and the fact that it is difficult to 
examine is the other factor due to which we can interpret competitiveness research 
as a root of a paradigm-shift. Here I refer only to the spreading of global 
(transnational) corporations. In small-scale national economies and their 
enterprises, the issue of globalization arises in a particularly harsh way and is 
accompanied by heated debates. 
 
This introduction is intended to point out the fact that competitiveness research has 
described for the first time certain phenomena having become commonplaces by now. 
Examples of such phenomena are the following: each developed market economy can 
be described as an open economy and we have to speak about a truly global world 
economy. Competitiveness research has also presented suggestions of how to manage 
the evolving situation. There are still a lot of theoretical and empirical problems to be 
researched in these fields. One such field is the modification and the reinterpretation of 
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the borderlines and the scope of traditional disciplines of science. From among the 
above-mentioned problems the issues of competitiveness related to economics, and 
primarily those related to business and management studies within economics, are 
going to be investigated.3  
 
 
2.1. Economics and business and management studies 
 
Although these two scientific disciplines are related to each other, to my mind, one 
cause of the debates on competitiveness research is that economics and business studies 
approach the same phenomena in rather different ways. Therefore I will begin this 
chapter of theoretical introduction with the definition of the subjects of the two 
disciplines. In my opinion, defining the subjects of the disciplines also involves 
hypotheses that often fall into oblivion when applying the results of the two disciplines, 
and they also lead to misunderstandings. Defining the subject of economics, I primarily 
rely on Samuelson`s and Nordhaus’ work (Samuelson-Nordhaus, 1988), and defining 
the subject of business and management studies, next to Cox’s, Elfring`s and von 
Raaij’ approaches (Cox, 1997; Elfring-von Raaij, 1995), I rely also on Chikán’s work 
(Chikán, 1997b). 
 
My starting point in defining the subject of economics is Samuelson`s and Nordhaus’ 
definition. One of my reasons for this is that according to The Economist (August, 
1997, p. 60.), their economics textbook has been the best-selling publication since its 
first edition and there is no question about its influence on knowledge and approaches 
in economics. My other reason is that it can be verified by methods of the sociology of 
science that the majority of representatives of mainstream economics accepts their 
approach. Economics studies how people and the society at large end up choosing 
scarce resources to produce various goods and to distribute them among various 
members and groups in society for current or future consumption (Samuelson-
Nordhaus, pp. 30-31). Economics is traditionally considered to have two branches: 
macro- and microeconomics. Macroeconomics deals with the economic problems of 
the whole economy, while microeconomics investigates the behaviors of individuals, of 
households, and of companies on the basis of various, well-defined assumptions. Both 
branches assume a national economic framework. There is a third branch of economics 
closely linked to these two: international economics. This one investigates how the 
behaviors of national economies and its main actors alter, when significant trade 
relations are established between them. 
 
Important assumptions of economics are that resources are scarce and that they can be 
employed alternatively. The various models also agree that the most important 
economic task is to employ resources efficiently (to achieve the greatest possible 
output with the least possible input) in order to raise the level of consumption. Apart 
from this, however, in J. Stigler’s words: “an economist should not tell the society what 
                                                 
3A comment belongs here. My research carried out in the Spring of 1999 at the Catholic University of 
Leuven (Belgium) and HEC (Jouy-en-Josas, France) was primarily theoretical and tried to disclose the 
interrelatedness and differences in theoretical literature of economic and business studies. In the next section 
I draw from some of the knowledge I obtained there. 
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to look for. His/her task is rather supporting society in achieving its objectives 
efficiently” (quoted in Piper, 1997, p. 188). During more than 120 years of the history 
of economics, the methodology and basic theories have been established and accepted, 
the application of which has made economics a respected science. 
 
I point out theories of firm in economics. As Archibald points it out (Archibald, 1987), 
economics does not have a unified firm theory. Kapás adds two firm theories to 
Archibald’s classification (Kapás, 1999): the firm theory of the new institutional school 
that she calls contract-firm theory and the resource-based view. The new institutional 
school can be regarded as a school aiming to establish a connection between economics 
and business studies. Based on Coase (1937) and Williamson (1985) this school 
investigates e.g. the boundaries of firms and the functioning of internal institutions. 
This approach is especially promising for the study of globalization and the operations 
of transnational corporations. The resource-based view has been rooted primarily in the 
firm theory, particularly in Penrose’s work (Penrose, 1959), and the results of research 
on corporate strategies (e.g. Wernerfelt, 1984; Prahalad-Hamel, 1990). It is still an 
unanswered question whether we should consider the various firm theories to be 
theories at all, or should rather consider schools based on the same paradigm within 
firm theory. In my opinion there are schools based on various paradigms that constitute 
the firm theories, and all contributed to relate economics to business studies. In 
economics such a school is the new institutional school, and in business studies the 
results of the research on corporate strategies should be mentioned. M. E. Porter 
represents one corporate strategy approach. He developed his models on the basis of 
the theory of industrial organizations. In respect of firm theories it should be pointed 
out that there is a new tendency in international economics as well, demanding a theory 
of multinational corporations (see e.g.: Caves, 1982 and 1998; and Guisinger-Brewer, 
1998). 
 
It is more difficult to define the subject of business and management studies. In this 
field there is no basic textbook accepted internationally, unlike in economics. 
Furthermore, this field is more heterogeneous and more dependent on contexts and 
practices than economics, due to the peculiarity of business and management activity. 
We might claim that business and management studies deals with the utilization of 
scarce resources within different organizations in order to produce and provide for 
society various products and services. The prototype of organizations is the enterprise 
that has to provide products and services with profit and under defined market 
conditions (Chikán, 1997b). 
 
Researchers of the different sub-disciplines of business studies (e.g. marketing, 
production management, logistics, and finance) aim at describing and systematizing the 
practices in their own fields, and at enriching the knowledge and skills (involving 
solutions and “recipes” as well) that help enterprises and their employees to be 
successful. Using this as a starting point, according to Cox, who intends to formulate 
meta-theory of business and management studies, business and management studies 
aim at nothing else but contributing to the sustainable success of individuals and 
businesses (Cox, 1997). Cox defines sustainable success as follows: “sustainable 
success is defined as the ability by individuals or companies to maximize their capacity 
to appropriate and accumulate material wealth for themselves in an environment of 
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absolute and relative scarcity” (p. 15). He identifies ignorance with two meaning as the 
main obstacle of achieving success: 
• People generally do not know what is the appropriate thing to achieve valued 
outcomes under different circumstances. (p. 17.) 
• They do not have an appropriate way of thinking, which will allow them to see or 
to understand what actually confront them. (p. 17.) 
These factors are problems in the internal decision-making of enterprises, and as such, 
they concern one of the elements of business operations, although an undoubtedly 
prevailing element of it. It is a considerable deficiency of Cox’ that he neglects the so-
called functional sub-disciplines of business and management studies (e.g. marketing, 
production management, logistics, and finance). 
 
It is more suitable to classify sub-disciplines of business and management studies by 
their subjects. That is to say, they belong to one group if one investigates the enterprise 
as a whole and to another one if one focuses merely on certain well defined areas in 
business operations. 
 
Strategy, organizational behavior, management, human resources management, 
information management, decision theory and -methodology fall into the first of these 
two groups. The most important task of these sub-disciplines is to provide managers 
and their employees with knowledge and skills that increase the organizational 
efficiency of enterprises. 
 
Figure 2.1 Fields of business and management studies and their interrelatedness 
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The focus of sub-disciplines investigating certain areas in business operations is set on 
certain value creating areas from the viewpoint of consumers. From the point of view 
of business operations the objective of these areas is to develop competences to market 
competitive products or services. I summarized this way of thinking in the figure 
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below. The figure illustrates the integrative approach to the sub-disciplines of business 
and management studies and points out the relationship between each of them and the 
enterprise as a whole. 
 
Cox (1997) classifies business and management studies literature - which, according to 
the bibliography, involves primarily books about strategic management - by the 
authors’ methodological thoroughness in trying to provide solutions and practical 
pieces of advice. He divides authors into two groups: barefoot empiricists and 
systematic empiricists (Cox, 1997, pp. 81-130). In Cox’s classification the prevailing 
approach in business and management studies literature is an empirical one and not a 
theoretical one. 
 
Barefoot empiricists strive to come up with new knowledge of general validity in terms 
of whole companies on the basis of a certain number of unique cases. Cox places into 
this group for instance the works on management of the non-discussed functional areas 
together with Hamel`s and Prahalad’s works. He may not be right when he puts into 
this group all the areas of functional management, since their type of model-formation 
and of verification quite close to those applied in economics. In Cox’s opinion the 
greatest deficiency of the authors in this group that their generalizations and points of 
reference offered do not provide the targeted users with any suitable way of thinking. 
The reason for this is that the circumstances, under which the suggested solutions 
would be applicable, have not been clarified. Let me comment here that according to 
Clark’s and Salaman’s work, who attempt to classifying primarily the American so-
called “management-guru” works (Clark-Salaman, 1998), most of the authors they 
regard management-gurus (e.g. Peter Drucker, Tom Peters, and Robert Waterman) fall 
into this group. The roots of their popularity in the US are to be found primarily in the 
culture of the American society. 
 
The group of systematic empiricists includes schools striving to formulate a 
systematical and descriptive typology of the possible strategies and the realized 
practices that companies may actually adopt. Cox lists here, among others, the works of 
Igor Ansoff and M. E. Porter. He maintains that the problem with these works (e.g. 
Ansoff, 1965; M. E. Porter, 1980, 1985, and 1990) is their failing to provide companies 
with a suitable methodology, which might help them to identify in advance the most 
suitable strategy in certain circumstances. 
 
Although Cox’s approach described above is primarily based on the literature on 
strategy, his grouping seems to be applicable to the other sub-disciplines of business 
and management studies as well. On can observe that in business and management 
studies research the so-called empiricist tendency gains an increasing role and 
quantitative research is spreading to verify the loosely formulated models and 
frameworks. 
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Table 2.1 Contrasts of economics as monodiscipline and business and management sciences 
 Economics as monodiscipline Business and management sciences 
- interdisciplinary 
Orientation theoretical improvement of theory applied solution of problems 
Reasoning largely deductive largely inductive 
Object aspect “whole” 
Context universal focused contextual comprehensive 
Approach normative 
 “could”  
confirmatory  
pure 
static 
situational  
“should”  
exploratory, descriptive  
applied  
dynamic 
Boundaries restrictive: ceteris paribus a-restrictive: “all-factors” included 
Education specialization de-specialization 
Orientation scientific career management career 
Source Based on Elfring-van Raaij, 1995, p. 30 
 
Table 2.1 summarizes the differences between economics and business studies. Elfring 
and von Raaij choose a very illustrative starting point for giving a sense of these 
differences. In separating them, they speak of mono-disciplines symbolized by the 
Olympus, and applied theories symbolized by the Agora. When a discipline is to solve 
practical problems, the discipline belongs to the sciences of the Agora. The authors list 
among the sciences of the Olympus mathematics, economics, psychology, and 
sociology. They list among the sciences of the Agora marketing, finance, 
organizational behavior, and strategic management, that is to say, practically the main 
fields of business studies. This illustrative classification is based on the practice and it 
points out that the more applied and therefore context-dependant a field of science is, 
the more numerous models, theories and suggestions compete with each other. 
 
The main characteristic of economics and business and management studies described 
above is that they work within the framework of a national economy. Foreign trade 
relations are present in economics (e.g. international economics) and in business 
studies as well (e.g. international marketing), but neither one is able to treat them in an 
integrated way. As I mentioned it in the introduction, competitiveness research 
questioned the national economy-framework, and tried to investigate foreign trade 
relations and their effects at different levels of the economy. I should mention research 
projects on global industries here as well (e.g. Porter, 1986a) that can be regarded 
antecedents of research on competitiveness and global corporations. 
 
 
2.2. Competitiveness Research and Competitiveness 
 
After the second oil-crisis macroeconomic interest turned towards the competitiveness 
of national economies, and at the level of big firms it turned towards the formulation of 
strategy. In 1985 reports were prepared about the competitiveness of the English and 
the American economy. The “Can America compete?” study of the Brooking Institute 
published in 1984 can be a preliminary version of latter reports (Francis, 1989). 
Practically up to this date there had been no mention of the problem of competitiveness 
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at the national economic level in economics. In this chapter I am first going to review 
the findings of competitiveness research projects, and then I am going to evalute them 
from the angles of economics and business studies. 
 
 
2.2.1. Competitiveness Research 
 
I reviewed three American competitiveness research projects in my Ph.D. thesis 
proposal (Scott-Lodge, 1985; Dertouzos et al., 1989; and Porter, 1990). One of my 
reasons for choosing them was that they were among the first works that generated 
further competitiveness research projects. My second reason was that when the In 
Global Competition research program was launched, we learnt a lot from these 
American projects. The detailed description of the three projects can also be found in 
Csernenszky’s work (Csernenszky, 1997), one of the most complete reviews on 
competitiveness research projects in Hungarian. 
 
I include a fourth project as well in the descriptive section on the basis of Zysman-
Tyson’s (1983) work, which anteceded the above-mentioned three projects but 
anticipated their approaches. This project investigated the position of six American 
industries in international competition: steel industry, color TV industry, semi-
conductor industry, the textile and apparel industry, footware industry, and automobile 
industry; and it also summarized the lessons of the Italian small business development 
from the point of view of industrial policy. The analysis was based on case studies and 
the editors concluded in 1983 “the structural and the competitive adjustment problems 
of individual industrial sectors require policy measures tailored to adjust their needs. 
Implicit in this view of course, in the resumption that industrial policy requires an 
understanding of competitive market dynamics and policy options in particular sectors 
of the economy" (pp. 7-8.). This study at the beginning of the 1980s meant to draw 
conclusions primarily for the government, although firm strategies are included in its 
subtitle. Its focus was on industrial policy and it considered the structural problems of 
industry to be as important as the adjustment to international competition. There is no 
trace of the industrial policy approach in the research projects a couple of years later. 
 
Each of the three projects I took as example was carried out in the 1980s at two well-
known educational institutions of Boston, the Harvard Business School and the 
Massachusetts Institute of Technology (MIT). Two projects were linked to Harvard 
Business School. Findings of the first research were published in a volume edited by 
Bruce S. Scott and George C. Lodge (B. S. Scott-G. C. Lodge, 1985a) and those of the 
second in Porter’s book (M. E. Porter, 1990). These two books are not only linked by 
Harvard Business School, but by their approaches as well. Scott and Lodge give more 
information about their concept, their interpretation of competitiveness, and their 
assumptions. Porter speaks less on his assumptions; however, he follows the line of a 
business approach in a much more determined fashion. The research was carried out at 
Massachusetts Institute of Technology is between the Scott and Lodge’s and Porter’s 
projects. It was started in 1986 and it focused on the competitiveness of the US 
industry. Michael L. Dertouzos et al edited the volume published in 1989 summarizing 
the findings of the research. 
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From the point of view of the United States the objective of competitiveness has been 
to preserve and upgrade the country’s position in the world economy. Therefore, the 
starting point of competitiveness research has been the declining competitive advantage 
of the U.S., as compared to other developed countries. Relied on macroeconomic data 
and data on certain industries, the projects called attention to the decreasing share of 
the United States in export markets with its imports increasing. This all resulted in an 
increasing trade deficit, while the rate of GDP-increase was behind those of Japan and 
West Germany, among others. Furthermore, together with the import competition, 
competitors appeared on the American market with inward foreign direct investment. 
The object of the research was the practices of the most developed market economies, 
that is to say, market economies that had functioned for several decades or centuries, 
were compared with one another. 
 
Each project based on macroeconomic data and each arrived at conclusions on the basis 
of international comparison. Conclusions of each were the necessity of going beyond 
macro-level analysis. Our three projects went beyond and they formulated the basic 
principle of a national economy being competitive when its firms are competitive. 
Therefore, the investigations should focus on and conclusions, and proposals deduced 
from them should serve the competitiveness of firms finally. 
 
Each research project accepted that the results of macroeconomic analysis provide 
important insight into productivity. Productivity can be considered to be the epicenter 
of competitiveness, but these macro-level research findings cannot be utilized in 
formulating proposals that could be addressed to firms. 
 
Each research project intended to contribute to the improvement of competitiveness, 
especially that of the United States. Competitiveness in general meant that the economy 
had to adjust to the changed conditions of the world economy and to international 
competition, and that the adjustment of the national economy had to take place at 
industry and business levels. Therefore, the research projects describe international 
experiences and discuss their lessons for the United States. The proposals are all 
addressed to enterprise managers and to the government. 
 
Neither Scott and Lodge’s, nor the MIT research intended to produce a model for 
improving competitiveness. Both research projects aimed at decision makers in the 
United States. In contrast to these, the objective of the international research project 
coordinated by Porter was to formulate a model suitable for explaining and forecasting 
competitiveness. 
 
Concerning the methodology of the research projects, we can see that each was based 
on case studies. Researchers thought that case studies were suitable to exploring 
business and government factors that may support the international competitiveness of 
firms and industries. Further international comparisons of other areas (e.g. education 
and training, technology, the institutional backgrounds of R & D and their influences 
on firms) were made within, or next to the case studies. The objective of these was to 
point at the most respected practice, and providing some benchmark to formulating 
proposals. We may summarize the common characteristics of these projects in  
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Table 2.2: The Common Characteristics of Competitiveness Research Projects 
Issues Characteristics 
Research question Declining macroeconomic performance in 
international comparison 
Unit of analysis Company-industry-government policies 
Aim of research Proposals for upgrading the eocnomic position of 
the U.S. in the world economy 
Orientation Applied business research 
Addressees of research findings Managers, government, professors 
 
According to several authors dealing with international economics, the comparative 
advantage of the United States should be analyzed before proceeding to 
competitiveness. This criticism was formulated first of all because of the neglected 
quantitative methods, and on the other hand, because research reports did not devote 
too much space to reveal links to international economics. Krugman (Krugman, 1996a) 
has expressed this view in the most pronounced way. 
 
Porter’s project was the only one that offered a theoretical model applicable by 
developed countries. There have been few empirically experiences as far on the 
practical relevancies of this model. However, it is worth pointing out that Porter 
(Porter, 1998b) refined his diamond model. Based on his findings of the 1990s his new 
model stressed determinants of local competitive advantage to support the 
competitiveness of clusters. He lists the countries and regions where his cluster-based 
reports and case studies had been carried out (pp. 284-87). 
 
Table 2. 3.: Studies and Reports Based on Clusters 
Country or region Number of studies or reports Date of studies or reports 
United States   
• Appalachia 1 1997 
• Arizona 4 1990, 1996, 1997 
• California 6 1992, 1993, 1995, 1993, 1997 
• Connecticut 2 1991, 1996 
• Massachusetts 2 1991, 1992 
• Minnesota 3 1995, 1996 
• New York City 2 1997 
• Pennsylvania 1 1994 
Brazil 1 1997 
Central America 1 1997 
Ireland 2 1992 
Netherlands 2 1990, 1995 
New Zealand 1 1991 
Northern Ireland 1 1995 
Portugal 1 1994 
Total: 15 countries 30 studies or reports between 1990-1997 
Based on Porter (1998a) pp 284-287 
 
Altogether 30 studies and reports were prepared in seven countries and on a region 
including several countries. It should be noted that two countries, Ireland and Portugal, 
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currently considered to be success economies of Europe, are listed in the above table 
just as New Zealand is doing, which is also considered to be successful. We may not 
state it unambiguously that these countries have achieved their admirable economic 
results due to the research mentioned above. However, analyses of economics and 
business studies usually point out that the conclusions of the research projects 
published under Porter’s name, have had some role in the “economic” and “firm” 
miracles that emerged 4-6 years after the studies or reports had been completed. 
 
Before turning to an analysis of the theoretical background of competitiveness 
research, I should briefly mention the so-called competitiveness lists. There is a single 
reason for this: they are very popular. To my knowledge, two works have been 
published in Hungarian about competitiveness lists. Pál Majoros prepared one of them 
in 1997 at my request, and Mária Findrik and Imre Szilárd published the other one in 
2000. In what follows, I am going to rely on these two works. 
 
Since 1980, when the World Competitiveness Report was first published, the term of 
competitiveness receives wide public attention at least twice a year. The reason for this 
is that the countries investigated (Hungary was the first country of the region to be 
included in the report in 1992) are ranked by several aspects. The order of rank is 
drown up on a complicated system, but the summarizing one is clear and illustrative. 
Therefore, they are popular and cited in spite of the criticism directed against their 
concepts and methodology. This is one of the reasons why Majoros’s, and Findrik and 
Szilárd’s review of the aspects of the different lists of competitiveness. Factors that 
lists claim to have influenced Hungary’s position in the competitiveness lists in certain 
ways are also instructive. Findrik and Szilárd devote most of their efforts to the 
analysis of main indicators. The following statements are on lists including 46 
countries and published annually in the World Competitiveness Yearbook. 
 
Hungary had a better position in the summarizing list in 1996 (39th) than in 1995 (40th). 
Since then we have been able to show further improvements: 1997 – 36th, 1998 – 28th, 
1999 – 26th. It should be noted here that several less-developed countries received 
better evaluations than Central and Eastern European countries. At the same time, 
several developed member states of the OECD and of the EU (e.g. Portugal, Greece, 
Mexico) are at a level similar to that of the countries in Hungary’s region.  
 
The following statement could be made about the competitiveness of Hungary based on 
the 8 main indicators (economic macro-performance, foreign trade achievements, 
government policies, financial services, infrastructure, leadership-management, 
science, technology, and the human factor) in 1996: “our technological backlog (36th 
position) is a considerable factor determining our competitiveness. To improve it, 
however, the country needs capital (43rd position) and suitable management (38th 
position); that is to say, Hungary is in a considerably poor position determined by three 
important input factors. We have better positions in infrastructure and the human factor 
that may be regarded important input factors as well, however, we do not stand out 
here, either, and the competitiveness and supportive government policies are of low 
levels” (Majoros, p. 40). According to Findrik’s and Szilárd’s review, we have 
achieved the smallest change, namely improvement, in the area of management (1996 – 
38th, 1999 – 30th position). The major ones we managed to improve are in the areas of 
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government policies (1996 – 40th, 1999 – 26th position) and financial services (1996 – 
43rd, 1999 – 28th position). 
 
The above has been an outline of the competitiveness list. From 1996 to 1999 the 
whole Hungarian economy advanced from the 40th to the 26th position, which is a sign 
of a considerable improvement of its competitiveness. The notion of competitiveness 
has become very popular; however, several issues concerning its measurement have not 
been clarified yet. Still, the above list comparing countries is also very popular. These 
lists are clear-cut, informative, and do indicate tendencies, but I think that they are only 
suitable for providing a basis for further research into various fields of competitiveness.  
 
 
2.2.2. The Questions and Theories of Economics 
 
Questions on the competitiveness of national economies are closely linked to 
international trade, therefore, at the level of economic policy such questions have been 
dealt with in the framework of trade policy. Economics is interested in the causes 
underlying (foreign) trade, because it “amplifies the consumption possibilities of 
countries. Trade allows countries to consume more of each type of goods than the 
limits of their national production possibility frontier allow when they have no foreign 
trade and have to self-supply” (Samuelson-Nordhaus, 1988, p. 1172). This principle of 
international economics has become the guiding principle of agreements regulating 
international trade, and of international trade policies applied after the World War II. 
The failure of national economic policies aiming at autarchy between the two Word 
Wars also encouraged the application of this principle in practice (Cameron, 1988). 
 
From the point of view of national economies, international economics is trying to tell 
why certain countries trade with each other, which factors influence their trade and how 
foreign trade influences their domestic economies. “The theories of international trade are 
often classified into three groups: the so-called pure theories, financial theories, and 
alternative theories” (Tóth, 1998, p. 31). Pure theories focus on the exchange of goods 
between countries, and they investigate the causes of foreign trade mainly from the 
production (or supply) side. The theory of comparative advantages belongs to this group. 
Financial theories discuss the currency problems of trade. They are interested in the effect 
of the international monetary system on international economic relations. Out of 
alternative theories I would only touch upon the Linder-theory and Vernon’s model of 
international product life cycle. Linder’s theory tries to explain international economic 
relations from the aspect of consumer preference. Vernon investigates how new products 
appear and diffuse in international trade. These two theories have brought macro-oriented 
theories nearer to the micro-sphere. 
 
According to Krugman and Obstfeld (1997), the same approaches and hypotheses are to 
be applied when analyzing international economics as in the case of internal trade. They 
suppose that the following subjects are the most significant: the advantages achievable 
through international trade; the types of trading; protectionism; the balance of payments; 
exchange rate policy, trade policies; and finally, international capital markets (p. 3). 
According to international economics, the trade policies of developed countries should 
encourage exports and, in some industries, hold imports back. In the opinion of 
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international economists, competitiveness is attractive to economic policy makers and 
businessmen, but its conception has remained a bit hazy (pp. 275-276).  
 
According to Török’s review published in 1996, international economics does not discuss 
the concept of competitiveness. In his opinion, this concept cannot be deduced from any 
basic paradigms of economics, either. He thinks that schools on “international trade 
performance, on specialization based on market theories, question one of the basic 
hypotheses of classic and neoclassic economic theory; the principle of the perfect 
competition”. Reviewing the applied methodology, he finds that competitiveness 
measured on the supply (production) and demand (market) side cannot be connected with 
each other satisfactorily, since competitiveness affects cost-advantages on the supply side 
and it affects market performance on the demand side. 
 
At national economy level competitiveness is best expressed by prices. According to 
Francis, we should deal with non-price-competitiveness, as well (Francis, 1989). 
• According to the price-competitiveness approach, everything affecting prices is a 
factor of competitiveness. 
• The non-price-competitiveness approach based on the fact that in international 
competition differentiated products compete, thus the field of competition may be, 
for example, price, the characteristics of products or after-sales services. (In this 
case innovation and developing new products are especially important. In the lack 
of these, the competitiveness approach seems to be much more proper, argues 
Francis, referring to the English example of the 1950s in a paper he published in 
1992.) 
 
In his paper published in 1992, Francis calls attention to the fact that the focus of 
investigations of economics, economic history, and the political sciences, is on national 
economic performance. He connects competitiveness with the renewal of industries, 
which is also rooted in research into management, apart from the above-mentioned 
disciplines. He argues that we have to separate these two groups for at least two reasons. 
On the one hand, altering interests controls the two groups of research and they also have 
various scientific bases, on the other hand, proper theoretical basis and conceptual 
apparatus to link them is missing (pp. 62-63). 
 
Francis’ approach (Francis, 1989) is close to Török’s approach (Török, 1996). In Török’s 
opinion competitiveness manifested in prices from the supply (production) side and non-
price competitiveness is rooted in the demand side (the market). Francis points out that 
problems are about the measurability, since it changes that are measured and not levels 
and non-price factors are neglected. Furthermore, the increase of productivity is much 
easier to measure than competitiveness itself, which is difficult to define (Francis, 1992, 
pp. 66-67). 
 
In the meantime it seems that the study of open economy has gained ground in 
macroeconomics (see e.g. Mankiw, 1999, Chapter 7). The novelty of this has been the 
introduction of the following issues of international economics into the macro-economics: 
trade relations, that is, the effect of movement of capital and goods; savings and 
investments in open economies; and the effect of exchange rates on the national economy. 
This is important to point out here, because traditionally only trade and exchange rates had 
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been subjects of macroeconomics (e.g. Samuelson-Nordhaus, 1988; Hall-Taylor, 1997). 
Macroeconomics fundamentally assumed closed economies. 
 
I must make a brief comment on open economy. Investigating the role of the export and 
the import in the United States their proportion to the GDP are illustrated by data for the 
period from 1950 to 1995. Their values from 4-5% of the GDP in 1950 had increased to 
10-12% by 1995 (Mankiw, 1999). Export had lower proportion to the GDP than import in 
the period from 1980 to 1990. On open economies, Mankiw displays the data for 1994 
shown in Figure 2.2. Let me comment here that the data of the figure below were 25.8% in 
respect of export and 35.2% in respect of import in their proportion to the GDP in the case 
of Hungary. Both of these values had increased significantly by 1997. Export had reached 
41.8% and import reached 46.4% to the GDP. 
 
Figure 2.2. Shares of Import and Export in Some Developed Countries` GDP in 1994 
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Source: Mankiw, 1999, p. 215 
 
Discussing common market theories, Palánkai points out that traditional theories of 
international economics had focused on trade, while currently, due to globalization, more 
attention is paid to the inter-country flows of factors of production (Palánkai, 1999, pp. 
64-82). “When evaluating the role of factors of production (e.g. capital, labor, technology, 
enterprises) it should be clear that these goods are special. Their prices are impossible to 
deduce simply from their marginal utility. The prices of factors of production are 
performance-based (determined on the basis of their marginal productivity). Since their 
quality varies by country, their prices necessarily alter, regardless of their scarcity. /…/ 
Classic authors’ supposition, who had focused on factors of production, while neglecting 
quality-differences between them, has become insupportable,” summarizes Palánkai the 
relation between factors of production and the comparative advantages (pp. 64 and 67). 
Then he points out that “in respect of factors of production, the opportunities to develop 
comparative advantages depend on the quality of factors of production and a lot of 
situations may occur when a given country has advantages or disadvantages in all factors 
of production” (p. 68). I have cited this because Porter’s (1990) approach on comparative 
advantages assumed that factors of production are renewable factors, and not natural 
endowments. Investigating firms, Porter intended to answer Palánkai’s question in another 
dimension. 
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I conclude the following from the reviews of the economic theoretical background of 
competitiveness: Competitiveness is related to the performance of national economies 
(e.g. productivity, GDP) and their foreign trade. It is investigated primarily when 
international market positions of a country change. It seems that this problem arose a bit 
later in the “mainstream” literature than it did in the case of smaller countries that went 
through this process some time earlier than others. One of the most important roots of and 
inspirations for competitiveness research is macroeconomics, particularly international 
economics. It is considered as axiom in international economic theories that international 
trade is useful for national economies. Some fundamental questions of international 
economics are: what are the causes of international trade; which factors explain that 
various countries establish trade relations with each other; how do these relations affect 
the national economies of the participating countries. Behind descriptive theories we can 
discover the research into the effects of the supply side, of the demand side, and of 
financial systems. Currently the issue of the flow of factors of production is being 
elaborated as a new school. The issue of the international flows of factors of production 
moves us closer to competitiveness research. 
 
 
2.2.3 The Business and Management Studies Approach 
 
The core of the business and management studies approach is the fact that it is first of 
all enterprises that involved in international competition, and if they are unsuccessful in 
it, their own countries will also become unsuccessful in the world economy. It is 
enterprises, particularly big corporations that trade internationally and make decisions 
on the flow of factors of production. As a result, the competitiveness research projects 
described above mention the competitiveness issue as a problem of enterprises. They 
try to identify the factors that governments and enterprises have to focus on in order to 
support national enterprises to compete with foreign ones. 
 
I mention again that behind the competitiveness issues and competitiveness research 
there is the process of the economy of the United States having become an open 
economy. At the end of 1980s American authors, criticizing the competitiveness of the 
United States in their works, consider the trade balance deficit and the diminishing 
internal and external market shares to be the manifestations of decline of American 
competitiveness in the world economy. The number of the subsidiaries of foreign 
(Japanese and West-European) corporations significantly increased during the 1980s. 
These phenomena are new for the U.S. but they are not for European countries and for 
Hungary. This is important, because since the end of World War II, the universities and 
researchers of the United States have always determined the main schools of economics 
and business and management studies. It is natural that the issues they raise have a 
considerable effect on the international scientific publications and on education at 
higher level. I also have to point out that, due to the empirical sensitivity of this 
discipline, the investigated economy has a fundamental influence on which questions 
the research projects are going to raise, on their research methods, on their theoretical 
background, and on their models as well. This influences the Hungarian research 
activity, as well, which I am going to introduce in more detail in Chapter 4. 
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Competitiveness research projects in this field were inspired by the performance of a 
national economy. Their focus is on enterprises. This issue introduced the international 
aspects into the competition from the point of view of enterprises. Researchers try to 
find out what the senior management of enterprises can do in order to increase the 
international competitiveness of their enterprises against their international 
competitors. According to Francis’ summary the competitiveness of enterprises has 
three components: 
• Efficient operation in the long run, 
• The ability to pay proper salaries to employees, 
• Providing expected returns to owners. 
 
Based on that the competitiveness “for a nation must be tied to its ability to generate 
the resources required to meet the national needs“ (Francis, 1989, p. 16). In other 
words, nations should be able to support both the internal and external allocation of 
factors of production, and government policies have to support the continuous renewal 
of this ability. 
 
Competitiveness research rooted in business and management studies is mainly 
conducted from the point of view of enterprises. On this basis authors try to draw 
conclusions and to provide proposals for economic policy on how to support the 
competitiveness of the national economy. Note that this approach is one of the main 
points for criticisms of international economics. The issue is interesting where there are 
global corporations. Globalization is accompanied by a new phenomenon, the flow of 
capital investments inside multinational corporations, which are cross-country 
organizations, and which is hard to investigate by international economics (see e.g. 
Krugman, 1996a; and Krugman-Obstfeld, 1997). In the Introduction of the cited book 
of Palánkai uses the expression of “megaeconomics”, since in his opinion, “the changes 
of the ‘globalized’ world economy can not be analyzed by the categories of traditional 
international economics. Several categories have to be revised, and in certain cases 
some completely new approaches are necessary” (Palánkai, 1999, p. 9). 
 
Competitiveness research accepts the principle of international economics that says that 
trade is beneficial for countries. However, this principle is valid to the world economy 
as a whole and in case of individual national economies the effects of trade have to be 
analyzed. Setting out from this principle of international economics, business and 
management studies conclude that foreign trade and international economic relations 
are results of the activity of enterprises. Therefore factors that promote or impede the 
international operations of enterprises should be examined. Investigating the 
international operations is a novelty. Next to trade, foreign direct investment became 
subjects of investigations. Foreign direct investment is also significant for nations, both 
as investors and as host country (Daems (1998) and Sleuwagen (1988) pointed this 
out). Porter has given the most comprehensive description of this conception and he 
has introduced the term of “competitive advantage” into business and management 
studies and economics as well (Porter, 1990). 
 
Porter (1990) concludes that since the existing theories are not suitable for explaining 
and analyzing the factors that make companies internationally competitive, a new 
theory is required. The new theory must meet the following requirements: 
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• “It must explain why a nation’s firm gain competitive advantage in all its forms 
not only limited types of factor based advantage contemplated in the theory of 
comparative advantage” 
• “A new theory must start from the premise that competition is dynamic and 
evolving” 
• “A new theory must make improvement and innovation in methods and 
technology a central element” 
• “Finally, since firms play a central role in the process of creating competitive 
advantage, the behavior of firms must become integral to a theory of national 
advantage.” (pp. 20-21.) 
 
The novelty of Porter’s (1990) approach was that his focus was on enterprises as well. 
His research intended to identify the national factors that contributed to the emergence 
of internationally successful enterprises that became prevailing in their industries 
internationally. Porter formulates his so-called diamond model as result of his research 
in ten countries. His central issue is that the factors of the international competitive 
advantages of enterprises are not natural endowments, as in the case of national 
economies. That is to say, he emphasizes just what Palánkai missed from traditional 
theories (Palánkai, 1999): they can be created and renewed. 
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Figure 2.3.  Sources of Locational Competitive Advantage 
 • A local context that encourages appropriate forms of 
investment and sustained upgrading 
• Vigorous competition among locally-based rivals 
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Source: Porter, M. E., 1998a, p. 211 
 
The model claims that basically four determinants can influence which industries in a 
national economy are going to be internationally successful. The four determinants are 
the following: factor conditions, demand conditions; the related and supporting 
industries; firm strategy, firm structure, and rivalry. Government measures can affect 
the development all of the four determinants. Chance refers to event that the 
participants of economies cannot influence, and that appear coincidentally (see Figure 
2.3). The figure below shows an improved version of the 1990 model. My reason for 
using this is that this version of the model stresses locational determinants of 
competitive advantage. 
 
 
2.3 An interpretation of competitiveness 
 
I have not defined the concept of “competitiveness” so far. Taking into account all the 
above, on the basis of Scott and Lodge I accept the definition of competitiveness 
formulated by Attila Chikán (1995): National competitiveness is the ability of a 
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national economy to create, produce, distribute and/or service products meeting with 
the requirements of international trade in a way that the return on its own factor 
endowments increases in the meantime (Chikán, 1995). 
 
This is a definition of competitiveness focusing on the maintenance and the increasing 
of economic efficiency in an open economy by taking into account the quality of the 
utilization of renewable resources available in the national economy. Its central factor 
is the adjustment and the ability to adjust. The openness of the economy is essential 
because the point of reference of their actors is provided by exports, imports, and 
foreign direct investment. Competitiveness is not an end but a mean to increase the 
living standards of the inhabitants of the given country. From the point of view of 
economic policy this mean is served by the maintenance of economic growth (GDP) 
and by employment at the highest possible level. It is necessary to specialize in 
producing products that increase the return on factors of endowments. This principle 
does not contradict the traditional theories of international economics. However, 
competitiveness research projects have called the attention to the necessity of 
interpreting factor endowments more broadly: renewable resources, and knowledge are 
of great importance in gaining competitive advantage. 
 
In accordance with the definition of competitiveness at national level, we may consider 
enterprises competitive if they are able to contribute to the achievement of national 
competitiveness. Continuing Attila Chikán’s definition (Chikán, 1995), this means that 
competitive enterprises 
• are able to transform available resources into a profit flow complying with the 
social values and 
• are able to perceive external and internal environmental changes that influence 
their long run operations and to adjust to them in order to maintain their 
profitability to support their long term operations. 
 
In this competitiveness definition social values means laws and legal regulations, and 
the unwritten social values and norms of a national economy, and they have an 
outstanding significance. In this respect one of the most frequent misunderstandings 
about competitiveness and one of the roots of the debates is the fact that competition in 
economics is interpreted as perfect market competition. I refer to the 1995 report of the 
Lisbon Group. There is still an unsolved issue both theoretically and in practice, that in 
global, regional and nation competition which economic and political actors influence 
or regulate, and what scope for action is left in it for a national economy? A further 
important assumption and debated issue is whether we should consider globalization a 
zero-sum game. These questions arise especially sharply in the cases of small national 
economies (see e.g.: The Group of Lisbon, 1995; Korten, 1996; Martin-Schuman, 
1998; and Schmidt, 1999). 
 
Another factor of the above definition is profit flow, which is a fundamental condition 
in adjustment and the basis of the returns expected by owners. 
 
The discussed concept of competitiveness starts from national competitiveness and 
ends up at competitiveness. There is still no theory model to connect national and 
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micro-level (industrial or enterprise) competitiveness. In Chapter 5 I am going to return 
to this issues and I propose a multilevel approach to competitiveness.  
 
It seems that globalization has thoroughly blurred the borders of disciplines. This is 
summarized in the figure below. All of knowledge of business and management studies 
knowledge is necessary for managing global (I use this word as a synonym of 
transnational) corporations, just as for managing corporations producing exclusively 
for domestic markets. However, operating internationally, in a cross-border way, is a 
new dimension of enterprise operations. I am going to enter into details about this 
Chapter 6. 1. 
 
The traditional field of economics is too narrow for investigation the flow of factors of 
production. These are renewable goods valued by their qualities, and their flow is the 
consequence of the operations of global corporations. Role of regional integration, the 
basic type of which is the European Union, is a further challenge. Economic policy of 
the member states of the integration should be harmonized, which affects the traditional 
relations of member states and global corporations alike. I am going to discuss the 
European Union in more detail in Chapter 3. 
 
Figure 2.4: Economics, Business and Management Studies, and Global Corporations 
E ff ic ie n t re s o u rc e  u t i l iz a t io n  a n d  its
e f fe c ts  o n  th e  e c o n o m ic  a c to rs
E c o n o m ic s
In te r n a t io n a l  e c o n o m ic s
M a c ro e c o n o m ic s
M ic ro e c o n o m ic s
T h e o r y  o f  In d u s tr ia l
O r g a n iz a t io n
G lo b a l  c o r p o r a t io n s
B u s in e s s  a n d
m a n a g e m e n t
D is c ip l in e s  o f   f ie ld s  o f  o p e r a t io n s  ( e .g .
m a r k e t in g ,  f in a n c e s )
S tr a t e g y
O p e r a t io n s  a n d
m a n a g e m e n t  o f
c o m p a n ie s  a n d  th e i r
f ie ld s  o f  o p e ra t io n s
O r g a n iz a t io n a l  b e h a v io r ,  M a n a g e m e n t ,
H u m a n  R e s o u r c e  M a n a g e m e n t
 
 
 
 
Discussing the approaches of the disciplines and summarizing my statements on 
concerning competitiveness in the theoretical review in Chapter 2, I relied on János 
Kornai’s conception of the system paradigm (Kornai, 1999). In what follows, I am 
going to summarize the characteristics of the system paradigm on the basis of the 
theories and concepts I have discussed, and to review the issues of competitiveness 
research in order to decide whether they can be called a system paradigm. 
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Table 2.4: Competitiveness Research and the System Paradigm 
Issues of the System Paradigm Competitiveness 
research 
Focus Relations among the choice system and its parts yes 
Subject Persisting institutions of great transformations which 
set economic, political and cultural events and 
processes 
yes 
Scientific 
background 
Multi-disciplinary yes 
Time span Longitudinal relationship among persisting 
institutions and historical processes 
yes 
Preferences Outcomes of the system ? 
Research 
method 
Comparison yes 
Main 
characteristics 
Discovering and revealing system specific 
antinomies 
? 
 
The answer to 5 out of 7 issues is “yes” in the above table. Competitiveness research 
has always focused on enterprises (as the part) and the performance of a national 
economy (as the whole). The subject of the research has been on the enterprise and 
government efforts to increase the performance of the national economy in an open 
economy and in the global world economy. Competitiveness research has to rely on 
several disciplines that have been various areas of economics, and fields of business 
and management studies. The time span of competitiveness research has always been 
several years and its most important method of investigation has been comparison. Two 
issues are marked with a question mark in the above table, because I do not deal with 
them in my thesis. One is the issue of preferences and the other is the main 
characteristic, which according to Kornai includes the recognition and the discovery of 
system-specific drawbacks. Preferences may be answered by yes, when 
competitiveness research uses the basic principles of traditional economics and of 
capitalism. The main characteristic can also be answered by yes, since it has called 
attention to the drawbacks of the existing theoretical systems and to globalization 
deserving further research. 
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3. The EU and competitiveness 
 
This chapter will review the EU objectives and policies supporting competitiveness and 
identify their position in the policy-making process. Also, I will list the proposals put 
forward in the 1990’s on EU competition. In the review I will rely on analyses and 
proposals by the European Commission as well as on Hungarian publications by Palánkai 
(1999), Hiritis (1995), Blahó (ed.) (2000), Inotai-Tamás (1996), Halm-Kőrösi (ed.) (1996) 
and Hargitainé et. al. (1995). The chapter will focus on the key aspects of industrial 
competition. The terms EC and EU will be used as synonyms. 
 
In terms of competitiveness, the points of reference of the EU are the US, Japan and the 
Far East. So the aim of the EU is to maintain its competitive position and sustain its 
economic performance towards those regions, particularly the other two major members 
of the Triad. Thus the major question for the EU is which EU principles, policies and 
regulations support the maintenance of its position in the global economy. In the 
traditional Triad approach involving the US, Japan and the EC, the EU represents an 
autonomous player in world economy (e.g. in OECD and WTO). As an organization 
composed of significant national economies, however, the EU plays a double role: on the 
one hand, it acts as an economic integration, on the other, as a representative of the 
interests of its dominant national economies. In this respect, the EU is a unique player in 
world economy composed of national economies and represents a new tier, which did not 
exist before. The principal national economies of the EU including the UK, France and 
Germany continue to play a key role in world economy and as part of the EU; they are 
influential actors in economic integration as well. This is one of the features of 
globalization, which could be subject to further research. The following review will focus 
on the internal, institutional operation of the EU, where the EU will be regarded as a 
consistent and autonomous member of the Triad, in terms of competitiveness. For this 
reason, the following review will primarily present and discuss the institutions of the EU.   
 
For the purposes of the present thesis, another aspect of EU competitiveness is the 
framework that the economy of Hungary as an applicant country must fit. The reason why 
this paper will study the issue is because “the market challenges that the applicant 
countries will have to meet will be practically competitiveness requirements. There are 
disputes over the question as details of the requirements are not clear and some rightfully 
argue that such requirements are exaggerated.”, Palánkai says (1999, p.366) in connection 
with the Copenhagen accession criteria to be met by applicant countries from Central and 
Eastern Europe.4  
 
 
3.1. European Union objectives and competitiveness  
 
Under the Treaty of Rome the Member States established the European Community 
because they were “committed to paving the way for an ever closer union among the 
                                                 
4 These two issues were not part of the research program entitled “In Global Competition” that served as a 
basis for the present thesis. The reason for this is that it was not until the government of Hungary adopted 
Resolution No. 2004/1995(I.20.) in 1995 that research projects and publications on integration gained 
momentum in Hungary, as reflected in the bibliography. 
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peoples of Europe and securing the economic and social growth by the removal of the 
barriers dividing Europe through joint action. They confirm that the primary objective of 
their efforts is to continuously improve the living and working conditions of their people.” 
(Hiritis, p.62.). 
 
As regards competition in the EU, Article 2 of the Treaty of Rome on the European 
Economic Community signed in 1957 states that the objective of the EC is to “promote a 
harmonious and balanced development of economic activities, sustainable growth, a 
higher level of stability, the raising of the standard of living and a higher degree of 
cohesion among Member States” (Hiritis, pp.60-61). These objectives are to be achieved 
by setting and meeting targets for the various areas of activities and implementing a single 
market. The Single European Act enforced on 1 July 1987 incorporates into the Treaty of 
Rome the major achievements made to that date and includes a decision to establish a 
single market by Dec 31, 1992. The White Paper that provides a basis for implementation 
states that “in order to create a Single European Market, the physical, technical and fiscal 
obstacles must be removed” (Palánkai, 1999., p.85.). This includes: 
• Removal of physical obstacles to the free movement of goods, persons, services 
and capital. This target was achieved in several steps, including the Schengen 
Agreement concluded in 1985. 
• The adoption of rules on fair competition 
• Removal of technical obstacles, the approximation of laws to the extent required 
for the completion of the common market. This includes the mandatory mutual 
recognition of national standards and specifications, the mandatory European 
harmonization and standardization of the rules providing for consistent standards, 
and the mandatory Community notification procedure before the adoption of a new 
standard or specification. In practical terms, this includes production and product 
standards, regulations and directives. 
• Establishment of a taxation system approximate to indirect taxation, which serves 
the purposes of the market. This includes the harmonization of VAT and business 
taxation.  
 
The above objectives are to be met through two different policy-making processes. At an 
all-EU level, on the one hand, and through a harmonized policy-making in the respective 
Member States, on the other. Common policy-making is particularly important in the 
following areas: 
• Agriculture, transport and trade. In terms of trade, this includes the removal of 
quantitative restrictions and customs duties to ensure the free movement of goods 
and services within the Community, and the creation of a common trade policy by 
specifying common customs duties for imports from third countries. 
• The removal of barriers to the free movement of factors of production within the 
Community. As a result, the goods, services and factors of production market will 
grow which will improve the division of labor in resource allocation and exchange. 
If possible, the Community “should meet this objective under the conditions of 
free market and free trade. /…/ More specifically, in view of the provisions of the 
EC Treaties competition is a mere means to achieve a well-defined end.” (Hiritis, 
p.62) 
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The European Council was established following the Paris Summit in 1974 “in order to 
facilitate the Heads of State and Government to discuss Community issues on a regular 
basis, in a sincere and less formal atmosphere, which is indispensable for the development 
of European integration.” (Palánkai, 1999, p.193.). In theory, the Council is the principal 
decision-making body of the European Union, but actually the entire Union operates via 
summits and the most important decisions are taken in summits, Palánkai (1999, p.195.) 
points out in summary of the role of the Council nowadays. Under the Treaty of Rome, the 
European Union Council and the European Commission were established in 1965 (Merger 
Treaty 1965). The European Union Council is the primary but not exclusive body of 
legislation. It is where high-level meetings of the Member States take place and it is 
responsible to determine the budget. The Commission is the supranational body of the 
European Union and responsible to embody Community interests and policies. (Palánkai, 
1999, p.209.) The drafters of the Treaty of Rome imagined the “Commission as an 
international ‘group of planners’ responsible to plan ways to meet the objectives identified 
in the Treaty of Rome.” (Halm-Kőrösi, (ed.), 1996, p.40.) Up to its reform in 1999, the 
Commission performed its duties through Directorates-General (DG). It was DG III, the 
Directorate-General for Industrial Affairs that studied and analyzed competition and 
drafted recommendations. As a first step of the reforms in 1999, the Directorates-General, 
referred to by Roman numerals before, were given comprehensible names and partly 
restructured. The Commission plays a key role in legislation. Hiritis (1995) and Palánkai 
(1999) divide its powers into the following groups:  
 
Initiate Community measures 
The Commission has the power to initiate measures in all the areas of common policy-
making. This includes the initiation of strategies and the planning of detailed measures to 
adopt them. The Commission adopts implementation rules for Treaty provisions and 
European Union Council regulations to carry out the various policies. This power of the 
Commission is so strong that, in practical terms, the Council is not authorized to formulate 
legislation on issues on which the Commission submitted no proposal. 
 
Executive body of the Community, guardian of the Treaties 
The Commission is guarding the Community and ensures that Treaty provisions and 
Community decisions are enforced by the Member States. As a consequence, it ensures 
that Treaty provisions are applied to specific cases involving governments, companies and 
persons. It has the power to apply the “exemption clause”, that is to grant exemption from 
the provisions of the Treaties for a limited period of time in exceptional cases. If 
necessary, the Commission may turn to the Court of Justice to enforce Community 
decisions. In order to enforce Community decisions, the Commission has certain 
administrative and limited decision-making powers to manage Community funds 
including the European Regional Development Fund, the Cohesion Fund and PHARE, 
which is the main financial instrument for Central and Eastern European Countries. 
 
Setting norms 
The Commission can set norms primarily for the implementation of the regulations passed 
by the European Union Council, and also has legislative powers in its own right. It issued 
a great number of regulations, directives or decisions especially in the first stage of 
European integration and during the creation of the single market. Recently, its executive 
and control functions have become dominant.  
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Role in budgeting 
Next to planning the budget, the Commission has the authority to keep control of the 
revenue side of the budget. In terms of expenditure, it is less clear what role the 
Commission plays as different principles apply to the management of the different EU 
funds.  
 
Representative capacity  
In its role, the Commission represents the European Union in international organizations 
(e.g. WTO, OECD) and it also acts on behalf of the Union in negotiations for example on 
international trade.  
 
The above roles suggest that holding powers of initiation, norm setting and execution, the 
Commission plays a major part in EU competitiveness. Thus the reports, directives and 
regulations issued by the Commission have a major influence on the competitiveness of 
the EU, including that of the individual industries in the single market.  
 
 
3.2. Policies and programs supporting competitiveness  
 
In this section I will focus on four of the EU policies that, in my view, play a major role in 
competitiveness: the single market, trade policy, industrial policy and regional policy.  
 
 
3.2.1. The Single Market 
 
As for a single market, the Treaty of Rome states “the objectives will be met by creating a 
single market and continuously approximating the economic policies of the Member 
States”. The market forces however, failed to create a single market. /…/ The internal 
market was completed as a direct act, following the adoption of the Single European Act 
in 1992, 35 years after the Treaty of Rome.” (Hiritis, 1995, p.70) There are two 
requirements for a single market to operate: 
• The removal of the barriers to the trade of goods, services and factors of 
production and 
• Common rules to regulate competition. 
 
Below 9 will study the first requirement in more detail and address the potential benefits 
of the single market. 
 
Eliminating customs duties and non-tariff barriers can achieve the free movement of 
goods among the Member States. The abolition of customs duties and quantitative 
restrictions, as well as the adoption of common tariffs was a major step in this respect. 
However, as a result of different taxation procedures in the Member States, several non-
tariff barriers such as product, technical, security, health care, environmental and 
consumer protection standards remained and revived. For this reason, Hiritis (1995, pp.70-
71) maintains that the creation of a single market requires a firm legal background and 
efficient law enforcement which facilitates  
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• The elimination of technical obstacles to a single market, 
• The approximation of the different taxation systems and tax rates, and 
• Mutual recognition of internal standards that only has to comply with basic health 
care and security harmonization requirements. 
Similarly to single market objectives, these considerations are not only important in terms 
of goods and services but also in terms of capital and workforce.  
 
Analyzing the benefits of the single market, Hiritis (1995) identified two groups of cost-
increasing obstacles to an efficient single market: customs duties and non-tariff barriers 
and barriers to entry the market. In line with the reasoning of microeconomics, a further 
reduction or elimination of those barriers would probably cut back costs. A reduction in 
costs would stem from the presupposition that if competition grows the allocation of 
resources become more efficient, which could set the basis for a more efficient use of 
economies of scale. As a result, production and exchange would specialize according to 
comparative advantage and the access to innovations and new procedures would become 
easier. A cutback on costs could probably result in a restructured production and trade of 
goods within the EU, improved efficiency and increased production. As a consequence of 
improved competitiveness, the EU could show a better performance in international terms.  
 
As it is rather complicated to quantify and forecast the total benefits that the above factors 
would provide in terms of finances and time, one can only give a rough estimate. The EU 
prepared impact studies on the common market from three different aspects (Hiritis, 1995, 
pp.79-86, Palánkai 1999, pp.923-102). In retrospect, I agree with these studies that very 
rightfully presuppose that although the introduction of a single market precedes the 
introduction of a common currency, it can only be completed under the stable 
circumstances of the European Monetary System.  
• Based on the theory of partial equilibrium, the impact studies looked into the static 
impacts that the elimination of price differences had on welfare, following the 
abolition of the above tariffs and non-tariff barriers. The studies addressed all the 
observed obstacles to market operation and all economic sectors.  
• They provided a model of the effects that cost-increasing trade barriers made on 
the economic output of the Member States at large and on integration. The study 
reviewed the increased efficiency of technology and the quasi-dynamic impacts of 
X-efficiency, that is the elimination of insufficient organizational and 
technological structures that are incapable of optimization and give away 
inefficiency. The research also addressed the increased assortments of goods and 
services that came as a result of the elimination of oligopolistic profit and better 
market access.  
They also addressed the impact of total active and passive macroeconomic policies 
resulting from the complete integration of the EU market on the EU’s GDP.   
 
To the best of my knowledge, no similar impact study on Hungary’s accession was carried 
out in Hungary. For that reason, I will quote Hiritis to review the model that analyses the 
impacts of the single market on the Member States. The study started out from the 
following presumptions: 
• Domestic supply is as competitive as that of the other Member States, this way 
there are no Member State has a comparative advantage. 
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• The direct costs of competitive import immediately drop after market opening and 
foreign producers cut their prices. 
 
Fig. 3.1 shows the process and results of adjustment where D stands for the demand of Z 
country. Pb represents price before the elimination of the obstacles, and Qb stands for 
balance quantity of goods. In order to stay competitive, domestic producers cut profit and 
wages (area A), and improve organizational efficiency i.e. X-efficiency (reduce 
administrative costs, dismiss redundant workforce and stocks etc., area B). As prices drop 
below Pb, demand rises above the original Qb. This increase in demand encourages 
domestic and foreign producers to make new investments. New investments and mergers 
result in the restructuring of the industry, which will encourage exploiting the benefits of 
economies of scale and further cut costs and prices in the long run (area C). Finally, price 
drops to Pc, and total demand rises to Qc. 
 
Figure 3.1 The impacts of the elimination of trade barriers in Member State Z of the  
Community 
Price
0 Quantity
A
B
C
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Qb Qc
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Source: Hiritis, 1995., p.82. 
 
The above model suggests that the single market intensifies competition that improves the 
efficiency of the Member States in three fields: 
• Adjustment to more efficient players in the market. (In practical terms, an 
intensified import competition forces the Member States to adjust, see area A). 
• Improved organizational efficiency of domestic companies (see area A). 
• The optimalization of factors of production leads to a better exploitation of the 
benefits of the economies of scale. (see area C). 
 
To sum up, the single market serves two purposes in terms of EU competitiveness. First, a 
larger single market improves the external efficiency of EU businesses by encouraging 
exploiting the economies of scale and comparative advantages. Second, the single market 
makes the EU an attractive place for foreign direct investment (FDI) that can bring 
considerable benefits for the EU through technology and knowledge transfer capital 
investments and new jobs.  
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As a matter of fact, it took rather long for the single market to be completed. The process 
had three stages. The first stage covers the period between 1958, the signature of the 
Treaty of Rome and 1968. During those years the customs union was completed and 
quantitative restrictions trade among the Member States were eliminated. The second 
stage covers the period 1968–1992 when the single market was elaborated and completed. 
The third stage started in 1993 and includes measures not accomplished, the improvement 
of the single market and the actual dovetailing of the national markets.  
 
In 1988 the government of Hungary passed its first resolution (No. 2023/1988/HT8/MT) 
on the need to adjust to the internal market of the Community. This resolution primarily 
provided for orientation and informing those interested as well as a step-by-step 
adjustment in the required fields. Thereafter, Resolution No. 2004/1995(I.20.) of the 
Hungarian Government represented the most important step in the process. It provided for 
the adoption of the law related to the EC single market and called for the development of a 
preparatory program. The model outlined above would presumably have the same impacts 
on Hungary’s economy as well, in the long run. It could be rather useful to quantify what 
we mean by “the long run” in terms of years, however, that would require a more specific 
analysis addressing the individual fields of economy: Which areas would enjoy the 
benefits and suffer from the drawbacks? How would they affect the domestic and non-EU 
trade relations of the Hungarian businesses? 
 
 
3.2.3. Trade policy 
 
The EU is based on the principle of free trade as it is built upon   a customs union among 
the Member States. As part of the customs union no customs duties are imposed on the 
trade between the Member States, whereas for non-EU countries common customs duties 
are levied. Thus trade policy addresses the issues of trade between the EU Member States 
as well as the common policies and measures to be applied to non-EU countries. The 
content of trade policy is not defined. “Common trade policy is developed according to 
common fundamental principles for the following areas: modification of tariffs, 
conclusion of agreements on tariffs and trade, harmonization of measures on 
liberalization, export policy, and trade protection measures including dumping and 
subsidies.” (Izikné, 1995, p.115). Trade policy covers the following areas: customs policy, 
exemption from duty for Member States, common tariffs for non-EU countries, the 
prohibition of imposing quantitative import and export barriers and the restriction of trade 
monopolies which adversely affect the internal market. The scope of trade policy, 
however, does not include the regulation of the following issues: the internal market, 
particularly non-tariff barriers, foreign currency policy and trade in agricultural products. 
Questions on the application of trade policy come to the forefront in particular when new 
Members are admitted and trade relations expand.  
 
Economic arguments in favor of free trade support the implementation of a liberal trade 
policy. Advanced industrialized countries, however, argue for an interventionist trade 
policy. Their arguments are as follows: sustain and encourage efficient industries, support 
and protect strategic industries like high technology, adapt to the special features of 
handicapped industries such as agriculture and protect the industries that are of high 
importance for national security and defense.  
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The most typical arguments for protectionism (the application of customs duties and non-
tariff barriers) include: 
• a lasting deficit of balance of trade causes macroeconomic problems, 
• The  growth unemployment that requires a high budget and social costs  
• Changes in exchange rates result in the instability of exchange rates 
• Unfair trading practice in other countries 
• Application a strategic trade policy to protect the domestic industries from the  
inefficient international markets, the impacts of excessive business profit and 
externalities. 
• Shelter the developing industries 
 
Owing to the achievements of GATT/WTO, the rate of protectionism considerably 
decreased. At the same time, the scope of non-tariff barriers expanded, which is referred 
to as new protectionism. 
 
The above issues require the EU to formulate a common trade policy by considering all 
those criteria that are applied differently to the different countries.  These issues fall in the 
scope of trade policy and the single market. In the narrower sense, trade policy includes 
the application of tariffs and quantitative quotas with non-EU countries, as well as related 
principles and the enforcement of those principles.  
 
In connection with trade policy, 9 have to mention past and present relations with the 
Central and East-European region, too. There had been no trade agreement between the 
EC and the COMECON as the COMECON refused to recognize the Community as a 
trading unit. The EC, however, argued that to conclude such an agreement the 
COMECON should have been supranational in nature. Eventually, a joint statement was 
signed in 1988 on the resumption of official ties between the EC and the COMECON. In 
trade policy, bilateral trade and cooperation agreements were typical. In the wake of the 
political changeover in 1989-90, Central and East-European countries expressed their 
request for EU integration, materialized in the form of association agreements.  
 
 
3.3.3. Industrial policy 
 
Török-Zsarnay (1996, p.220) points out that “the EC never had an industrial policy as 
such. This rather strong statement does not only suggest that compared to its policies on 
agriculture, the other principal sector, the Community failed to formulate a common 
policy on industry including objectives and measures. In fact, it means that there is no 
such thing as common industrial policy.” At the level of intentions, however, the issue of 
industrial policy was brought up several times.  
 
A review by Hiritis (1995) suggests that economic circumstances in the 1950s and 60s, at 
the time of the establishment of the EC supported a laissez-faire industrial policy. For this 
reason, no reference was made in the Treaty of Rome to the need for an industrial policy. 
That time the purposes of integration were supported by the fact that the Member States 
opened up their market to competition and established a base for a common industry. 
These steps can be nold as first steps towards the single market.  Late in the 1960s, 
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priorities were identified for the first common action program and laid down in the 
Memorandum of Industrial Policy. The memorandum proposed to develop an industrial 
policy that serves the purposes of economic growth and technological development in the 
frame of a European industry. The proposals were adopted in 1973 and, in fact, hardly had 
any effects. They included five major areas (Hiritis, pp.294-296): 
• Establish a common market by removing barriers to intra-Community trade. 
• Harmonize law, taxation and finance as well as grant the right of undertaking. This 
should be used as a basis for the development of a European Company Law. This 
way companies would be formed in accordance with Community law rather than 
that of the respective Member Provide active support for intra-Community mergers 
to help European companies meet common market requirements and maintain a 
competitive position towards non-EU companies. 
• Improve methods of management to help the companies smoothly adjust to 
changing industrial and employment conditions. 
• Build a shared attitude and establish solidarity in the Community against external 
competition. In addition, elaborate a Community funded Research and 
Development scheme, involving all Europe.  
 
Ideas on an active industrial policy began to materialize in December 1982, followed by 
the drafting of memoranda with specific details. Then a proposal was made to protect the 
industries endangered by international competition, including the steel, textile, clothing, 
shipbuilding and car industry and promote the development of high-tech industries. Also, 
an agreement was made on the need to strengthen the internal market, speed up industrial 
research and set aside greater reserves for investments in industry, high technology and 
energy management.  
 
At the same time as the Member States drew up their memorandum, in 1983 and 1987 the 
European Roundtable of Industrialists (ERI), a lobby group consisting of the CEOs and 
presidents of the major European corporations recommended programs for a common 
industrial policy. A key element of the programs was the creation of a single market. It 
appears that it was the establishment of a single market rather than EC proposals and 
programs that brought about the adjustment of the European industrial structure and 
enterprises at an EC level: a great number of enterprises joined the supranational 
associations of the EC, established joint ventures with companies from other Member 
States, international mergers and acquisitions took place, and at the same time SMEs 
entered a closer cooperation with large companies to survive.  
 
The purpose of the EU’s industrial strategy is to improve the business environment. In 
order to do so, the EU encourages integrating the European market and making any 
necessary changes in the industrial structure. A great number of integrated research 
programs were launched to help the EU catch up with the Unites States and Japan in terms 
of state-of-the-art technology, production and trade. The most problematic areas of 
industrial policy are as follows: the lack of consistency and coordination of measures by 
the Member States, an increasing international competition, the restructuring and renewal 
of the industry as a follow-up to rapid development of technology.  
 
Török-Zsarnay (1996, p.220.) points out “the notion of common industrial policy, 
although not in the traditional sense of the word, first appeared in the Maastricht Treaty. 
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/…/ The most significant intent was to improve the competitiveness of Community 
products, as earlier national industry political measures had failed to do so. To this end, a 
more suitable economic environment had to be developed within the Community to 
protect national efforts and strengthen the Community at large in terms of economy”. It 
appears that a competitiveness approach prevailed in industrial policy. A review by 
Csernenszky (1998) suggests that some of the objectives stated in the Maastricht Treaty 
such as restructuring, the improvement of enterprise environment as well as a better 
exploitation of the industrial potential relying on technological and scientific 
developments may be considered as competitiveness policy objectives. From 1994 efforts 
were made to strengthen horizontal policies related to R&D, environment protection and 
SMEs.  
 
As part of the institutional reforms of the Commission in 1999, the organization of the EU 
was restructured. The new structure enforced on January 1, 2000 reflects a 
competitiveness approach as well. The newly formed Enterprise DG is responsible to 
integrate industry, SMEs, innovation areas and their former DGs. The Enterprise DG is 
committed to “supporting a business environment that supports the European enterprises 
fully exploit their potential, supporting economic growth and job creation within the 
European Union.” (EC 2000b). The Enterprise DG consists of the following directorates: 
• Enterprise Policy 
• Promotion of entrepreneurship and SMEs 
• Innovation 
• Services, commerce, tourism 
• Environmental aspects of enterprise policy, specific industries 
• Single market, regulatory environment, industries under vertical legislation 
• Conformity and standardization, new approach, industries under new approach 
 
In the course of the operation of the EU, there has been a shift in focus in the industrial 
policy. In the 1990s, commitment to improving the competitiveness of the industry was 
given high priority. This intention was reflected in the restructuring of the DGs within the 
Commission. It appears that the leading corporations and their lobby groups had a major 
part to play in developing, implementing and identifying priorities for industry policy. 
 
 
3.3. The EU’s approach to competitiveness 
 
On the one hand, the EU’s approach to competitiveness covers the entire EU. This 
suggests that competitiveness for the European Union includes assessing the 
competitiveness of the EU as an economic region, and drafting related EU policies. On the 
other hand, the fact that the EU’s economic integration is composed of national economies 
brings about problems and impacts that do not occur with a nation state or a federation 
such as the United States. Experience with single markets shows that a structure composed 
of nation states requires a longer time for adjustment and the special decision-making 
mechanism of the EU drags the process further out. 
 
In December 1993, the European Council adopted a White Paper on competitiveness, 
entitled “Growth, Competition and Employment”. The Paper discussed the issue of 
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industrial development from the perspectives of global competitiveness; factors generated 
growth, and employment. In response to the Paper, the Commission issued a great number 
of reports and proposals and, as a result, a decision (EC 1996c) was passed in 1996 to 
make a report on EU competitiveness every year.  
 
According to the Commission (EC 1996c), the competitiveness of the European industry 
is a prerequisite for sustainable economic growth and it contributes to the EU’s economic 
and social cohesion by creating jobs. Fundamental action program principles designed to 
improve the competitiveness of the industry include: 
• Renew intangible investment, industrial cooperation as well as the industrial 
aspects of competition. Update the role the authorities play. 
• Promote the establishment of a learning society, in particular by supporting life-
long learning. 
• Support industrial cooperation in specific situations with countries in the following 
regions: Central and Eastern Europe, Baltic states, CIS countries, the 
Mediterranean region, Latin-America, Asia, ACP and South-Africa. 
• Strengthen and deepen relations between the EU and the US by improving Trans-
Atlantic Business Dialogue.  
• In cooperation with the directorate in change of trade policy, the qualified national 
authorities and the industry put together a database that lists the obstacles to be 
overcome in third countries by the European enterprises. 
• Study the relocation of industry and services, and report to the DG for Industry on 
the findings. 
• Improve the operation of the single market, particularly by speeding up 
standardization procedures and supporting Member States initiatives to remove 
barriers to intra-Community trade between the enterprises.  
• Analyze and strengthen complementarities between industrial activities and 
complementary services.  
• Make a report on the competitiveness of the European industry each year.  
• Provide a regular report to the DG for Industry on the current action program and 
the adjustments to be made in the following years.   
 
A report made in 1996 on the competitiveness of the European industry addresses eight 
areas (EC 1996b). On analyzing the individual areas, the report used descriptive statistics 
for each EU Member State. As for EU statistics, the EU average served as a basis for 
comparison. As for international statistics, Japan and the US were used as point of 
reference. The areas under scrutiny include: 
 
Performance of the European economy 
This chapter starts with an analysis of living standards in the EU. The analysis starts out 
from the presumption that living standards are determined by two factors: employment 
rate and productivity. The section attempts to decompose the two factors by analyzing 
capital-productivity, workforce, investment and taxation practices. 
 
Performance of the European industry 
This chapter asserts that the performance of the European industry depends on the 
performance of the enterprises. Therefore priority has to be given to the identification of 
mechanisms that establish a relation between enterprise competitiveness and 
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macroeconomic performance by converting enterprise performance into high growth, 
improved productivity and job creation. Accordingly, the chapter provides an analysis of 
the EU enterprises (a breakdown of enterprises by size, an analysis of their performance), 
followed by a breakdown by sectors, an analysis of the performance of technology, and 
finally an assessment of the enterprise profitability. 
 
Internationalization 
This chapter studies two domains including trade performance and foreign direct 
investment (FDI). The analysis of trade performance addresses export and import relations 
as well as comparative advantage. The section on foreign direct investment studies the EU 
stake in the world FDI, the size, the origin and destination of inwards and outward FDI. 
 
Labor markets 
The section provides a breakdown of the labor market by employment rate and 
employment composition. It also addresses employment costs and wages as well as 
workforce mobility and flexibility. 
 
Corporate finance  
Sources, composition and related expenses of corporate funding (retained earnings, new 
equity and debt) are discussed. The chapter includes a comparison of corporate funding 
within the EU. 
 
The operation and competition of markets for services  
This chapter provides a breakdown of services by sectors including telecommunications, 
transport, energy and business services. Business services are considered important 
competitive clusters including professional (e.g. legal, accounting services), technical (e.g. 
quality control), operational (e.g. cleaning, office services) and marketing services (e.g. 
advertising, market research, fairs and exhibitions). 
 
Intangible investments 
The report studies the application of knowledge and skills. It addresses Research and 
development, achievements, patents and human resources. 
 
Organizational and product innovation 
The chapter studies innovations from the perspective of organizations and products. 
Accordingly, the organizational and management solutions including lean-management, 
TQM, and just-in-time methods that improve operation are regarded as organizational 
innovations. To measure operational efficiency, the analysis uses sales growth per capita. 
As for product innovation, the chapter reviews the following areas: making a product 
more appealing, speed of new product development, cutting the payback period, and the 
rate of new products. The section also addresses the sources of innovations (own, co-
operative) and provides an analysis of the diffusion as well as issues of financing and 
institutions.  
 
Environment 
The chapter focuses on requirements related to environmental protection, the costs 
involved and some features of the environmental protection as a sector. It also addresses 
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the relations between environmental protection and market efficiency, as well as 
environmental protection and innovations. 
 
 
The structure outlined above is in accordance with the competitiveness approach set for 
the European industry (EU 1996c). According to this approach, competitiveness can be 
interpreted as a pyramid (see Figure 3.2 below). This Table is in line with the concept 
developed by the European Roundtable of Industrialists in 1996, which relied on a similar 
approach for enterprises and regions. Both concepts propose to make benchmarking, 
identify and measure points of reference as well as analyze and follow-up on best practice. 
The same approach is applied by the Fifth research and technological program (EC 1999b 
and EC 2000a) designed to improve the competitiveness of the European industry for 
1998-2002. 
 
Figure 3.2 Competitiveness pyramid of the European Union 
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Source: EC, 1996, p.9. 
 
Living standards are placed at the top of the European Union’s competitiveness pyramid 
suggesting that competitiveness has to improve the EU citizens’ living standards. 
According to this approach, the improvement of living standards are in fact determined by 
two factors: employment rate and productivity. This implies that a policy aimed at 
improving competitiveness is expected to create jobs and improve productivity at the same 
time. The left hand side of the Table shows a breakdown of the employment rate, 
highlighting the major macroeconomic factors affecting employment and the relations 
among them. The right hand side of the Table summarizes the factors affecting 
productivity. Decomposing productivity puts the micro level into the focus of productivity 
improvement, as Porter (1990), Dertozous et al (1989) and Scott-Lodge (1985) 
emphasized. The listed categories primarily include business categories. Nevertheless, 
they are interchangeable and measurable within certain limits at both macro and micro 
level. This approach suggests that productivity is primarily determined by two factors: 
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market and financial performance, influenced by intangible investments, innovations, 
fixed capital investments and infrastructure. We must stress at this point that giving high 
priority to intangible investments and innovations is a sign of the intention to establish and 
improve a knowledge-based economy and society. 
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3.4. Summary 
 
 To sum up, the European Union’s approach to competitiveness includes the following: 
 
In the global economy EU should maintain its competitiveness toward the U.S., Japan and 
the Far East. So the aim of the EU is to maintain its position and sustain its economic 
performance towards those regions, particularly the other two major members of the 
Triad. As an economic integration, the European Union represents a new tier in world 
economy. 
 
Under the Treaty of Rome, the Member States established the European Community 
because they were “committed to paving the way for an ever closer union among the 
peoples of Europe and securing the economic and social growth by the removal of the 
barriers dividing Europe through joint action. They confirm that the primary objective of 
their efforts is to continuously improve the living and working conditions of their people.” 
(Hiritis, 1995 p.62.). This intention is crucial, as competitiveness should be considered to 
be a means of implementation rather than an end in itself. This approach is reflected in the 
fact that sustainable development and job creation are central to EU competitiveness.  
 
The competitiveness of the EU is supported by several EU policies in an indirect way, 
including the single market, trade policy and industry policy. These policies are primarily 
there to improve the efficiency of the EU’s economy as a whole, and sustain and 
strengthen its world economic position. In terms of competitiveness, these policies reflect 
the intention to improve the conditions of internal, intra-Community operation and thus 
pave the way for increasing competitiveness outside the EU.  
 
In strengthening the EU’s competitiveness, the improvement of industrial competitiveness 
is given high priority. It is treated as a key issue by the General Directorates, especially in 
the field of industry policy and from the beginning of 2000 by the Enterpriser DG. 
Competitiveness Supported by the Fifth research program rendering projects and 
resources for it. 
 
In terms of competitiveness, the EU’s approach to industry does not use the traditional 
breakdown by sectors. There is a tendency to support the competitiveness of the 
companies that do industry and services. The traditional approach based on a breakdown 
by sectors is important for the sectors that are either problematic or critical from a 
competitiveness point of view. That approach is akin to US competitiveness approaches. 
 
EU programs and proposals on competitiveness advise to study and diffuse the best 
practice and methods, and identify benchmarks for the monitoring of competitiveness. 
This can be relevant for the Hungarian economy, as competitiveness criteria are included 
among the accession requirements to be met by Central and Eastern Europe an countries. 
However, since no considerable methodological progress has been made in this field, it is 
rather difficult to judge whether or not the requirements are met. 
 
 53
Bibliography 
Blahó András – Juhász László (2000) Európai Unió intézményrendszere (Institutions of 
EU), in Blahó András (szerk.) Tanuljunk Európát (Let`s Learn Europe!), Budapest, pp.28-
51. 
Blahó András – Palánkai Tibor – Rahói Zsuzsanna (2000) Az Európai Unió és a Kelet-
Közép-Európai átalakulási folyamatok (The EU and the Central and East European 
transition), in Blahó András (szerk) Tanuljunk Európát (Let`s Learn Europe!), Budapest, 
pp.264-296. 
Blahó András – Palánkai Tibor (2000) Az Európai Unió struktúrapolitikája (Structural 
Policy of EU), in. Blahó András (szerk.) Tanuljunk Európát, Budapest, pp.71-102. 
Blahó András  (szerk) (2000) Tanuljunk Európát (Let`s Learn Europe!), Budapest 
Csernenszky László (1998) Az Európai közösségi jogrend Iparpolitika címmel megjelölt 
részének átvilágítása (The Industrial Policy in the EU Law), Iparpolitika szemle, 4.szám, 
pp.4-6. 
Dertouzous et.al. (1987) Made in America, Harper Perennial, New York 
EC (1994) 394Y1206(01) Council Resolution of 21 November 1994 on the Strenghtening 
of the competitiveness of Community industry, http://www.europa.eu.int 
EC (1996a) The Commission`s Work Program for 1996, http://www.europa.eu.int 
EC (1996b) The Competitiveness of European Industry, Working Document of 
Commission Services, Brussels 
EC (1996c): 96/413/EC: Council Decision of 25 June 1996 on the Implementation of 
Community Action Program to Strenghten the Competitiveness of European Industry, 
http://www.europa.eu.int 
EC (1999a) The Commission`s Work Program for 1999. The Policy Priorities, 
http://www.europa.eu.int 
EC (1999b) Council Decision of 25 January 1999 Adopting a Specific Program for 
Research and Technological Development, Including Demonstration, to be Carried out by 
Means of Direct Actions for the European Community (1998 to 2000) by the Joint 
Research Centre, 1999/174/EC. http://www.europa.eu.int 
EC (2000a) Communication from the Commission to the European Parliament, the 
Council, the Economic and Social Committee and the Committee of the Regions. Strategic 
Objectives 2000-2005. Shaping the New Europe, Brussels, 9.2.2000. COM(2000) 154 
final, http://www.europa.eu.int 
EC (2000b) The new Enterprise DG has been created with effect from 1st January 2000, 
by merging the old directorates-general for industry, SMEs, and the innovation directorate 
form the Information Society DG, http://www.europa.eu.int 
ERT (1996) Benchmarking for Policy Makers. The Way to Competitiveness, Growth and 
Job Creation, European Round Table of Industrialists (ERT), Brussels, October 
EU (1996) Benchmarking the Competitiveness of European industry, Brussels – 
Luxembourg 
 54
Farkas György (1996) Magyar vállalatok felkészültsége (Preparedness of Hungarian 
Companies). Tapasztalatok és problémák az EK-csatlakozással kapcsolatban (Experiences 
and Problems on the Accession), in. Inotai András – Tamás Pál (szerk.) Európai Politikai 
Évkönyv, 1995-1996. Magyar Tudományos Akadémia, Budapest, pp.127-143 
Farkas György, dr. (1999) A magyar EU-integráció és a csatlakozás közeledése: 
alkalmazkodási sajátosságok a vállalkozói szférában (The EU-integration of Hungary and 
the Aproach of Accession: Adjustment of Businesses), Miniszterelnöki Hivatal Integrációs 
Stratégiai Munkacsoportja, Budapest  
Halm Tamás – Kőrösi István (szerk) (1996) Európáról a katedrán. Középiskolai tanári 
kézikönyv az Európai Unióról és Magyarország csatlakozásáról (About Europe in 
Sschools. Manuals on the EU and Accession of Hungary), Euro Info Service, Budapest 
Hargitai Árpádné – Izikné Hedri Gabriella – Palánkai Tibor (szerk) (1995) Európa 
Zsebkönyv. Az Európai Unió és Magyarország (Europe in Brief. The EU and Hungary.), 
Euration Budapest – Hanns Seidel Alapítvány 
Hiritis, T.(1995) Az Európai Unió gazdaságtana (European Community Economics), 
Műszaki Könyvkiadó, Budapest 
Inotai András-Tamás Pál (szerk) (1996) Európai Politikai Évkönyv, 1995-1996. (The EU 
Yearbook, 1995-1996), Magyar Tudományos Akadémia, Budapest 
Izikné Hedri Gabriella (1995) Kereskedelempolitika (Trade Policy), in Hargitai Árpádné 
et.al. (1995), pp. 110-113 
Kovács Zoltán Ákos (1996) Magyarország és az Európai Unió: a külkereskedelmi 
forgalom dinamikája és áruszerkezete (Hungary and the EU: Dynamism and Structure of 
the Foreign Trade), in. Inotai András – Tamás Pál (szerk.) Európai Politikai Évkönyv, 
1995-1996., Magyar Tudományos Akadémia, Budapest, pp. 173-191. 
Palánkai Tibor (1999) Az európai integráció gazdaságtan (Economics of the European 
Integration), Aula Könyvkiadó, Budapest 
Porter M.E. (1990) Competitive Advantage of Nations, The Free Press, New York  
Scott B. R. – Lodge G. C. (1985) U.S. Competitiveness in the World Economy, Harvard 
Business School Press 
Török Ádám – Zsarnay Judit (1996) Az Európai Unió struktúrapolitikája, 
versenyszabályozása és a recesszió várható iparpolitikai hatása (EU Structural Policy, 
Competition Policy and the Probable Effect of Depression on Industry Policy), in Inotai 
András – Tamás Pál (szerk.) Európai Politikai Évkönyv, 1995-1996., Magyar 
Tudományos Akadémia, Budapest, pp. 220-242. 
 
 55
4. Some research findings about the Hungarian competitiveness 
 
In this chapter I review the research done in Hungary in connection with competitiveness. 
The goal is to show the novelties brought in Hungarian research by the competitiveness 
research in the framework of  „In global competition” research program. As the review 
written by Szamuely and Csaba (1998) about post-war economic research issues in 
Hungary could not give us a full view of Hungarian economic research, I do not find any 
means to do it so either. The writers reviewed research and results concerning the 
investigation of the „macroeconomic system and the views and perceptions in connection 
with it, and the development of theories that are sometimes closely connected with 
practice” (Szamuely-Csaba, 1998,p.8). As the writers emphasize, the survey of textbooks 
used in higher education and literature on enterprises cannot be found in their review. In 
the transition period of 1989-1996 many studies were written in these fields that 
established the approach and research of the Hungarian economy by market economy 
theories. In their review the authors divide the 1945-1996 periods into two parts. The first 
is the 1945-1970 period, which is actually finished by the first experience of the new 
economic mechanism. The second is the 1970-1996 period, which is the time of reforming 
socialism and creating market economy. Partly on the basis of the above quoted work, and 
partly on the basis of my own research I am prepared to outline that competitiveness 
research necessarily appeared in the middle of the 1990s, while the transition was going 
on in Hungary. The character of the Hungarian economy had raised some questions on 
foreign trade adjustment even earlier.  
 
The chapter consists of two parts. At first I review ideas formulated in connection with 
foreign trade and industry adjustment by the end of the 1980s. After that I give an account 
on the problems covered in the reviews of the 1990s. Admitting that research issues 
chosen at random are not unquestionable, there is a line formed by the reviewed literature, 
which shows that there was a transition in Hungarian research, as well. It came after 
practice in choosing, revealing and approaching the examined problems and it shows a 
close relationship with the research typical for market economies. One of its explanatory 
factors is the creation of market economy and appearance of its special problems. The 
other factor is the quick adaptation of knowledge necessary for this phenomenon. 
 
 
4.1 The world economy, foreign trade and industrial adjustment at the end 
of 1980s 
 
The Hungarian economy can be regarded as an open economy since World War I. As a 
consequence, economic research has almost always dealt with foreign trade relationships 
to a certain degree because of its practical relevance since then. In the approach of 
Szamuely and Csaba (1998) the investigation of foreign trade relationships in the period 
between 1945 and 1970 came up as a reference point of setting prices and a push for 
achievement of international level of performance. The basis of this approach was given 
by the article of Tibor Liska and Antal Máriás (1954) in the first issue of the newly 
launched Közgazdasági Szemle (Economic Review), who, in analysing the textile 
industry, argued for being align with world market prices as the case of such a little 
country like Hungary. Keeping in mind our topic the final event was perhaps the lecture of 
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Béla Balassa read at Marx Károly Közgazdaságtudományi Egyetem (Budapest University 
of Economics) in 1970.  
 
In the interpretation of Szamuely and Csaba the second period means the post-1970 era. 
After the reform of the new economic mechanism, especially in the 1980s, that approach 
became stronger which said that the Hungarian economy, because of its given size, could 
sustain the intensive growth just in case of integration into the world economy. 
Furthermore, in this period, which is after the oil price crises of the 1970s, it became clear 
that foreign trade both with the COMECON countries and with developed capitalist 
countries is essential for the Hungarian economy. The situation evolved by the political 
change in 1989 can be characterized by the works about foreign trade in which there were 
often critical analyses and suggestions in the works about world trade adjustment, which 
went beyond the horizon of national economy, limited by ideological taboos and 
government non-acceptance „because of the backwardness of practice and hopelessness of 
having changes”.(Szamuely-Csaba,1998,p.129) After that the authors analyze the works 
from the point of view of the economic reform. In the second half of the 1980s there were 
four fields where different ideas were formulated on changing the Hungarian economic 
reform in their system. These are the organizational reform, the reform of the monetary 
system, ownership reform, and the opening up foreign trade. Although realizing the ideas 
given in the studies below were practically not achievable until the political changes in 
1989, in the further part of this Chapter I emphasize those works which discussed the 
opening up foreign trade in the second half of the 1980s from different aspects, and which 
raised similar problems as it did the American competitiveness research approximately at 
the same time. My survey is arranged around three subjects, that is around world economy 
adjustment, questions of foreign trade, and approaches to industrial adjustment, taking into 
consideration that statements connected with competitiveness can be found in these fields. 
 
 
4.1.1. World economy adjustment 
 
As I have already shown it in the 2nd Chapter, one crucial element of competitiveness is 
adjustment. Work of Palánkai (1986), this book is not reviewed for Szamuely-Csaba 
(1998), examined the world economy adjustment of developed countries. In his book 
Palánkai employed inductive approach and, referring to articles describing the phenomena 
and other documents, gives us an overall picture of those factors which droved the 
adjustment of developed market economies and enterprises in the middle of the 1980s. 
Meanwhile he draws attention to some theoretical relations. The book drafts the 
theoretical framework of adjustment, then lists the main tendencies of company and 
national economy adjustment. At the end he discusses the main tendencies of international 
adjustment. 
 
He says in his introduction that „world economy adjustment is not a new task. It is of the 
same age as the existence of world economy. There has been a new situation in the recent 
world economy after the beginning of the 1970s. Compared to earlier times it requires 
grater intensity of adjustment, and solving more complicated problems./.../The adjustment 
to occurring problems from time to time has never been satisfying. In many aspects it had 
just started until the mid 1980s, like the structural modernization of the Hungarian 
industry.” (Palánkai, 1986, p.11) 
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Palánkai (1986) shows that the economic interpretation of adjustment referring to world 
economy is a novelty, while speaking about it in biology the situation is different. That is 
why he chooses a biological starting-point. From this point of view he interprets 
adjustment as „a modification of the qualities, structure and function of some organism 
which is caused by the external environment and its changes”( Palánkai, 1986, p.13). The 
adjustment makes the survival or the suitable operation certain. The must of adjustment 
and its process can be equally interpreted of the society and economy. The book interprets 
economic adjustment in the way given in Figure 4.1. It examines company adjustment 
from micro-level adjustment, and both the national and international adjustment from 
macro-level adjustment.  
 
Figure 4.1. A model of economic adjustment 
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Source:Palánkai, 1986, p14. 
 
 
 
The following characteristics of adjustment as an economic process are mentioned. 
(Palánkai, 1986, pp.19-22) 
• This interpretation starts from certain actors of the economy who are conscious 
and active. 
• It emphasizes actors' behavior. Their behaviors are formed by conscious 
recognition and assessment of environment and their subjective qualities. 
• In the classical economic theories market mechanisms adjust. 
• Adjustment is the object and category of applied economics. 
 
By his summary, in the 1980s the micro- (enterprise) and also the macro-level adjustment 
in the developed market economies are obtained by the following factors: 
• It is the second phase of the scientific - technical revolution when new, special 
materials and new sources of energy are employed, and application of computer 
technology is spreading. 
• After the oil price hikes natural resources got overestimated. 
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• World economy becomes more and more international. World trade and, 
dependence of each national economy on foreign trade grow. International 
corporations again bigger and bigger importance in the world economy, and  the 
international capital flow is increasing. At the same time global world economics 
problems have arisen. 
 
As a consequence of the above factors, the national economies became dependent on each 
other. So the crucial factor of their development and efficiency growth becomes their role 
in the international division of labor, sums it up Palánkai, (Palánkai, 1986, pp.32-37). 
 
We highlight the statements about enterprise adjustment in the book. (Plank, 1986, pp.76-
105): 
• Rapid technical and structural modernization can be seen because of fast product 
changes and the reduction of product life cycles. The same process can be seen in 
the system of productions, especially because of the influence of computer 
technology. 
• Enterprise reconstruction can be seen, especially after following the examples of 
Japanese companies. 
• Concentration, decentralization, and specialization become the means of world 
economy adjustment, which make the living space of little and intermediate 
companies bigger. 
• Market competition in oligopolistic markets becomes fierce, and it appears in 
many fields and sectors. 
• International cooperation among enterprises are increasing. 
• Appearance of the transnational industry structures can be seen. 
• Money and credit markets became even more international, and the number of 
players became more than before. 
 
With the reference to the national economy adjustment he draws attention to the fact that 
four factors became crucial: growth, structural change, inflation, and managing 
unemployment. To manage these problems new instruments of economic policy 
employed, like for example, investment instead of direct subsidies to encourage of 
modernization in structural policies, revitalization of privatization, and cutting back the 
welfare states’ former scope. In connection with the main ways of international 
adjustment he draws attention to the regional rearrangement following technical 
development. He points out the lagging of Western Europe and the United States behind 
Japan in the mid 1980s, and significant international cooperation takes place to change 
this situation. International institutions (like OECD, GATT, IMF, EEC) move to 
harmonizing their member-countries’ economic policies. These institutions also actively 
shape the institutional terms of international division of labor. For example, GATT plays 
an important role in the liberalization of international trade, and so does it in the shaping 
of new tendencies of trade policy. After presenting the developed countries adjustment 
tendencies, he also gives lessons for the Hungarian economy. Hungarian economy needs 
to be modernized technically. In that process intensive cooperation between enterprises, 
especially between the Hungarian and Western market economy companies, is vital. The 
adjustment of the Hungarian economy is inconceivable without additional capital 
investment. The author’s conclusion is that the key of successful intensive development 
among the above described world economy tendencies is how the Hungarian enterprises 
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would be able to join transnational industry structures. To be successful, improving 
conditions of joint ventures is of great importance. By Szamuely-Csaba (1998) András 
Inotai’s doctoral dissertation of 1990 also presents this thought. Palánkai formulates 
suggestions concerning the competitiveness of the Hungarian economy, which give a 
lesson about company productivity. Realization of these suggestions really harped upon 
the political frames of the Hungarian economy. 
 
 
4.1.2. Foreign trade adjustment 
 
In the review of Szamuely and Csaba (1998) works published about this topic touched the 
most the following fields: orientation of foreign trade (e.g. Kádár, 1979 and Inotai, 1980), 
comparative advantages and foreign trade (Török, 1986), foreign trade and its relationship 
with exchange rate policy (Riecke - Szalkai - Szász, 1985), and at last, investigating 
foreign trade, especially with the COMECON (e.g. studies of Köves, and Oblath). Works 
in how the practice of Hungarian foreign trade influenced the performance of the internal 
economy. 
 
The work of András Nagy (1977) can be considered as one of the keynotes of the 1980s. 
The book gives us a model and description of the international trade’s structural analysis, 
and a prognosis of the international trade’s flow. As research precedents, the author 
mentions the research done first in the KOPINT, between 1969 and 1973, then in MTA 
Közgazdaságtudományi Intézet (Hungarian Academy of Sciences, Institute of Economics) 
between 1973 and 1974. The author points out that the interest towards the whole of world 
trade incited in the 1970s gained more and more ground, besides the research reviewing 
bilateral and multilateral commerce of countries or zones. The reason of it, on the one 
hand, is the growing interest towards decisive factors of foreign trade, which became more 
important. On the other hand, there are 15-18-year-long periods for analysis at our 
disposal. When doing research, these analyses put emphasis on groups of products. 
Gravitation models did the first modeling approach. The goal of it was „first of all to make 
factors influencing the flow of world trade measurable. That is to make such a theory 
which can be verified by statistical observations.” It was a new approach in many respects 
that derived, or sometimes even opposed the "pure theory" of international trade. (Nagy, 
1977, p.29.) I picked out this work because it meant a sort of appeal for quantitative 
research of foreign trade relations. Later several such studies were written. 
 
The other also determining writing is the work of Botos (1982), which investigates the 
relationship of international competitiveness and price revolution. Perhaps this is the first 
book that expounds competitiveness systematically in Hungary in the area of Socialism. 
The basic premise of the book is that the fuel price shocks of 1973 and 1974 influenced 
heavily the world market prices, and such events could be made visible with long-run 
trends. The author tries to find out what characteristics the oil price shocks had on 
products and country groups. It deals also with the lesson given by statistical analyses 
concerning some countries. It defines the notion of competitiveness at the level of 
products and economy. In this sense the competitiveness at product level means that the 
company can enter the market with lower prices, better quality and better supply services 
than the competitors. For a long lasting, in the author’s opinion at least two of the three 
components should exist. Competitiveness at national level the most crucial point is if the 
 60
GDP grows or not on the basis of foreign trade. For having a positive foreign trade effect 
in the growth of GDP it is necessary to have a higher productivity, or expenditure lower 
endowments’ than in the competitors` countries. Botos, 1982, p.33). To measure 
competitiveness the author finds the price indices  (average change of products prices), the 
world market price indices (the price change of the most important products in world 
trade), and also the change of terms of trade index applicable. 
 
One important statement of the analysis concerning Hungary is that after the oil price 
shocks the Hungarian economy’s international competitiveness definitely started to 
decline. The reasons of it were the unfavorable changes in terms of trade, also the low 
productivity of labor, and the significant underdevelopment of technology. In the author’s 
opinion "we can not think of a significant improvement in the Hungarian economy’s 
competitiveness by the turn of the millennium, unless the situation changes in the respect 
of technological transfer and interest.” (Botos, 1982, p.169) We can learn from the 
international statistics that in the second half of the 1970s finished products’ prices rose 
more intensively, and the pace of the change of product structure and modernization was 
accelerated. To keep up with these two tendencies the author suggests different factors to 
improve effectiveness of company management: to improve solvency, a change in product 
line in a way to make the competitive products dominant, better employment of capacity, 
to improve cooperative relationships, keep deadlines, develop spare part supplies, improve 
after sales and customer of services. You can keep up with the changing environment just 
in case „if our economy keeps its openness, even if it temporarily seems to be 
disadvantageous in a given moment, if it improves its intellectual flexibility, and if it 
develops entrepreneurial skills”, says the author. (Botos, 1982, p.185) . This work came to 
the same conclusion as Palánkai (1986). That is to the necessity to create on openness 
economy. All in the entire author had suggestions at the beginning of the 1980s very 
similar to this day’s to improve competitiveness. The reason of it is that the author started 
from the price competitiveness and followed an economic reasoning. 
 
Debates over competitiveness in the 1980s can be divided into two parts. The first group 
includes works about the Hungarian economy’s openness, and the other one focuses on 
the productivity of economy, emphasizing the role of structural and company issues in the 
growth of export efficiency. The review of openness theories and debates can be found in 
Práger’s work (1998). He recalls the main issues in the light of joining the EU, and forms 
some questions of it on the basis of the home and international economic processes. The 
openness theories of the 1980s touched the following questions (Páger, 1998, p.1026): the 
degree of openness of the Hungarian economy, foreign relations, openness of politics, 
openness of human relationships, openness of cultural relationships, and at the end, 
openness of the country’s internal institutions and mechanisms. This approach asserts in 
the classification the fields of would-be changes to create economic openness. The 
analyses about foreign trade seemed to be extremely critical until the end of the 1980s. 
The course of apparent tendencies showed that the Hungarian economy’s vital interest was 
foreign economy and foreign trade openness. But the Hungarian economy was linked to 
COMECON, so its opportunities for further development were limited, and the attributes 
of the political and social system also contributed to it. 
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4.1.3. Industrial adjustment 
 
The formulation of proposals concerning industry is tightly connected with the research 
done in the Ipar- és Vállalatgazdasági Kutatóintézet (Research Institute of Industry and 
Enterprise Economics. The symptoms of weak industry, and means of their management 
to improve industrial efficiency, were discussed by Román, Zala and Viszt at the end of 
the 1980s (1988). Two studies of that book included the analysis. Zoltán Román in his 
study Ipari szervezetünk jelene és jövõje (Present and future of our industrial organization 
in Román - Zala - Viszt, 1988, pp.9-54 ) first described the situation of the Hungarian 
economy in the 1980s. It stated that economic growth slowed down, and at the same time 
the balance of production and consumption of the national income was negative, inflation 
started to grow, growth rate of export volume was decreased, like the terms of trade rate. 
After 1982 the most important macro economic priority behind those phenomena was the 
maintaining the solvency. This economic priority took stabilization as its most important 
task in the first place, instead of adjustment. There could be seen inconsistencies in the 
policy and practice of government Meanwhile company and personal motivations were 
reduced. 
 
Zoltán Román considered structural adjustment of enterprises as the most important duty. 
Three factors should have been necessary to have it performed. First companies should 
have given more freedom in shaping their operations. (e.g. strengthening of inter-company 
cooperation, more financial and organizational and flexibility). The second factor would 
have been releasing general impediments, such as e.g. responsibility for producing goods 
and providing jobs.  The third factor is the economic openness. This one would have 
meant the must and inducement, which could have made the companies adjust constantly. 
In connection with international competitiveness he outlined the conditions of it as it 
follows: „ a) the expenditures of our products should not exceed the sum justified by 
world market prices and b) our lag at work productivity should not be bigger than the 
difference in wage levels, or our productivity should be higher than that of the developing 
countries’, which have lower wages.” (Román, Zala, Viszt, 1988, p. 34.) 
 
The other study in the book was made for the long-term planning program of the Állami 
Tervbizottság (State Planning Committee), and it is called Termelékenység és 
versenyképesség (Productivity and competitiveness). The study starts up with a definition 
of productivity.  The authors show that in measuring productivity they try to take into 
consideration more and more factors, like measuring the improvement of quality and they 
give some examples for that. In their understanding competitiveness is a broader category 
than productivity. In international competitiveness the features of the product and its 
quality have a major role, and the more unique the product is, the less important the 
productivity, the market share, relative prices and the exchange rates are. „ From the 
example of the developed countries we can learn that. They consider the productivity 
growth is important only if it helps to improve competitiveness.” (Román-Zala-Viszt, 
1988, p.62) They mention practices of, the United States and Japan. In the example of the 
United States, they perhaps referred to the Reagan package to improve competitiveness. 
They picked out three factors: supporting research, reduction of central regulations, and 
encouraging export. In discussing decisions of MITI  (the Japanese ministry of industry on 
selecting competitive industries they point out two factors, one of them was the 
productivity and the other was the R and D and the value added production. In Hungarian 
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situation, they had a look on how the changes in productivity influenced competitiveness. 
They measured productivity in the face of labor productivity and wage level changes. 
They stated that nominal wages in the 1980s were above the lab our productivity index. 
Main reasons for lagging productivity in the Hungarian industry can be attributed to limits 
of rational utilization of resources. In the background of it both the economic policy and 
enterprise factors can be found. 
 
 
4.2. Specific problems of transition and questions of market economy in the 
1990s 
 
The studies of the first half of the 1990s dealt with the questions of transition. In the 
review of Szamuely-Csaba (1998) the bibliography of the first half of the 1990s was 
directed towards two subjects. The first tried to find out what sort of capitalism could be 
created in Hungary. The second had its aim to interpret and describe the going-on 
processes (e.g. Árva, 1995, Hamar, 1996, Kapitány, 1996, Várhegyi, 1995, Voszka, 1995) 
.  We can put into the first group ideas about ownership (e.g. ed. by Lengyel, 1988, ed. by 
Matolcsi, 1991, Sárközy, 1991). The descriptive wing did research upon the industry, and 
partly on company adjustment. During the economic transition such a serious structural 
changes started up, that research aimed at companies was made really difficult. In the 
Hungarian economy this period was about the build-up of the market economy 
institutions, and reintegration into world economy. Most of the authors dealt with either 
the macro questions of transition, or were solving concrete company problems as 
consultants. This period touched thoroughly the establishment of economic research too. 
The earlier state dominance disappeared in the way making research institutes limited 
companies (like Gazdaságkutató Rt., that is Economics Research Ltd., Pénzügykutató Rt., 
that is Financial Research Ltd., Kopint-Datorg Rt., Növekedéskutató Rt., that is Growth 
Research Ltd.). At the same time the determining influence of academy institutions in 
economic research was reduced. In the higher education institutions this period was 
devoted to the creation of new subjects or renewal of the old ones. For some years the 
starting point of that was the developed countries’ practice, which could have been 
underpinned by Hungarian examples with difficulty. 
 
We should keep in mind two characteristics of the Hungarian economic research. In the 
2nd chapter, which described economics research, I pointed out that economics and 
business and management research were tightly connected, and business and management 
research is usually put into enterprise research, see e.g. Szamuely-Csaba (1998). The other 
characteristic of the Hungarian economic research is that it was rather political economics 
research than economic research. Two schools are distinguished here. The most 
remarkable approach represented by János Kornai’s works that analyze problems 
systematically (e.g. Kornai, 1993a, 1993b). The other school relies on international 
economics literature with less effort on systematizing and more on giving practical advice. 
First of all, books published by Növekedéskutató (Growth Research Ltd.) could be put 
into this group (Árva-Diczházi, 1998, Cséfalvi, 1999, ed.by Matolcsy) . We can find 
political economy approach in writings about the transition. This is justified by the nature 
of transition, which is deeply influenced by the social circumstances of the Hungarian 
economy. 
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4.2.1. Questions of transition 
 
The basis of the Hungarian economy’ transition on economic policy level was created by 
the reform draft of the Németh government in 1988 in the opinion of Szamuely-Csaba 
(1998, pp. 138-141). In that draft there was „the emancipation of private ownership and 
liberation of trade and the market of all production” (ibid., p.138). After the set-up of the 
new Antall government" realized and formulated soon that the guarantee the competitive 
nature of the economy is the main link between private ownership and efficiency”, move 
on the authors. (p.140) In their opinion "the main distinctive feature of the Hungarian 
transition is prevailing continuity and spontaneity dominating plans for transition. It is 
particularly emphasized /.../ by comparative international analyses. It is inevitable in each 
case, where business considerations proved to be more important than political/social 
shaping elements /.../. Whatever is the analyst’s judgement, the dominance of business 
sales forms undoubtedly formed the aspects of the Hungarian capitalism.” (p.141) 
 
On should agree with the above assessment, keeping in mind that many case studies seem 
to underpin the important role company management played in the privatization 
ownership structure (e.g. in the case of Graboplast Marosán, 1996). When assessing the 
privatization of pharmaceutical industry Antalóczy (1999), or when analyzing the 
privatization structure, Voszka (1995) came to the same conclusion. 
 
The Állami Privatizációs és Vagyonkezelõ Rt. (ÁPV Rt. State Privatization and Trustee 
Ltd.) launched a series on national privatization. Volumes contain well-documented 
descriptive analyses about different sectors. The documents are from ÁPV Rt. I used the 
volume dealing with the pharmaceutical industry, which is the above-mentioned 
Antalóczy book (1999). 
 
 
4.2.2 Problems of market economy 
 
The research of the second half of the 1990s describe the problems of the Hungarian 
market economy, such as foreign direct investments and their influence on the whole 
Hungarian economy (e.g.Árva-Diczházi, 1998, Árva, 1995, Éltetõ-Sass,1997, Éltetõ,1999, 
Hamar,1996, Szanyi, 1997), and the problem of globalization (e.g. Cséfalvi, 1999, 
Matolcsy ed., no year). In this period writings dealing with competitiveness also appeared 
(e.g. Török, 1997, Findrik-Szilárd, 2000), like writings trying to test market economy 
models on data of the Hungarian conomy (e.g. Török-Petz, 1999). With closing the 
transition and with the arising problem of joining the European Union, the number of 
studies dealing with the experience of those countries that joined it, increased (e.g. Nagy, 
1999a and 1999b, Farkas, 1999, and also see the bibliography of Chapter 3). 
 
Question of foreign direct investment. In connection with this subject I pick out the work 
of Árva (1995), Árva-Diczházi (1998), Éltetõ-Sass (1997), and Szanyi (1997). Árva’s 
work gives a review of the foreign direct investment in our region. It presents the world 
tendencies of foreign direct investment, and East European experiences. Then he describes 
the institutional frames of foreign direct investment in OECD, and the countries in our 
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region. From a certain point of view the Árva-Diczházi work can be regarded as a 
continuation of the book of Árva. It brings some new when presenting case studies on the 
Hungarian situation to make us feel the influence foreign direct investment had on 
companies’ behavior. As for the footnotes, the other two works are connected. Szanyi’s 
work (1997) contains a theoretical review, and the Éltetõ-Sass work (1997) contains the 
results of empirical research. In the Szanyi paper (1997) there is a novelty of dedicating 
much room to transnational (global) enterprises’ motives. The Éltetõ-Sass paper (1997) 
investigates company motives, from the point of view of investments and exports. 
 
The challenges of globalization. Many translated books were published in Hungary upon 
globalization. The specialty of these publications is that they usually coincide in two 
fields, that is in diagnosis, identifying the phenomenon’s many features, and in the 
conclusion to have a doubtful outcome of globalization. The other common feature of 
these books is that they are very eclectical both in their way of discussion, and listing the 
chosen examples. Neither of them tries to define the phenomenon of globalization (see 
e.g. Korten, 1996, and Martin-Schuman, 1998). Two Hungarian works on globalization 
are picked out, the first is Cséfalvi (1999) the other one is Matolcsy (ed., no year). 
 
Cséfalvi reviews the phenomenon of globalization relying on German language literature 
with the intention to give a feasible scenario to the Hungarian economy, as a whole and 
Budapest. We should remark here that the precedents of this pursuit go back to the middle 
of the 1990s. Then the Magyar Gyáriparosok Országos Szövetsége (The Union of 
Hungarian Industrialists) had such a study made about the Hungarian economy with the 
same intentions in 1995. The most valuable part of the study outlines Europe’s economic 
regions and the probable links to them. His statements on global enterprises are 
disputable. They miss the business and management approach and the basic Hungarian 
references in this field The other work (Matolcsy, ed., no year) discuss globalization from 
the point of view of the Hungarian economy’s growth perspectives, and it contains many 
authors’ independent studies. These writings are essays. Some of them analyze macro 
statistical data, the others refer to company case studies and reports. The value of the 
volume is in its description of many fields (e.g. foreign direct investments, the problems 
of the Hungarian companies’ expansion opportunities, problems of economic measure). It 
does not provide the authors' understanding of globalization. We should note that these 
outlined problems are the same in the works of foreign writers too. 
 
In my understanding it, these works struggle with a problem which is a really challenging 
one. That is, it is really difficult to examine globalization from a single discipline’s point 
of view, while the authors’ pens are just led by the imminent threat of its nature. The 
already started-up work upon foreign direct investment shows that more scientific, 
professional results could be shown in this field than on globalization.  
 
 
4.3. Summary 
 
The changes in the Hungarian economy, both in economy and society, touched those 
relationships among which meaning of efficiency and competitiveness should be 
rethought. A very serious part of the 1980s research called attention to the main reference 
points, which should not be other than an adjustment to world economy processes. The 
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research workers dealing with world economy and foreign trade questions formed this 
opinion basically. The 1989-1995 period can be called the transition period. That time the 
political economy approach was dominant, which served a double aim. On the one hand, it 
formulated visions about the Hungarian market economy’s formation, and on the other 
hand, it tried to describe and give a good interpretation of the going-on processes. 
 
Since 1995 more and more writings have tried to describe the challenges and problems of 
market economies, and issues of competitiveness are frequently discussed. These works 
describe questions connected with globalization, like foreign direct investments, or the 
Hungarian economy’s possible position in Europe. The writings about foreign direct 
investments show more scientific and professional results, despite the need for further 
research. The 6.1 sub-chapter of my thesis is about globalization. It describes the 
phenomenon from the enterprises and industry’s point of view. 
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5. Major lessons of the industry competitiveness research project of the “In 
Global Competition” research program 
 
One of the goals of this chapter is to point out the findings of my research, which differ 
from those of other research projects done in Hungary in the 1990s. In this chapter, I will 
present a methodological description of “Competitiveness of Selected Hungarian 
Industries” research project carried out in 1995-1997 and list its most important findings. I 
will give an explanation of the concept for competitiveness as well. At the end of the 
chapter, I will draft my issues by which I chose the pharmaceutical industry and my 
research questions that will be analyzed and assessed in Chapter 6. 
 
The following is the outline of Chapter 5. In Chapter 5.1, I will explain the most important 
concepts and frameworks that formed the industry competitiveness research project in 
1995-1997. These concepts and frameworks will be also applied in Chapter 6, especially 
in Chapter 6.2. The methodological issues of industry competitiveness research project 
will be discussed in Chapter 5.2. There is a summary of the lessons of industry case 
studies completed in 1996-1997 in Chapter 5.3. Firstly, I will give a summary of the 
factors, which greatly influenced the competitiveness of each analyzed industry in 1989-
1995. On the basis of Porter’s diamond model, I will review the factors, which determined 
the competitiveness based on the analyses of the industry case studies. In Chapter 5.3, I 
will give an interpretation of competitiveness on the grounds of the ‘In Global 
Competition’ research program and the industry case studies and their analyses. This 
interpretation of competitiveness will be specified at the end of Chapter 6 when assessing 
the competitiveness of the pharmaceutical industry. In Chapter 5, those industry 
competitiveness research issues will be drafted which will be analyzed in Chapter 6. 
 
The hypothesis of the research project of industry competitiveness was based on the fact 
that a national economy can only prosper when they have industries which are able to 
meet the requirements of the international markets at all times under changing 
international circumstances. This is why the key issue of the national economic strategy is 
the formulation of the industry portfolio of the economy considering the fact that 
competitiveness is not only an endowment but it may be created and renewed. The 
analysis of competitiveness based on industry case studies is carried out on the grounds of  
this hypothesis. 
 
Thus, the research of industry competitiveness first and foremost to prepare and analyzes 
the case studies of the selected industries of the Hungarian economy. 
 
 
5.1 An interpretation of industry and competitiveness in the research project 
 
I relied on the works of Porter (1980/1993, 1985 and 1990) to formulate the research 
concept and the research plan. On the one hand, I considered Porter’s works to provide the 
framework to set the structure of the case studies; on the other hand, they seemed to be 
suitable reference. 
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An industry is a group of companies, which produce products that are close substitutes of 
each other (Porter, 1993, and Varian, 1991). Consequently, when defining an industry we 
take products as starting point. Companies competing with each other in the same market 
are considered to belong to the same industry. A basic review of the technologies 
employed in the products a product also belongs to defining an industry. 
 
What requirements should a product meet? Basic needs and expectations of consumers 
and the functions, which a group of products wants to meet, are almost the same. As 
products and services are close substitutes from the viewpoint of economics their cross-
demand elasticity is high. From the standpoint of statistical analyses, this covers the 
products and groups of products, which fall into the same statistical category. 
 
How can a product be produced? Products and services in the same industry are produced 
through considerably similar technological steps, which cannot be eliminated. The applied 
technology, however, may differ from company to company. Consequently, it is necessary 
to know the basic activities of the production of products, that is the value chain as 
described by Porter (1985) in order to define an industry (see Figure 5.1). It is not only 
essential to know the value chain to define an industry but to discover the value creating 
activities which the companies of that particular industry need to have control over in 
order to create and provide value. 
 
Figure 5.1 The value chain 
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Source: Porter, 1985, p.37. 
 
Who take or rather who are able to take a product to the market? All the companies that 
meet the two criteria referred above belong to the same industry. An industry means a 
group of companies competing with each other. Companies of an industry following the 
same or similar strategy may form different strategic groups. Sociologically, however, the 
competing companies of an industry set and follow industry standards, they make co-
operation, and regulate themselves for the sake of the industry. 
 
Before going on with Porter’s concept, I want to point out one of the fundamental 
problems of this concept. It is the setting the boundaries of an industry. The above 
approach is theoretical, implicitly presuming that the companies operate in only one 
industry that is they are one-business companies. Or they are multi business companies 
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when they operate in totally different industries and they can exploit their synergy to 
improve their effectiveness. This model can only be applied with difficulty for analyzing 
industries including large diversified companies. This issue is especially exposed when 
talking about globalization. Global (trans-national) companies operate in a way that they 
cross not only the borders of countries but that of different industries. On the basis of 
Porter’s concept, the following question arises. How can we define the boundaries of an 
industry in the case of global corporations and industries? I will return to this issue in 
Chapter 6.1. I state here that the root of the problem is the following. The economic 
theories and approaches of Porter’s conceptions of economics concerned the national level 
with special regard to the theory of industrial organization.  
 
 
Figure 5.2 Forces driving industry competition 
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According to Porter (1980) model there are five forces which influence the profitability of 
an industry. Porter's model is based on the theoretical context of the ‘theory of industrial 
organization’ and was developed to support competitive strategy formulations. These 
forces are the following: barriers to entry, bargaining power of buyers, and suppliers the 
threat of the substitute products, and rivalry within the industry. (See details in Chapter 1 
Porter, 1980.) In addition to these forces, we must add the analysis of the prospects of the 
growth of an industry. It means an analysis of the factors influencing the consumption of 
the products of an industry. This is especially justified when the buyers of an industry are 
not the consumers of its products. Here we need to take into consideration the exports, 
which is a factor reducing the national consumption and the import, which is a factor 
increasing the national consumption. The analysis of an industry can especially be applied 
for analysis of national industries to map the changes in the competition. Companies with 
import and foreign direct investment will appear as newcomers for the incumbents. The 
question the incumbents will have how the newcomers will change the market competition 
within the industry? 
 
My objective in analyzing the economic structure of selected industries was to explore 
those national factors, which influenced the opportunities and threats of companies in the 
examined period. Main forces and steps of competitors, which had changed industry 
competition, were to discover. Changes in strategic behavior of the dominant companies 
in each industry as a result of the new forces and the new competitors, were also 
examined. 
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International competitiveness at industry level can be defined on the grounds of Porter 
(1990) as follows. An industry is considered to be internationally competitive when its 
companies are able to meet the efficiency requirements of the international trade. By the 
requirements of the international trade, we mean that the companies of an industry are 
able to market their products in foreign markets. In addition to the exports, the foreign 
direct investments (FDI) is an indicator for the international competitiveness of an 
industry as well. 
 
This means that the companies of an industry are able to export their products, they are 
also able to compete with import products. They are able to make capital investment 
abroad, and present in foreign markets with their own subsidiaries. These factors can be 
measured by macro-economic statistics: exports to its national production, and 
maintaining market share against imports, and outward FDI. 
 
The above-mentioned approach of international competitiveness is based on national 
economies. When the competitiveness of the companies of the largest market economies is 
discussed, the boundaries of the companies do not only extend in a geographical sense but 
in terms of their ownership and operations. Moreover, the international strategic alliances 
fundamentally changed the traditional picture of a company in this regard. It raises 
interesting issues not only from the standpoint of research, such as the unit of research, but 
also the standpoint of competition regulation. 
 
The macro-statistical data can be interpreted as reflecting company and industry 
effectiveness in meeting the requirements of the national and international competitions. 
The companies of an industry meet the effectiveness requirements when they make a 
profit. This comes from the fact that they managed to cope with the determining forces of 
the competition and they could take a position in the national and foreign markets by 
adapting to the changing market, regulation and technological environment. This involves 
the abilities of companies to change their own production factors, and choose their market 
positions in a way that they will accumulate sufficient resources long-term to carry out the 
necessary changes. Statistical data do not provide us with the right picture of the factors 
that determine or determined the behavior of economic actors. 
 
Porter’s research projects (1990) created a model of the factors that support national 
companies to become internationally competitive, and provide help in their foreign market 
operations such as developing export abilities and foreign direct investment. The title of 
the Porter's (1990) book about the findings of the research is misleading. It is not about the 
competitiveness of national economies. Rather it is about their companies’ international 
competitiveness and their determining and influencing factors at a national level. This 
misunderstanding laid itself wide open to attack. In the further development of his 
conception, Porter calls his model ‘sources of locational advantage’ (Porter 1998. p. 211). 
It specifies the name and practically adjusts it to the content as I have already referred to it 
in Chapter 2. At the start of my analysis of the industry competitiveness, I choose Porter’s 
diamond model (1990) to be a competent model to assess the sources of the international 
competitiveness in the selected Hungarian industries. Porter’s diamond model has not 
changed significantly as a result of the experiences gained in the meantime. What did 
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change was the application of the model, especially for analysis factors creating industry 
clusters.  
 
Considering the fact that we often come across misunderstandings in Hungary regarding 
the diamond model, I will briefly sum up the essence of it. 
The factor conditions 
All the inputs, from skilled workers to infrastructure, belong here which are necessary for 
a company to become competitive in a particular industry. This group of factors contains 
those components, which are essential to make products competitive. Their examination 
stands the closest to the traditional comparative advantage model. Some of these factors 
such as the capital and the workforce are part of the analysis. When analyzing the factor 
endowments, we need to put a special emphasis on the institutionalized mechanisms that 
play a role in changing the factor endowments. The following are these factors: 
• Natural resources (e.g. favorable natural conditions, geographical location, natural 
resources) 
• Infrastructure (e.g. transportation, telecommunications and the media, financial 
infra - structure, factors influencing the quality of life) 
• Human resources (e.g. education, the role of public and private sectors in 
education, the structure of education and qualifications, foreign language skills, 
levels of aspiration, system of apprenticeship, participating in voluntary education, 
the relation between the educational system and industries, manager training, 
emigration, work relationships, role of trade unions) 
• Knowledge as a resource (e.g. R and D expenditures, government and industry R 
and D expenditures, technical, market and scientific knowledge) 
• Access to capital (e.g. savings of households, government expenditure, budget, 
interest rates, sources of capital tending, the extent of capital market, financing 
exports) 
Competition between companies, changes in the national demand, related and supporting 
industries promote renewal of the factor endowments. 
 
The demand factors 
The national demand plays a determining role in creation internationally competitive 
industries. The following determine the national demand: the nature of the demand for the 
products of an industry, especially its segments, and expectations, the size, growth, and 
international nature of the demand. Customs, habits and hobbies, and the role of 
multinational companies forming the national demand also belong here. They are usually 
listed in two groups: 
• Individual consumers (e.g. specialties of an industry, consumption per person in 
international scale, concentrated producers and organizations of sale, demanding 
national consumers) 
• Organizational/industry buyers (e.g. multinational companies being important 
customers of an industry) 
Fierce national competition has an impact on renewal of demand where the competitors 
play a significant role in influencing the customers to expect higher standards. The 
national competition contributes to the fact that the outstanding companies may gain 
significant national and international acknowledgement and appreciation. Excellent factor 
endowments may attract the international companies and they may have a significant 
impact on renewal of the national demand. Industries supplying to internationally 
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successful companies can become producers of internationally successful products 
themselves. 
 
Related and supporting industries 
International competitiveness research projects carried out earlier showed us that the 
companies/industries of the national economy are competitive in groups, ‘dusters’ and not 
in themselves. They are related to one another horizontally and vertically. In prominent 
international competitiveness of a company, those industries can play an important role 
which, produce supplementary products, apply similar technology, inputs, marketing 
channels or sell to common consumer segments. We can often notice that the companies 
of related industries are regionally concentrated. 
The available factor endowments of a given industry can be transferred to the related and 
supporting industries. They contribute to their further development. Successful national 
companies encourage the production of special products and services. This way, they have 
an impact on the development of the related and supporting industries. Great and growing 
demand stimulates growth and improves the suppliers. 
 
Strategy, structure, rivalry 
This group of factors includes “the conditions in the nation governing how companies are 
created, organized, and managed, and the nature of domestic rivalry.” (Porter, 1990, p.71) 
The social and political milieus greatly influence this group of factors. The following 
factors can be listed have: 
• Objectives (objectives and motivation of managers and employees, dominant way 
of life, and life style influencing attitude toward work, prestige of business life, 
risk-taking versus safety, willingness to upgrading skills, self-training, non-
economic national goals) 
• Company objectives (e.g. ownership structure from the viewpoint of goal setting, 
the influence of the capital markets) 
• Company strategies (focusing on costs or uniqueness of products, production 
versus market orientation, diversification, time horizon of planning, reactive versus 
proactive approaches, international orientation) 
• Competition (to what extent the industries are concentrated, the concentration of 
economic power, the regulation of competition) 
• The conditions and expenses of creating, the reshaping or closing down of 
companies 
When factor endowments stimulate entries into an industry, it may lead to changing this 
group of factors (strategy, structure, rivalry). The companies of the related and supporting 
industries may appear among the companies of an industry by forward integration. 
Demanding buyers may stimulate the product development. The early national use of 
products and their success can stimulate new entries, which makes incumbents rethink 
their strategies. 
 
Government policies 
Government policies may have both a positive and a negative impact on all four groups of 
determinants. Some examples are as follows: 
• In the case of the factor endowments, education, science and technological 
changes, the infrastructure, providing subsidies, and promoting or impediment 
informing the economic actors are mentioned. 
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• From the viewpoint of demand factors, government purchases and standards are of 
greatest importance. 
• Concerning the related and supporting industries, there are the industry supports, 
development projects, regional policies, and the media policies in connection with 
marketing. 
• In connection with the strategy and structure, there are the ways and methods of 
markets regulation; the impact on the workforce (agreements of wages, minimum 
wages, bargaining mechanisms), and the impact of social and welfare programs on 
the motivation of the employees; trade and industry policies; liberalization and the 
conditions of establishing a company. 
The role of the government decreases with the development of the national economy. In 
R&D and Welfare driver economies, companies formulate their own expectations and 
require indirect devices to create a favorable environment of their competitiveness. 
Government, should have a clear understanding of the particular conditions of the national 
economy, and should stimulate the exploitation of them. The government policies should 
enforce a long-term approach in their provisions to stimulate the companies of different 
industries to a continuous upgrading. 
 
Chances 
External, accidental events that are out of control of companies (and the national 
governments) belong here. They may influence all four determinants; they may change the 
structure of demand for instance, or influence the company strategy, organization and 
rivalry, and the related and supporting industries. Such factors may be big technological 
breakthroughs (e.g. in biotechnology, and microelectronics), original innovations, the 
sudden change of the cost of inputs (e.g. oil crisis), political decisions of foreign 
governments, or wars. These chances may be advantageous for the industries of some 
countries, and may be disadvantageous for others. From the standpoint of competitiveness, 
the determining factor is what a national economy is able to produce of these accidental 
events. 
 
Figure 5.3 Determinants of national advantage: the diamond-model 
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In addition, an industry is also considered to be competitive in a national economy when 
the economic structure of a given industry provides adequate profitability to foreign 
investors to run companies long-term on national premises. Based on the definition of 
competitiveness at the national level, an industry is also competitive when it attracts 
foreign direct investment. This may be a decisive factor in the case of countries with small 
national markets. In such a case, from the standpoint of foreign direct investments in an 
industry, it is worthwhile separating the attractiveness of a country (e.g. premises), and the 
competitiveness of the companies. (Daems, 1997, and Sleuwagen, 1988) This standpoint 
and approach of analysis was not applied ‘In global competition’ research program. It will 
be explained and applied in the next chapter. 
 
 
5.2 Methodology of the research 
 
The competitiveness research at industry level was based on case studies. I relied on the 
works of Babbie (1995), Christensen (1987), Stake (1994), Huberman-Miles (1994) and 
Yin (1994) in establishing the methodology of my research. Preparing case studies is very 
popular both in teaching and research in the field of business studies. Their application 
and the scientific validity of the explanations deducted, however, is argued. According to 
Stake (1994), case studies form a part of scientific methodology, which can be applied in 
improving theories. They can also be applied in further research of complex problems and 
setting limits of generalizations. He emphasizes that case studies can be especially useful 
for government policies. Huberman-Miles (1994) point out the fact that the greatest traps 
of case study method are the interpretation of causal relations, and the validity of the case 
studies, the analysis and the conclusions. In connection with causality, they point out that 
qualitative research projects may especially be applied to explore causal relations when 
the chronological order of local processes and events are important from the standpoint of 
the examined phenomenon. An audit, involving experts from the outside to assess the 
contents, the analysis and the conclusions of the case studies, can support validity. The 
transparency of the research process deserves especially great attention in qualitative 
research projects. I tried to avoid these traps by involving an advisory board into the 
research, from establishing the conception of my research to discussing the case studies 
and drawing the final conclusions. The members of the advisory board were experts of the 
selected industries, academic and government personal. 
 
The purpose of the research was to discover how the companies of traditionally export-
oriented industries managed and maintained their exporting abilities in Hungary in the 
period of 1989-1995. It was the period of privatization and the development of market 
economy. This period was characterized by an increased import and the appearance of 
new competitors of the developed market economies. 
 
The research was based on Porter’s models that, I explained in the previous chapter. These 
models seemed to be suitable to structure the qualitative and quantitative data and 
information, which could be collected about the industries. They could also be relied on to 
give an answer to the questions what happened and why in the industries? Porter (1990) 
applied case studies as well. He, however, did not provide methodologically detailed 
arguments for the choice of using the case study method. Next to the argument based on 
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the principle of authority, the following arguments give reasons for the choice of case 
study method. 
 
Information about the industries of the Hungarian economy undergoing intense changes 
since the end the 1980s had to be gathered and structured in the midst of a learning 
process touching every level of the economy. The brief introduction of the history of a 
particular industry and the introduction of the international tendencies were to give a 
better understanding of the processes in the industries and outline their trends. There were 
no comprehensive descriptions about the industries to show what happened in 1989-1995. 
The statistical data system of the Central Statistical Office (KSH), which was in transition 
as well, did not provide a sufficient base to describe and analyze that. The reasons for this 
are the change of the macro, micro and company data systems, and the different 
information management within companies. The statistical data system was in transition 
because of introducing new economic, business and the international standards. Collecting 
and processional data that took place with significant delay due to the uncertainties caused 
by the significant changes of the economy and businesses. New entrants in industries 
turned a deaf ear to providing information of all sorts, thus inducing an aggressive 
competition. The industry associations tried to find their own places and roles in the 
industries dominated by privately owned companies. All company information was 
declared as strategic, and at the beginning of the 1990s, almost all served internal 
company objectives. It was a common phenomenon to withhold the public data required 
by Public Accountancy Law concerning company operation. Meanwhile, the systems and 
registers of accountancy and finances changed a great deal. 
 
Table 5.1 Criteria for Industry Selection 
Criteria Matching industries 
Traditionally export-oriented. Considerable 
exports for several years according to the 
Hungarian Statistical Office data. 
Pharmaceutical, poultry, iron and steel, 
textile, vegetables and fruits, plastic, 
aluminium 
Higher export ratio in the Hungarian 
exports than that of the Hungarian exonomy 
according to United Nations statistics in the 
wold trade 
pharmaciutical, poultry, iron and steel, 
textile, processed vegetables and fruits, 
plastic, aluminium 
Keen import competition Pharmaceutical, dairy, textile, plastic 
processing 
Long traditions and/or social usefulness Poultry, pharmaceutical, textile, vegetabbes 
adn fruits, dairy, aluminium, iron and steel, 
tourism 
Hungarian analysis had considered them as 
competitive 
Tourism, car and car components 
Strong local competition Dairy 
 
 
In the industry case studies, I took products as starting-point to define the industries. In the 
first round, the research project considered those companies competitive which 
significantly contribute to the exports of the Hungarian economy. When choosing the 
industries, the starting-point was the export statistics of groups of products basically. On 
the one hand, the KSH statistics (according to HS (Harmonized System) and SITC 
(Standard International Trade Classification) codes) of groups of products provided a 
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base. On the other hand, the yearbooks of the UN (United Nations) on the trade statistics 
were employed. Out of the considerably insufficient export statistics of the UN about 
Hungary, I tried to filter the groups of products which, based on the findings, have a 
greater share in the world trade than the Hungarian economy.  
 
Next to the export statistics other considerations were also measured in selecting 
industries (see Table 5.1.). These considerations came from the numbers of the advisory 
committee of the research project. The following considerations were of great importance 
availability of data and information, access to the dominant companies, and senior above 
Table 5.1 shows the emphasis was on the exports. The export ratios of the selected 
industries are shown in the Table 5.2. 
 
Table 5.2. Analyzed industries in exports statistics 
Industries 1992 1993 1994 1995 
Aluminium (10) 2.36% 4.22% 4.57% 5.31% 
Pharmaceutical (3) 1.92% 2.41% 2.25% 1.93% 
Car and car components (5) 4.85% 6.06% 4.90% 4.94% 
Plastic materials (4) 3.05% 2.99% 3.05% 3.52% 
Plastic processed (7) 0.98% 1.07% 1.30% 1.52% 
Clothes (16) 10.24% 6.72% 8.45% 7.30% 
Textiles (12) 1.54% 1.44% 1.52% 1.34% 
Iron and steel (12) 4.39% 5.47% 5.05% 4.90% 
Poultry (4) 3.15% 3.55% 3.47% 3.14% 
Dairy (1) 0.25% 0.30% 0.22% 0.21% 
Vegetables and fruits(16) 3.86% 4.47% 4.53% 3.72% 
Total 36.58% 38.70% 39.30% 37.83% 
Exports. million HUF 843 566 819 915 1 128 708 1 621 991
Tourism. gross income 98456 110312 151430 219795 
as % of exports 11.67% 13.45% 13.42% 13.55% 
Tourism. net income 45883 41351 52734 87854 
Tourism. net income as % of 
exports 
5.44% 5.04% 4.67% 5.42% 
Notes: the table comprises the product groups worth more than 1 billion HUF. according to 4 
digit HS codes. Next to the name of industries there are the number of product groups.  
Source: Hungarian Statistical Office foreign trade statistics books, several years 
 
 
I have mentioned several times that the case studies were made with a dual purpose. On 
the one hand, their important assignment was to explore and describe national and 
international tendencies in the selected industry. The other assignment, based on this, was 
to discover the causes of success/failure by applying Porter’s models and to outline the 
progress of each industry. 
 
In accordance with these purposes, I prepared the case study structure as shown in Table 
5.3. The number of pages of the case studies was between 50-120. As it is seen in the 
Table, the main aims of points 1, 2, 3 were to define the industry. The purpose of point 4 
was to describe the national traditions of the industry and map the characteristics of the 
transitional period. Points 5, 6 and 7 served to examine competitiveness. Point 8 served 
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the purpose of outlining the tendencies based on the statements of the researcher carrying 
out the case study. 
 
Table 5.3 Structure of the case studies 
1.) Introduction of the industry 
(main product gorups, its share in the hungarian exports, in the GDP, in world production and 
trade, most important exported product gorups) 
2.) Characteristics of the product and its production 
(product groups and market segments, most important activities in the value chain 
3.) Short history of the industry in Hungary 
(why and how it evolved, the most important changes, starting exports, professional 
organisations in the industry) 
4.) International tendencies 
(changes in products, in technologies and in markets, the most important international 
competitors, international rules and reguletions, international self regulation) 
5.) National economic structure of the industry 
(according to Porter`s 5 forces model an evaluation) 
6.) Sources for international competitiveness of the industry 
(based on Porter`s diamond model giving conclusions on the international competitiveness of 
the industry) 
7.) Conclusions (opportunities in the following 3-10 years) 
8.) Appendices 
9.) References 
Source: Czakó (1996) 
 
 
The common structure also served the purpose of providing a common ground to compare 
and analyze the case studies of the different industries. The structure of the case studies 
provided an opportunity for explaining factors in the case studies that are not or not 
extensively considered in Porter’s models. The structure gave an opportunity to expose the 
characteristics of the Hungarian transition period. Retrospectively, we must consider this 
approach to be appropriate. The work of O’Shaughnessy (1996) may be considered to be a 
verification of the appropriateness of the structure of the case studies established in the 
autumn of 1995. It blames Porter’s (1990) international competitiveness research projects 
for neglecting the roles of cultural factors, historical approach, and political will. Even if 
we did not manage to employ each of the considerations with appropriate thoroughness, 
we must state, without doubt, that our aim was to do it. This way we did not apply Porter’s 
models mechanically. 
 
The structure of the case studies was to show what the fundamental changes took place 
and how the companies of that industry managed to adjust to these changes. It was also to 
show the factors that should we paid more attention to for the sake of the future success. 
By this approach, I tried to gain a better understanding on what economic and other 
factors determine the exports as one phenomenon of international competitiveness. 
 
The validity of the case studies was assured by workshops. In each workshop, the 
participants emphasized that it was very important in itself that a comprehensive 
description was prepared about the industry. It was mentioned that the descriptions are 
correct, and they correctly outline the changes of the examined period. The companies and 
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the government used the case studies. Industry case studies were the most popular among 
the working papers of the research program. The government used these studies in its EU 
derogation project that started at the same time when this research completed. 
 
5.3 Lessons of the case studies 
 
This chapter primarily summarizes the most important findings of the research of the 
competitiveness of individual industries based on the case studies. When summarizing the 
findings of the research, the main purpose is to determine what changes took place in the 
first half of the 1990s, and what adjustments these changes caused in the companies of the 
industries. In this chapter, I relied on the following case studies prepared for the research: 
Antalóczy (1997), Barta-Poszmik (1997), Cseh (1997), Dévai-Petruska (1996), Lakner-
Sass (1997), Legeza (1996), Lengyel (1997), Némethné-Németh (1996), Orbánné (1996), 
Szabó (1996). 
 
During the research period, the economic structure of the examined industries 
significantly changed. The industry factors influencing the behavior of the companies 
remarkably changed. In what follows, based on Porter 1980 and 1985, I will emphasize 
the factors, which fundamentally determined or influenced the behavior of the companies 
in the given industries. On the basis of this, I will define what we closely mean by the 
competitiveness of the industries. I will also name the factors the companies of an industry 
had or have had to adjust to. 
 
In the dairy industry, competitiveness did not and has not meant competitiveness 
prominently appearing in the exports data. We find reasons for this in the special 
characteristics of the dairy industry. Three factors played significant roles in the economic 
structure of the industry influencing the strategies and behavior of the companies in the 
dairy industry. They are the entry of new competitors as a result of foreign direct 
investment, the fierce national competition, and the marketing channels (esp. retailing) in 
transition. The events of the first half of the 1990s gave us an example of how the fierce 
national competition stimulated the competitors to meet the demands of the buyers and 
customers with an ever increasing standard, and what a significant role foreign direct 
investments played in that. In the dairy industry, competitiveness meant the adaptability to 
the fierce national competition and considerable adjustment to the expectations of the 
consumers. 
 
In the first half of the 1990s, the poultry industry and fruits and vegetables industries 
managed to keep their previous positions in the Hungarian exports. On the other hand, 
there were no significant foreign direct investments in either industry. Consequently, we 
interpreted competitiveness as an ability to maintain exports. 
 
Both industries were greatly concerned by the shrinking markets. In the poultry industry, 
we need to emphasize the role of the new owners and the fierce national competition. The 
fierce national competition was significantly induced by over capacities and the 
postponement of their rationalizations. In the fruits and vegetables industries, all 
participants were influenced by the remarkable ownership uncertainties of the agricultural 
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land. The position of the farmers is further corrupted by the fact that, as many small 
sellers, they face the more and more concentrated retail trade of increasing standards. 
 
Both industries possess significant and favorable factor endowments to maintain their 
exports in the future. In the coming years, however, the present expertise may prove to be 
insufficient to exploit the factor endowments. Increasing economies of scale is the next 
step for the dominant competitors to be internationally competitive. This must be done in 
the processing in the poultry industry, in production, selling, and food processing the fruit 
and vegetable industries. Tourism has excellent opportunities due to the location and 
endowments of our country. The chances of increasing the incomes of tourism by 
increasing the numbers of tourist are becoming more and more limited. This is why we 
examine factors which can extends the basis for revenue increase. Improving domestic 
and upgrading services tourism in the whole industry are of the same significance. 
Upgrading services requires the development of exclusive tourism and increasing the 
quality of services. 
 
The pharmaceutical industry, the car and car component manufacturing, the aluminum 
industry, the iron and steel industry, the plastic raw material and plastic processing 
industry, and the textile industry are all global and export-oriented industries. It turned out 
that these global industries provide one third of the Hungarian exports. We, however, 
knew much less about the global industries and global competition at the closure of the 
research than now. This fact drew our attention to the phenomenon of globalization. Its 
characteristics and tendencies significantly determine the chances of our export-oriented 
industries and companies. Consequently, it is an issue to be examined in spite of the fact 
that our companies are not global corporations, and they are not the dominant participants 
in the global industries.  
 
Table 5.4 Shares of global industries in the Hungarian exports, 1992-1995, % 
Industries 1992. 1993. 1994. 1995 
Alumíniumipari products 
(10) 
2.36 4.22 4.57 5.31 
Pharmacenticales (3) 1.92 2.41 2.25 1.93 
Cars and car comparents (5) 4.85 6.05 4.9 4.94 
Pastic. row materials (4) 3.05 2.99 3.05 3.52 
Palstic. processed (7) 0.98 1.07 1.3 1.52 
Clothing (16) 10.24 6.72 8.45 7.3 
Textile (12) 1.54 1.44 1.52 1.34 
Iron and steel (12) 4.39 5.47 5.05 4.9 
Total 29.33 30.37 31.09 30.76 
Notes: The table companies the products groups with more than 1 billion HUF according to 4 
digit HS Codes. Next to the name of each product group, the figure denotes the number of 
belonging product groups. 
Source: Hungarian Statistical Office (KSH). Foreign Trade Statistics 
 
In our global industries, we can interpret the first half of the 1990s as a re-integration 
process into the world economy. The emphasis fell on integration into the world economy 
when examining the factors of competitiveness. The companies managed re-integration 
into the processes of world economy and their management had a significant role in 
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successful adjustment. The government did not give remarkable support either by 
provisions of economic policy or by economic diplomacy. We must consider integration 
as a fact, a well-done job in the industries. This has a very important consequence. In the 
next 3-10 years similar cataclysmic changes cannot be expected in the industries, and this 
is true for joining the EU as well. 
 
Let us take a look at the changes of competitiveness based on exports and imports of the 
Hungarian economy in the world trade (see Figure 5.4.). We can see that regarding both 
the Hungarian economy regained the same position it had in 1988 measured by its share in 
the exports and imports in the world trade. The Figure 5.4 also reveals that the period of 
case studies prepared at the end of 1996 and at the beginning of 1997 covered the years of 
‘low-altitude flying’ in the exports. It was a period, on the other hand, when the import of 
products was soaring. 
 
Figure 5.4 Shares of the Hungarian exports and imports in the world trade, 1988-1997 
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In general competitiveness of a particular industry meant the abilities of its companies to 
change and adjust. Forces of changes and benchmarks of adjustment differed industry by 
industry and we took the characteristics of the industries and their economic structures 
into consideration. By doing this, our aim was to draw attention to the fact that both the 
companies and government policy have to pay attention the different characteristics of 
competitiveness at industry level although they will emphasize different factors.  
 
 
5.3.1 Factors influencing the competitiveness of industries 
 
Relying on Porter’s  (1990) diamond model and based on the conclusions of the case 
studies, I give a picture of factors that promoted or impeded the competitiveness of 
selected industries in the period of 1989-1995. The following statements may be 
considered as an assessment of the transition economy in that period from the viewpoint 
of the competitiveness of the analyzed industries. 
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Factor endowments 
• Human resources: In adaptation to the changed industry structures skills and 
expertise of human resources were very important. Where there were not proper 
management knowledge and techniques and/or government support the existing 
skills and expertise were not satisfactory. In several industries low motivation and 
unreliability of workers were also mentioned. The Hungarian wage level is low in 
comparison with EU countries, and it comes from our low development. Low-level 
wages are source for competitive advantage in those industries where Hungary as a 
location offer advantages for foreign enterprises. 
• Capital resources and financing. In access to capital resources the main problem is 
the low level of profitability and it is closely connected to the low efficiency of 
operations and the financing costs. This is serious disadvantage in financing R&D 
projects. Access to capital is a problem for small and medium size enterprises. 
Venture capital could help medium size enterprises. Small and medium size 
enterprises also have problems in financing their export. 
• Technology. Technological level of industries is satisfactory due to the 
development projects in the 1980s. The available technology is medium category 
by international standards. Renewal and development of technology is prevented 
by the lack of financial resources. In development of technology applying 
computer technology were frequently mentioned. 
• R&D The institutions of the national R&D has been confused and the government 
role decreased considerably. Enterprise R&D is mainly with big players. 
Subsidiaries of multinationals are far ahead of the Hungarian owned enterprises 
and in global industries R&D is with parent companies. Necessity for R&D was 
frequently mentioned in connection with operations processes and technology. 
• Information. Lack of information and information management is a disadvantage 
especially in the national owned enterprises. This lack of information leads to 
unawareness of international tendencies, customers, markets, competitors, prices 
and access to financial resources. 
 
Demand factors 
• After dramatic decrease in demand at the beginning of the 1990s, national demand 
is stagnating or there is a slow increase. Enterprises expect considerable increase 
from the economic growth, but it cannot be considered as realistic. 
• In consumer product markets there are well defined segments both at the high and 
the low end. National consumers appreciate foreign products and services much 
more than national ones. In low segments black and gray economy and retailing 
has a significant role. In these segments enterprises suggest that by respecting 
national taxation laws it is impossible to be competitive with those who do not do 
that. 
• There is only one segment where a demanding national market induced high level 
of product innovation: the national poultry product line is far ahead of the 
international expectations. 
• Subsidiaries of multinationals as organizational buyers - especially in car 
components manufacturing and retailing - have very important pull effects on 
developing products quality and packaging. 
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Firm strategy, structures and rivalry 
• Changes took place in the first half of the 1990s led to reshaping the industry 
structures: privatization, entry of foreign subsidiaries, new ownership structure, 
shrinking of markets. The reshaped industry structure provided the basis for 
repositioning enterprises in the industries. 
• Those enterprises that had corporate or competitive strategies and followed them 
were much more successful than those which did not had clear view on their 
future. The further development requires more sophisticated management 
approaches and techniques, as well. In this area there are room for development 
especially for the national owned enterprises. In most cases lack of these 
knowledge prevent to employ excellent natural endowments. 
• Keen competition is due to the import liberalization, collapse of COMECON 
markets, new entrants and decrease in national consumption. Hungarian owned 
enterprises expect less competition from a demand increase, and less force for 
continuous adaptation. It is not widely shared by them that the competition itself is 
the inherent characteristic of the market economy that should be taken into 
consideration both in strategies and operations. 
• Keen national competition is associated with incorrect behavior. This may result in 
a very few cooperation both at horizontal and vertical relations. This lead to a 
lower level efficiency especially in consumer markets, where retail chains 
growing. 
• The prestige of industries preferred in the area of “socialism” has decreased 
considerably, and these industries produce the same ration of export that they did 
and attracted foreign direct investments as well.  
• Foreign direct investments had a considerable push effect both on competitors and 
suppliers. However there are as much positive as much negative argumentation on 
their role in the Hungarian economy. The main reason for that is that Hungarian 
government noticed impartial for the sake of foreign investors in privatization 
deals, and new entrants were aggressive competitors and more effective than the 
national owned enterprises. 
 
Related and supporting industries  
• There is not much trace of clusters in the analyzed industries. The previous 
clusters are ceased to exist and they are not formed again. Forming cluster is not 
present or enterprises do not like to speak about that. 
 
Government  
• The role of government was judged as negative in every industries. The main 
reason for that is that the Hungarian government do not prevent Hungarian 
enterprises as much as those developed countries where the eloquent Hungarian 
enterprises enter the market. 
• Expected supports are industry neutral measures and well known in the 
international practice. The following were mentioned: supporting small and 
medium sized enterprises in access capital and export markets, supporting 
technology change and development by credit guarantees and financial means, 
supporting R&D, making steps for information systems to reduces transactional 
costs, supporting management training, and more transparent and stable regulation. 
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Chance  
• The only chance was mention is the recreating the regional connections with 
Central and Eastern European countries. Hungarian enterprises are well prepared 
for that, however these markets are still risky. Joining the European Unions is not a 
big chance for enlarging opportunities. It is considered as an extra factor that heat 
up the national rivalry. 
 
Based on Porter’s (1990) diamond model, the above factors gave an overview on 
determinants of national competitiveness in competitive Hungarian industries. This way 
we pointed out the factors in the Hungarian economy determining the international 
competitiveness of companies. When starting the research, as explained in Chapter 5.2, 
competitiveness was understood in broader terms at an industry level than the ability to 
export and outward foreign direct investment. The case studies gave a picture of the 
changes in the industries in 1989-1995 and they pointed out the factors which determined 
the competitiveness of the companies in the industries but they did not give a picture of 
how the competitiveness of each industry contributed to the competitiveness of the 
national economy. 
 
 
5.3.2 Interpretation of competitiveness 
 
When starting the ‘In Global Competition research program’ we defined competitiveness 
for the sake of the research. As a result of several arguments, it is a definition at the 
national economy level. I stated it in Chapter 2. I will briefly repeat what I said earlier 
since this chapter will expound on the definition. 
 
According to Scott-Lodge (1985 pp.14-15.), “national competitiveness refers to a nation 
state's ability to produce, distribute and service goods in the international economy in 
competition with goods and services produced in other countries, and to do so in a way 
that earns a rising standard of living. (.....) To be competitive as a country means to be 
able to employ national resources, notably the nation's labor force, in such a way as to 
earn a rising level of real income through specialization and trade in the world economy.” 
From this respect company is competitive what it contributes to its fulfillment. To do so a 
company should be able to operate and change that is: 
(i) By transforming the available resources it earns the greatest profit possible or 
at least makes an average industry profit while keeping the social values. 
(ii) It is able to perceive and adjust to the changes in the internal and external 
environments of the company in order to maintain a profit level that may make 
long-lasting operation possible for the company. 
 
Main condition of competitiveness at company level is the ability to meet better quality, 
time and cost criteria than the rivals. Main condition of competitiveness at the national 
level is to having the environment to facilitate the companies to meet these criteria 
(Chikán, 1995). 
 
The above approach is based on business and management studies. This is a normative 
problem-oriented approach. We used an inductive approach and reasoning in the research 
program and the research was contextual and comprehensive. Our aim was to map all the 
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factors influencing company competitiveness by giving descriptions as well (see Chikán, 
1996 and 1997a). We had a situation-oriented approach and all along, we focused on 
proposals for the business community and the government. 
 
The above definition of competitiveness defined competitiveness at national economy and 
company level. It did not try to link competitiveness at the national level with 
competitiveness at company or industry levels. The research projects we knew in the 
middle of 1990s did not try to do this either, since their aims were different. In the 
workshops on of the studies during the research program this link was missed. Main 
arguments did not question the existence of the empirical research projects. It was, 
however, not clear what the program as a whole was all about, and what its proposals 
aimed at. An understanding was reached on interpretation competitiveness at four 
different levels. These are the national level, the levels of products, companies, and 
industries. The logic of this interpretation was that companies compete with each other 
first and foremost via products. The companies compete with each other within an 
industry, which means they firstly have to meet the requirements of the industry. Putting 
these levels next to one another and presenting them as a system tailed. On the grounds of 
the studies and workshops of the research program, I summarized the levels and 
conditions of competitiveness in the following Table. I know what I have done is risky 
since there are different levels and approaches. The Table below may give a subtler 
picture of competitiveness together with Porter’s diamond model (1990). The levels and 
factors in the Table seemed to be suited to give more detailed view on the competitiveness 
of the industries at national and international levels, based on the industry case studies: In 
addition to Porter's works, I relied on the following works to prepare the Table: Chikán 
(1997b), Frances (1992), Grant (1998), Johnson-Scholes (1999), Kay (1993), Milgrom-
Roberts (1992), Penrose (1996), Rumelt-Schendel-Teece (1991), and Wernerfelt (1984). 
 
I presented four levels of competitiveness in the Table. The factors of competitiveness 
contain (i) conditions for long-lasting effective operations, (ii) main stakeholders and their 
takes, and (iii) main risk takers. Under the title of ‘conditions of long-lasting effective 
operations’, I listed the conditions of successful operations at the different levels. We will 
see that effective operations at each level. Under the title of the ‘main stakeholders and 
their stakes’, I list the groups with their stakes that are able to influence long-lasting 
effective operations the most. The column of ‘main risk takers’ emphasizes those who 
take the greatest risks at their level of competitiveness. We need to point out here that the 
main risk takers do not necessarily coincide with those making the decisions. The third 
column of the Table ‘Points of reference’ refers to the fact that competitiveness is a 
relative category. This column points out the benchmarks we compare the advantages with 
at each level of competitiveness. 
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Table 5.5 Levels and factors of competitiveness 
Levels Factors of competitiveness Points of 
reference 
 Contitions for long-
lasting  effective 
operations 
Main stakeholders and 
their stakes 
Main risk takers  
Products 
or services 
Knowledge of 
consumers` needs 
and infenency their 
buying decisions. 
Product 
choracteristics. Costs 
be less than price 
Consumer: 
value. 
Companies: 
sales revenner 
Companies: 
profit. 
Products of 
national 
companies, 
export markets 
and import 
goods. 
Company Profitable operations. 
Ability for renewal. 
Companies: cash flow. 
Management: prestige, 
income, ownership 
rights. Employees: 
income, job, working 
conditions and climate. 
Owhers:return on 
invested capital, 
cash flow. 
National 
companies. 
International 
companies. 
Industry Demand: competitive 
products. 
Technological 
renewal. Mastering 
core activities in the 
value chain. 
Employees: jobs. 
Suppliers: market. 
Buyers: products and 
services 
Companies: survival 
and growth. 
Foreign 
industries 
National 
economy 
Long run effective 
resource utilization 
and renewal 
 
Citizens: fair income 
distributions and rasing 
living standards. 
Industries: supporting 
national operations. 
Governments:macroeco
nomic stability and 
growth. 
Government: stay in 
power. 
Previous 
achievements. 
Similary 
developed 
countries or 
regions. 
 
 
The level of products or services 
 
The first level of competitiveness is that of products or services. By products, we mean the 
things and performances which companies offer to their customers in the market. So, the 
category we use for products include both products and services. Competitiveness is 
decided at the level of products. At this level the condition of staying  in the market and  
having a long-lasting effective operations is to meet customers need. The products should 
be able to influence the decisions of the customers via their qualities. The price of the 
products should exceed the expenses of their production. 
 
Main stakeholders at this level are the consumers, who expect to gain value and usefulness 
form the product, and the company that receives sales via selling their products.  
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The company takes the greatest risk by investing into product development, production, 
and marketing. It does all this in hope of profit. In this case, profit simply means that sales 
exceed the expenses of the company. 
 
Points of reference at this level are with the ‘In comparison with?’, products of national 
companies, the export markets and the import products. 
 
 
Competitiveness at company level 
 
By company, we mean an enterprise with legal entity. In national competitiveness, the 
companies with high exports and outward foreign direct investment have a significant 
role. The conditions of effective operations are the ability to change and make a profit. 
Making a profit is the key of the long-lasting existence of a company. The ability to 
change means the ability to adjust constantly to the changing environment. In addition to 
the adjustment to the changes in the product markets, in broad terms it also requires the 
adjustment to the conditions of the environment. Main segments of environment are the 
political, macro-economic, technological and social changes. 
 
There are three major stakeholders: the company as a whole, the management, and the 
employees. In the case of the company, its existence as an operating system is primary. 
The most important factor here is the cash flow, which provides the basis for the ability to 
change. By management, we mean the top management of a company. Prestige, salary, 
and ownership rights are the motivating factors for them. These are closely linked to the 
company and its success. In the case of the employees, we mention the salary, the job,  
and the working conditions and climate. Job, working conditions and climate are of the 
same importance as the salary in motivation of the employees. 
 
In the case of competitiveness at company level, the owners take the greatest risks, who 
take financial risks via capital investment in hope of a profit. 
 
Competitiveness at company level is measured against national and international 
companies. The separation the national and the international companies is determined by 
the premises of the mother company.  
 
 
The industry level 
 
Based on Porter (1980) by an industry, we mean a group of companies, which produce 
products that are close substitutes of each other. As a result, this interpretation of an 
industry does not correspond with the statistical listing of companies in the national 
economy. Industries can operate and exist long-term when there is demand for their 
products and they are able to upgrade their technologies. 
 
At the industry level, the most important stakeholders are the employees of the industry. 
They are linked to the industry via their workplace. Suppliers and buyers have an 
economic interest in the industry. 
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At the industry level, the companies take the greatest risks. They are bounded to an 
industry since it gives them a chance to survive and grow.  
 
We assess competitiveness in comparison with foreign companies in the most important 
foreign markets of the given industry. If an industry is global, then the practice of the 
leading companies of the industry is also a basis for comparison. 
 
Competitiveness based on business and management studies are at home at these three 
levels in analysis and giving scientific explanations. We must, however, point out that 
there is a growing need to tinge deeper our knowledge in these what I have mentioned 
fields as a result of globalization, the tendency to open national economies. 
 
 
Competitiveness at the national level 
 
The approach of competitiveness at the national economy level based on business and 
management studies come to a ‘marshy land’ as I referred to this in explaining the model 
and findings of Porter’s (1990) research. We can outline the following at this level 
balancing between the approach of economics and business and management studies. 
 
Competitiveness at national level means that a national economy is effective in long-term 
when it is able to exploit the available factors efficiently , and can permanently renew 
them. 
 
At this level the most important stakeholders are the citizens, the industries, and the 
government. In the framework of economics the expectations of the citizens are a fair 
income distribution, and the raising of living standards. The industries primarily expect 
support for national operations. The government is an actor that can do the most for 
improving competitiveness of the national economy. We want pick out two national 
economic, they are maintaining the macro-economic stability and creating the conditions 
for economic growth. 
 
At the national level, the government takes the greatest risk. Supposing there is 
democracy, the government is tested by the votes of its citizens from time to time in 
general elections. This, however, exceeds the subjects of economics and business and 
management studies. 
 
Points of reference in judging competitiveness of national economies are their 
improvement in comparison with their previous achievements and achievements of with 
similarly developed countries or regions. This is an area where especially the international 
economics have results. Comparing achievements at this is level can rely on mathematical 
and statistical analyses the macro-economic data. 
 
Based on the above Table we can answer the question whether a selected industry belongs 
to an industry portfolio of the economy that is able to meet the world trade efficiency 
requirements and how it contributed to the change of the competitiveness of the national 
economy in the meantime? 
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5.4 Research questions 
 
The research project on industry competitiveness was finished in 1997. My so far results 
stimulated me to continue my empirical work in three areas: (i) globalization and the 
characteristics of global companies and industries, (ii) the factors determining 
international competitiveness in the Hungarian market economy on the grounds of Porter 
(1990) model, and (iii) the contribution of industries to the competitiveness of the 
Hungarian economy. 
 
Based on the case studies, I summarized the most important findings of my research on 
the competitiveness of the industries. When summarizing my findings in chapter 5.3.1, the 
main idea was to point out the changes in the first half of the 1990s, and the adjustments 
done by the companies in each industry. One of the greatest changes and challenges for 
the companies in the Hungarian export-oriented industries was to keep their positions in 
global industries. Therefore, further research should cover globalization and operations in 
global industries. 
 
The findings based on Porter (1990) diamond model, gave us a view of the factors that 
contribute to the international competitiveness of the leading companies in competitive 
Hungarian industries. The case studies also gave us a view of the factors, which may 
contribute to their further development. This way, we pointed out the determining factors 
of the international success of companies in the Hungarian economy. Further research 
projects starting after closing the privatization may specify the picture and they can show 
changes that took place in the second half of the 1990s. 
 
Basic hypothesis of the research of the competitiveness at industry level was, that a 
national economy could prosper when it has several industries, which are able to meet the 
international efficiency requirements in the world trade in changing international 
environment. This is why the key issue of the economic strategy of a country is forming 
and influencing the industry portfolio of the economy. Competitiveness is not only ability; 
it can be created and renewed. The levels and factors of competitiveness are outlined in 
the Chapter 5.32. Based on them, I will examine how a selected industry can be evaluated 
from the standpoint of national and international competitiveness. 
 
My first question in going on with my research was which industry I should choose for 
further research. As a result of several factors, I picked the pharmaceutical industry. It 
seemed that my research questions could be analyzed and answered in the pharmaceutical 
industry based on the available public information and data. 
 
In continuing the research, I used the case study method and relied on the developed 
methodological approach to competitiveness. Due to the changes that took place in the 
meantime, statistical data and company information were more available.  
 
I made the following hypothesis in the pharmaceutical industry at starting my empirical 
work: 
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1. The pharmaceutical industry is a global industry and the Hungarian pharmaceutical 
industry faced this in its markets during the 1990s. Globalization did not reduce 
the competitiveness of the Hungarian pharmaceutical industry.  
2. The chances of the export-oriented Hungarian pharmaceutical industry are 
influenced by the characteristics of the global industries. Global competition and 
the strategies of global corporations influence the opportunities of the Hungarian 
pharmaceutical corporations. 
3. The pharmaceutical industry belongs to the industry portfolio of the Hungarian 
economy that promote the competitiveness and the achievements of the economy 
due to its competitiveness in national and foreign markets. Besides export-
orientation, R and D demand industry contributes to the pharmaceutical industry's 
being a progressive industry in that national economy.  
 
I relied on my own research to prepare the case study of the pharmaceutical industry that 
set limits to the depth of the analysis. Due to the case study method, there are particular 
traps, however, the social embeddedness of the pharmaceutical industry such as the role of 
the government, made it necessary to choose this approach. I present the case study and 
summarize my findings in Chapter 6.3. 
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6. Industrial globalization and its influence on enterprises in global 
industries in Hungary 
 
This chapter will discuss what globalization means at the level of industry, and what 
adjustment opportunities and constraints it imposes on the companies in global industries. 
What makes such a discussion necessary are the facts that the research program entitled In 
Global Competition found that the leading enterprises of the Hungarian economy operate 
in global industries, and globalization is the most important challenge that we face these 
days. 
 
Chapter 6 consists of two sections. Section 6.1 analyses globalization at an industry level 
and possible strategies. It also discusses what globalization means in the pharmaceutical 
industry. Section 6.2 will address the changes that have taken place in the Hungarian 
pharmaceutical industry, partly as a result of globalization, and partly due to the 
development of market economy. The section also touches upon how these changes have 
affected the competitiveness of the Hungarian pharmaceutical enterprises. Based on the 
case study presented in Section 6.2, Section 6.3 will sum up the findings of the empirical 
research carried out for the purposes of this thesis. By way of introduction to the sections, 
some fundamental concepts related to globalization will be discussed. 
 
The phenomenon of globalization has been presented in the by business literature since 
the mid-1980’s (see e.g. Porter, 1986, Bartlett-Ghoshal, 1989, and Bartlett-Ghoshal, 
1991). We will rely on these approaches as they describe globalization from the point of 
view of enterprises and provide guidelines for the business sector. The examples and 
analyses presented are based on mega- or rather gigantic businesses and address the 
executives of the businesses whose dominance may appear rather discouraging for the 
future of their smaller competitors as well as consumers. Although the examples may 
seem discouraging, we believe that the practice presented and analyzed there could be 
instructive for the enterprises operating in the Hungarian market. As we pointed out 
earlier one of the greatest challenges for business literature was the operation of global 
(transnational) enterprises that stretch out the borders of national economies. This is a 
challenge for economics as well. However, as the issue is complex, we will not go further 
than formulating questions on some of the elements of the problem when national 
economies will remain the basis of analysis.  
 
The growth rate of foreign direct investment (FDI) has been on the increase all over the 
world since the mid-1980s (see Figure. 6.1.1). The curve shows that the growth rate of 
FDI surpasses that of the exports and GDP. In 1997 in Hungary, over 60% of the GDP 
was produced by companies owned by foreign investors. In the manufacturing industry 
the rate was 10-12% higher, and in terms of exports it amounted to 75% (Bayer, 1998 and 
Éltető-Sass, 1997). The capital of the foreign owned operating in Hungary companies are 
several times greater that that of the national owned companies. Capital import is essential 
in the current stage of development of the Hungarian economy. 
 
In order to understand the motifs behind the decisions made by the executives of 
multinational businesses (the term will be used as a synonym for global and transnational 
corporations) it is essential to become familiar with the political and economical 
environment they operate in as well as their information system, mindset, values and 
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knowledge. These factors fundamentally determine what strategic and operative decisions 
the executives make. 
 
Figure 6.1.1 Foreign direct investment, exports and GDP in the world economy, 1970-1997, 
1970=100% 
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Source: The Economist, 1998b, based on WTO and UNCTAD data 
 
In the broadest sense of the word, globalization means the opening up of the national 
economies. According to Moss Kanter-Pittinsky’s (1991) “globalization is a process of 
change in which the world’s countries and their economies are increasingly as a function 
of integrated cross-border economic activity”. Integration in Hungary takes place at least 
at two levels: by integrating Hungary’s economy into the EU through accession and by the 
presence of global enterprises in Hungary on both the supplier and buyer sides as 
competitors. “Cross-border exchange includes material transfers of people and things and 
instantaneous communication enabled by emerging information technology”. (p.1.) 
According to an analysis by Rodrik (1997), a process similar to the current globalization 
was observed at the turn of the century. There are four factors, however, that were not 
prevalent in the past but play an important part today. These include the application of 
immigration quotas, which has an effect on the movement of labor; the competition of 
similar products which results in a considerable intra-industrial trade nowadays; the 
national governments’ function as welfare providers being unavoidable; and the use of 
information technology.  
 
As the degree of integration increasing, rationalization is becoming crucial in the 
operation of national economies and global enterprises. In globalization, rationalization 
includes the strengthening of supranational organizations that make rules for their member 
states. One of the most important purposes of these rules is to co-ordinate economic 
activities (especially trade policy) of the countries in a region, thus enhancing the 
competitiveness of the region compared to non-member states. Such organizations are the 
EU (Western Europe), the North American Free Trade Area (NAFTA) and the 
Association of South-East Asian Nations (ASEAN), involving a few countries of the Far 
East (Blahó et al, ed., 1989). From an economic perspective of globalization, these regions 
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i.e. the Triad countries constitute the three most important regions, which are determining 
the moves of multinational enterprises (Ohmae, 1985 and Choi et al 1996). As pointed out 
in Chapter 3, the European Union is considered to be unique among the regional 
organizations. 
 
From the perspective of governmental policies, rationalization means that upon accession 
to a regional organization, any new member states are obliged to adopt and enforce the 
rules made by the old members. As a first step, regional organizations co-ordinate the 
trade policies of the member states, thus establishing a free trade area first. As a next step, 
budgetary and monetary policies are harmonized. In this respect, the greatest progress was 
made by the European Union. In addition to regional organizations, (Blahó et al, ed., 
1989), global enterprises are also strong integrating forces in world economy. Global 
businesses integrate the activities of their subsidiaries in different countries, co-ordinate 
and keep control of the development and global spreading of their basic skills. Usually the 
parent company’s headquarters are based in the mother country that is responsible for 
those functions.  
 
When discussing globalization, we have to determine what global market means. It is 
mostly used as a synonym for the Triad countries. (The term Triad was coined by Ohmae, 
and 1985) traditionally, the term referred to the United States of America, Japan and the 
member states of the European Community. Its scope is changing with the expansion of 
the economic integrations (Choi et al, 1996). Today by global markets we mean North 
America (NAFTA), Western Europe (EU) and certain countries of the Far East. A global 
enterprise is expected to be present by national subsidiaries in all of these regions. If we 
look at what regions most of the global enterprises come from, i.e. what their home 
countries are based in, we see that the Triad countries are at the top of the list (see Figure. 
6.1.1). The Business Week produced a list of the top one thousand companies on the basis 
of their market value. Out of the thousand, 480 are U.S. based. With 116 global 
businesses, Japan ranks the second in the list and Great Britain the third with 115 
companies. These three countries own 71% of the most valuated global enterprises. 
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Table 6.1.1 Origins of the most valuable corporations of Business Week top 100 
Region Number of 
global 
companies 
% of 
total 
Number of 
home base 
countries 
Number of 
companies 
among the first 
500 
% of 
the 500 
Europe, total 350 35,0 16 191 36,6
European Union based 328 32,8 13 178 35,6
Non-EU based 22 2,2 2 13 2,6
North America, total 
(US and Canada) 
511 51,1 2 251 50,2
Australia and Far-East 146 14,6 5 62 12,4
Notes: The list by countries contains 1007 companies since are mentioned in two home base 
countries. 
There are 7 companies that were merged. Companies like that are UNILEVER (United Kingdom 
and the Netherlands) or ABB (Switzerland and Sweden). Their home countries are as follows (in 
brackets there are the number of companies): Australia (1), Belgium (2), France (1), The 
Netherlands (4), United Kingdom (4), Sweden (1), Switzerland (1). Based on Business Week, 
Global 1000, July, 1998 
 
 
As outlined in Chapter 2, from the perspective of the countries that have a powerful 
national market (e.g. the United States), two processes characterize globalization that were 
less common in the 1970’s and 1980’s. On the one hand, the companies based in these 
countries have started to expand abroad intensively by means of foreign direct investment, 
on the other hand, companies from other countries have entered these countries by means 
of exports and foreign direct investment. Globalization came to transparent when 
enterprises that had carried out considerable exports and imports, started their operations 
in other countries by foreign direct investments. Their objective is to enhance their profit 
potential and they take a greater risk than by traditional international trade. That is why 
foreign investors often expect a higher return on their investment, which makes most 
counties rather irritated. 
 
In terms of quantifiable activities (e.g. exports, imports, foreign direct investments), the 
rate of globalization has considerably and dynamically increased since the middle of the 
1980’s. It has become more and more important for the US based enterprises that were 
relatively modest before. As a result, international trade and FDI became central to 
mainstream business literature, which started to deal with globalization from a corporate 
point of view. At first the discipline of corporate strategy formulation, then strategy 
implementation took a close look at how to manage global corporations. The phenomenon 
is described and analyzed from the viewpoint of the largest enterprises such as General 
Electric, a company present in Hungary and featuring the Global 1000 list by Business 
Week. In order to understand the magnitude of the problem, it must be noted that 
Hungary’s GDP amounted to USD45,000 million in 1997, which is close to the sales by 
Nestlé, a company present in Hungary as well. We should not lose sight of the fact, 
though, that a country is not a company and sales are not added values.  
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6.1. Globalization of industries and enterprise strategies 
 
In line with the introduction to Chapter 6, the structure of Section 6.1 will be as follows: 
Section 6.1.1 will discuss the features and motifs of globalization at industry level. 
Section 6.1.2 will review the potential corporate strategies from two perspectives: global 
companies, as parent companies, and from the perspective of their subsidiaries. Such a 
review is explained by the fact that the global enterprises make more and more 
investments in Hungary and it is crucial for the national subsidiaries to know what role 
they are allocated by the parent company in domestic competition and economy. 
 
Section 6.1.3 reviews globalization from the perspective of the pharmaceutical industry. 
Section 6.1.3.1 provides an overview of the factors that drive globalization and the 
corporate strategy of global enterprises. The section will also identify types of strategy in 
the global industry. As the European Union plays a key part in globalization, Section 
6.1.3.2 will review the EU’s plans and principles for the pharmaceutical industry. EU 
intentions concerning the pharmaceutical industry will be addressed because integration 
into the EU is of high priority for the Hungarian economy. Section 6.1.3.3. presents an 
overview of the position of the pharmaceutical industry in Hungary and Central and 
Eastern Europe. The section includes the bibliography used for the introduction to Chapter 
6 and Section 6.1.  
 
6.1.1. Global industries 
 
One of the apparent features of globalization is that in certain industries more and more 
companies have globalized, i.e. more and more companies started cross-border operations. 
According to Porter (1980/93), the term global industry refers to the fact that the position 
of a company in the major geographical or national markets is defined by its global 
position. Since markets in global industries expanding geographically and businesses 
operating cross-border, the companies that are less powerful at a national and international 
level must keep an eye on the steps of their largest global competitors. In global industry a 
company’s potential position depends on the attitude of the players involved. In practical 
terms, it means that strategic opportunities in the pharmaceutical industry, e.g. in Hungary 
depend on how firms are positioned in relation to the leading competitors, and what 
global, regional and national strategies they apply. 
 
Keen international competition is a typical feature of the global industries. Part of the 
reason is that major competitors operate in the key markets. The sales of standard products 
all over the world and high-level international trade are key features of the global 
industries. Industrial globalization is essentially driven by three factors: technological 
development, the liberalization of markets and an increasing mobility of factors of 
production. Porter (1980/93) points out that the factors encouraging global industrial 
competition are the following: 
• Governmental measures (e.g. the predictability of government policies, 
liberalization of imports, standardization of products and production) 
• Cost factors (e.g. economies of scale in size, selection, production and sales) 
• Market factors (e.g. standard products and consumer demands) 
• Stages of the competition and moves of the competitors  
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As opposed to the factors outlined above, obstacles to global competition include:  
• Economic impediments (e.g. complicated segmentation of the market, high costs 
of transportation and storage) 
• Management obstacles (e.g. different marketing tasks in different countries, 
rapidly changing technology) 
• Institutional impediment (e.g. government regulations, obstacles of attitude or 
resources) 
 
A study by the OECD (1996b) reveals that four areas could provide a basis for industry 
globalization: knowledge and R&D (e.g. pharmaceutical industry and computer 
manufacturing), size (including car manufacturing and entertainment electronics), raw 
materials (iron and steel production, processing of non-ferrous metals) and manpower 
(textile industry). The study considers these four factors of global industry to be the main 
reasons for the global expansion of enterprises. In industries that have become global on 
the grounds of knowledge and R&D, high foreign direct investment is made. As for 
international trade, trading between companies and international co-operations in the field 
of R&D and technology is predominant. 
 
Another feature of global industries is that the largest companies (the largest in terms of 
sales in absolute value) involved in a particular industry operate across borders and 
continents. Porter (1986a, p.16) refines his definition of global industries by raising the 
question what makes an industry global. An industry is considered global if the integration 
of its activities on a global scale provides a competitive advantage; the leading companies 
operating in such industries are called global enterprises. These enterprises are open 
corporations and have their shares registered at the largest stock exchanges. Their goal is 
to grow, especially in terms of corporate value. In order to achieve this objective, these 
businesses do the following (Daniels-Radebaugh, 1998): 
• When making foreign direct investment, they prefer having the majority or, if 
possible, 100% of the ownership, 
• In order to finance their operations, they rely on international financial markets,  
• They organize and co-ordinate their production, resourcing as well as marketing 
across borders, 
• Competitors enter international strategic alliances, ranging from the acquisition of 
minor ownership to long-term contractual relationships. 
 
As outlined in Chapter 5, the industry approach, especially that of Porter (1980/93), is 
based on the national economy. This applies to the global industry approach as well 
(Porter, 1986). However, one of the features of the global enterprises operating in global 
industries is that they are involved in several industries. Some global enterprises operate 
in several global industries, at the same time. This is a new development since paper 
published out and it raises the following questions: what are the criteria for a global 
industry and what is the unit of analysis global enterprises or global industries could 
provide a more consistent analysis? From the perspective of corporate strategy, the 
question is the following: what are the areas and factors that could provide the companies 
with a competitive advantage? It appears that industry specific features (e.g. those that are 
due to the specific technology) are only part of the factors. Other important factors include 
e.g. size, capital expenditure, distribution network and innovation.  
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6.1.2. Strategic opportunities in the global industries 
 
The multinational enterprises operating in Hungary were driven by a variety of motifs and 
interests entering the Hungarian market. However, they had one feature in common: the 
aspiration to gain a competitive edge over their competitors and thus increase profit and 
value. As part of the research program ‘In Global Competition’, one project focused on 
industry competitiveness and one of the major findings was that the former flagship 
industries of the Hungarian economy, that continue to produce nearly one third of 
Hungary’s exports, were global industries (see Czakó, 1997 and 1998a). Part of the 
Hungarian owned companies have turned global by becoming subsidiaries to global 
enterprises, and part of them operates as a non-global business in a global environment. 
This makes it necessary to review what opportunities the Hungarian companies have, 
including all the companies operating in Hungary, from the perspective of globalization, 
more specifically, the global industries. First, the conceptual framework outlined in Figure 
6.1.2 will be discussed (Porter, 1986).  
 
Porter’s conceptual framework (Porter, 1986b) takes the segments scope and the 
geographic scopes  starting points. The segments scope may be many, that is the company 
may compete in many markets and alternatively, the number of market segments served 
may be limited. Selection of geographical markets is the geographic scope dimension. 
Global strategy includes the markets of the Triad states, and country-centered strategy 
includes a limited number of countries. Long time has passed since the conceptual 
framework was formulated, which enables us to add to the geographical focus a regional 
strategy potential which is becoming a more and more feasible option for the EU.  
 
Two of the strategy types in Porter’s conceptual framework (Porter, 1986) the global cost 
leadership or differentiation, and the global segmentation (see the two cells on the left-
hand side of Figure. 6.1.2.) are primarily applied by global enterprises or national 
subsidiaries of global enterprises. These strategy options are based on the strategic 
advantages of general strategies in the global markets. In the Hungarian privatization 
global segmentation could be feasible in most of the cases. This reasoning is supported by 
the fact that the majority of the Hungarian enterprises were large in size to serve only the 
Hungarian market and faced with a considerable shortage of capital and management 
skills to go international in the 1990s. This made it difficult for them to retain their former 
product portfolio and market segments and forced them to focus it. The successful 
privatization cases show that most of the companies were forced to narrow down and 
specialize their product and market portfolio, and use the channels of the parent company 
in entering the global markets. A typical example is the ALCOA-Köfém is acquisition by 
ALCOA (Aluminium Company of America) (Czakó, 1998 c).  
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Figure. 6.1.2 Strategic alternatives in a global industry 
Segment
Scope
Many Segments
Few Segments
Global Cost
Leadership or
Differentiation
Protected
Markets
Global
segmentation
National
Responsiveness
Global Strategy Country-Centered Strategy
Geographic Scope  
Source: Porter, 1986, p.46 
 
 
The two cells on the right-hand side show the strategic options, which provide an 
excellent opportunity for enterprises that are not owned by a global enterprise. Focusing 
on the national markets is a feasible alternative for medium and large Hungarian 
enterprises alike. Focusing on protected markets can be a viable alternative for those 
Hungarian companies that are operated and maintained for social and national economic 
reasons. Nevertheless, rather than using the traditional trade policy measures to protect the 
market, more sophisticated means must be applied: means which are specific to consumer 
safety, production procedures and products. Such means are rather common in home 
countries of the global businesses.  
 
 
6.1.2.1 Alternative strategies for parent companies 
 
The international and global strategy that a parent company selects is closely related to the 
configuration of activities, when global enterprises may perform different activities of 
their value chain in different countries. International businesses also should take strategic 
decisions along the lines of co-ordination of their activities. Porter defines configuration 
as a company’s decision on how to position its value adding activities and how to disperse 
them geographically, i.e. how diverse these activities will be at an international level. The 
term co-ordination of activities refers to how like or linked the activities, performed in the 
different countries are coordinated with each other”. Porter points out (1986b, pp. 23-25.) 
The following alternative strategies are available on these two dimensions. 
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Figure. 6.1.3 Types of international strategies 
Types of International Strategy
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Coordination
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Operating in only on
Country
Export-Based
Strategywith
Decentralized
Marketing
Geographically
Dispersed
Geographically
Concentrated
Configuration of Activities  
Source: Porter, 1998a, p. 28   
 
In terms of co-ordination, the alternatives range from a complete lack of co-ordination to 
the harmonization of value chain activities in several countries. As for configuration, the 
operation of a business may be concentrated (one factory in one country) or dispersed 
(production and sales are performed in a great number of countries). The basic types are as 
follows: 
 
The bottom left-hand cell shows the case where a parent company decides not to co-
ordinate the operation of its foreign subsidiaries, however, its operations are rather 
dispersed geographically. In such a case, multinational businesses apply a country-focused 
strategy; alternatively, they concentrate their home businesses in one country where their 
subsidiaries are dotted around.  
 
If a parent company decides to co-ordinate the activities of its foreign subsidiaries and 
expand its operations geographically, it is characterized by an extensive co-ordination of 
the operation of its subsidiaries, that came about as a result of high foreign investments 
(see the top left-hand side cell in the matrix). 
 
If a parent company decides to co-ordinate the activities of its foreign subsidiaries and its 
operations are geographically concentrated, then the strategy applied is export-based and 
the operation is decentralized with along marketing (see the bottom right-hand side cell in 
the matrix).Adopting a simple global strategy, a company co-ordinates its activities 
performed in different countries and concentrates its operations geographically. That is to 
say, it concentrates as many of its activities as possible in one country, thus serving its 
international markets from there, and keeps control of its foreign subsidiaries by 
standardizing their activities which should be performed close to the customers.  
 
In light of the above strategy types, Porter (1986, p. 29) maintains that global strategy is 
what “as one in which a firm seeks to gain a competitive advantage from its international 
presence through either concentrated configuration coordinating among dispersed 
activities or both”. 
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Table 6.1.2 Organizational characteristics of the transnational  
Organizational 
Characteristics 
Multinational Global International Transnational 
Configuration of 
assets and 
capabilities 
Decentralized and 
nationally self-
sufficient 
Centralized and 
globally scaled 
Sources of core 
competencies 
centralized, others 
decentralized 
Dispersed, 
interdependent, 
and specialized 
Role of overseas 
operations 
Sensing and 
exploiting local 
opportunities 
Implementing 
parent company 
strategies 
Adapting and 
leveraging parent 
company 
competencies 
Differentiated 
contributions by 
national units to 
integrated 
worldwide 
operations 
Development and 
diffusion of 
knowledge 
Knowledge 
developed and 
retained within 
each unit 
Knowledge 
developed and 
retained at the 
center 
Knowledge 
developed at the 
center and 
transferred to 
overseas units 
Knowledge 
developed jointly 
and shared 
worldwide 
Source: Bartlett-Ghoshal, 1989. p.65. 
 
Bartlett-Ghoshal (1989) is more specific in defining the term global enterprises. In a 
previous study, Bartlett (1986) discusses how to organize and manage a company’s 
international operations and classifies the options according to the factors influencing 
global integration and national differentiation. In his study, a great importance is attached 
to flexible organizations of a network type. Bartlett-Ghoshal  (1989) addresses the issue 
from the perspective of global business management. According to geographic profile, 
four types of businesses are identified: multinational, global, international and 
transnational. Their management and organizational features were classified accordingly. 
The study provides an interpreting of global businesses, which is close to that of Porter 
(1986b). Global businesses aspire to gain cost benefits by centralizing production at a 
world level. Transnational businesses represent a new, ideal type of business. 
Transnational businesses aspire to improve their efficiency in order to gain a competitive 
edge in the world, and to make their response to local markets and international operations 
flexible. They regard innovation as a result of organizational learning, with all the 
employees of the company involved.  
 
Bartlett-Ghoshal  (1989) points out that the strategic capabilities of transnational 
companies are determined by three factors: global competitiveness, multinational 
flexibility and global learning that involve the entire organization. These three factors are 
given highest priority in the building and management of transnational businesses. The 
following Table provides a summary of the organizational features and management tasks 
for each factor. 
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Table 6.1.3  Building and Managing the Transnational 
Strategic Capability Organizational Characteristics Management Tasks 
Global competitiveness Dispersed and interdependent 
assets and resources 
Legitimizing diverse 
perspectives and capabilities 
Multinational flexibility Differentiated and specialized 
subsidiary roles 
Developing multiple and flexible 
coordination processes 
Worldwide learning Joint development and 
worldwide sharing of knowledge
Building shared vision and 
individual commitment 
Source: Bartlett-Ghoshal (1989), p 67. 
 
Bartlett-Ghoshal’s (1989) moved Porter’s strategy formulation to management. Their four 
types of global businesses emphasized different features of global business operation and 
by creating transnational businesses, they presented one feasible option to realize the 
slogan “Think globally, act locally” in terms of management and organization. They also 
showed what might be commonplace today, that for a global business to be successful, it 
has to work as a learning organization.  
 
Table 6.1.4 Characteristics of global, regional and local companies 
 Global company Regional Company Local Company 
Marketing 
approach 
Mass-marketing Segment-marketing Sales for one segment 
Need for 
Information 
Limited Periodical Real-time 
Decision making Mostly centralized Centralized Decentralized 
Organization Functional Functional and teams Integrated systems 
Focus of strategy Product Product/market Opportunities 
Direction of global 
companies 
  Marketing: mass 
customization 
Source: Winger-Edelman (1998) 
 
Carrying on with the above reasoning, the Table 6.1.4 summarizes the organizational and 
management tasks for global, regional and local enterprises. The table demonstrates that 
global mass production requires very strict and centralized management. The closer a 
company moves to the local particularities and special consumer needs, and the more 
value it adds, the more decentralized the decision-making becomes. And this requires a 
suitable information technology. Depending on size and structure, enterprises may be 
rather different in terms of strategic management and decision-making. The reason behind 
is that the businesses have to identify the conditions under which their competitive 
advantage provides them with a maximum profitability. The bottom line of the Table 
demonstrates that in the globalization, a new notion is developing, namely mass 
customization, which enables the global enterprises to respond to the local needs in a 
flexible and economic manner, by means of mass production and mass marketing. 
Combining them is the greatest challenge for the global enterprises these days.   
 
 
6.1.2.2 Global parents and their subsidiaries 
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Another interesting question in terms of global operation is how their foreign subsidiaries 
contribute to the efficiency of the global corporation. To answer the question, the findings 
of a case study and a questionnaire (Bartlett-Ghoshal, 1989) will be presented. The roles 
that a subsidiary may have can be grouped from two perspectives. 1. The strategic 
importance of the market served by the subsidiaries for the parent company. 2. The local 
resources and capabilities of the subsidiary that may be crucial for the parent company. 
The matrix in Figure 6.4 identifies the various types of national subsidiaries.  
 
‘Dark Hors’ includes subsidiaries that operate in strategic markets to the parent company. 
In such cases, it is critical for the parent company to be present in those markets. The 
group mostly included subsidiaries operating in the markets in Japan. These subsidiaries 
are responsible to gather information on growth and expansion opportunities. Their major 
goal is to pave the way for progress, either by entering strategic partnership with the local 
businesses or by concentrating on one single product range or buyer segment.  
 
Figure. 6.1.4 Generic roles of national organizations 
Black Hors Strategic
Leader
Implementer Contributor
High
Low
Low High
Strategic
Importance of
Local
Environment
Level of Local Resources and Capabilities  
Source: Bartlett-Ghoshal, 1989, p. 106 
 
‘Strategic leader’ includes foreign subsidiaries whose markets, resources, capabilities and 
opportunities are crucial for the entire corporations. These subsidiaries are expected to be 
creative and thus generate resources and capabilities transferable to other subsidiaries. A 
typical example was the privatization of the Hungarian Tungsram Rt. by General Electric, 
which made Tungsram a leading player in the manufacture of lighting equipments in 
Europe. 
 
‘Contributor’ includes foreign subsidiaries that, similarly to the implementers, operate in 
markets that are not strategic to the parent company at large; however, they help it have 
access to resources, business capabilities and opportunities that may be shared with other 
subsidiaries as well. In order to benefit from those resources, capabilities and 
opportunities, creativity is a high priority. Brand names that were introduced in the 
Eastern European markets, connections and local knowledge could be typical examples in 
Hungary. 
 
‘Implementer’ includes foreign subsidiaries whose markets are not large enough to be 
strategic to the company at large, and the same applies to their resources and business 
capabilities. This group mostly includes subsidiaries operating in developing countries and 
small European countries. These subsidiaries usually do not have access to information 
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that is key for the company at large, and they do not have an overview and control over 
the resources that are critical to the company. Their role is to deliver added value (sales 
revenue and profit) to the company and thus generate resources to enable the company’s 
strategy and innovation processes. Efficiency is a major expectation towards them. They 
most often operate in form of a limited company. 
 
In Hungary, the majority of subsidiaries to multinational companies would probably 
qualify as implementers. Out of the 200 largest companies in Hungary that listed on the 
Top200 on list by Figyelő, a Hungarian economic weekly, 19 were analyzed by Bayer-
Czakó (1999). In 1997, those 19 subsidiaries produced 25.3% of the total exports of 
Hungary and employed 12.5% of all the employees in Hungary. Their parent companies 
are global companies and 15 of the subsidiaries operate in the form of a limited company. 
The overwhelming majority of the local executives control only operational functions and 
their main responsibility is to increase the value added. With a minimum of 0.17% and a 
maximum of 4.68%, the Hungarian subsidiaries generated 0.7% of the revenue of the 
parent company, on average. Our hypothesis is that the Hungarian subsidiaries of global 
pharmaceutical companies can be classified as implementers. 
 
In subsidiaries of the implementer type, the management is responsible to increase the 
value added and thus make profits. Several major issues like sales strategy, strategic 
guidelines and promotion strategy are centrally determined. The tax and accountancy 
consultants to be hired are nominated by the parent company. Under the centralized and 
standardized conditions, the local management is able to concentrate on the particularities 
of the local market and the local competition. A high degree of centralization and 
standardization ensures that the same priorities and values be applied across the company 
all over the world. It is imperative that the structure of the quarterly report presented to the 
shareholders be consistent. The reliability of these reports is guaranteed by a carefully 
monitored database. So the success of the local management depends on their efficiency in 
the day-to-day operation.   
 
 
 
6.1.3. Globalization in the pharmaceutical industry  
 
In this section, two topics are discussed from several points of view. On the one hand, the 
leading companies of global industry and the large companies in the region are briefly 
introduced, and on the other hand, an answer is given to the issue on what processes 
referring to globalization have taken place in the Hungarian pharmaceutical industry in the 
course of the 1990s.  
 
 
6.1.3.1 Global companies  
 
It should be pointed out that the largest pharmaceutical companies in the world also take 
high place based on their market value among the most valuable companies in the world. 
On the Global Top 1000 list compiled by the Business Week, 12 companies, mostly 
headquartered in the United States, are ranked among the first 100 most valuable 
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companies. Sales, profit and profitability of these companies are shown in the table 
below.5  
 
Table 6.1.5 Pharmaceutical companies in the Business Week Global top 1000 among the first 
100, million USD or % 
Company Country Market 
Value 
1998 
Sales 
1997 
Profit 
1997 
Return on 
sales 
1997 
Market 
Value 
1999 
Sales 
1998 
Profit 
1998 
Return on 
sales 
1998 
Merck Co.  USA 139845 23637 4614 19.5% 159797 26898 5248 19.5%
Pfizer USA 133026 12504 2213 17.7% 138370 13544 2627 19.4%
Bristol-Myers 
Squibb 
USA 110791 78508 6093 7.8% 136526 18284 3636 19.9%
Johnson and 
Johnson 
USA 92866 22629 3303 14.6% 124635 23657 3059 12.9%
Rosch Holding Switz. 98901 12692 2893 22.8% 103719 16164 1879 11.6%
Novartis Switz. 116174 21088 3524 16.7% 101626 20437 3415 16.7%
Glaxo- 
Welcome 
GB 96070 13013 3017 23.2% 101535 12799 2867 22.4%
Eli Lilly USA 67968 8518 -385 -4.5% 78671 9237 2096 22.7%
American 
Home Products 
USA 63415 14196 2043 14.4% 75950 13463 2384 17.7%
Smith Kline 
Beecham 
GB 60888 12711 1760 13.8% 72922 12957 1791 13.8%
Abbott Labs.  USA 57257 11883 2094 17.6% 68703 12478 2333 18.7%
Schering-
Plough 
USA 61353 6778 1444 21.3% 66346 8077 1756 21.7%
Source: Business Week (1998) July and (1998) July 
 
 
As it turns out from the above table, there are 8 pharmaceutical US companies, two Swiss 
and two English companies among the top 100 most valuable corporations. The market 
price of these companies fluctuated between USD 60-160 billion in 1999. Their sales were 
between USD 8-27 billion. Their return on sales was between 13-23%. It seems that the 
American companies are the most influential in the pharmaceutical industry of the world. 
This and the fact that they can be examined – being listed on stock exchanges requiring a 
considerable publicity – are the reasons for that the American pharmaceutical companies 
are frequently mentioned in research studies. Thus, when speaking on the global strategy 
of pharmaceutical companies the findings refer to US ones.  
 
As the first step, strategic groups identified among the American companies will be 
discussed. Bogner-Thomas has investigated the strategies of the American pharmaceutical 
                                                 
5 One methodological remark on the table should be made: ranking in to the pharmaceutical industry is 
based on the main profile of the company, however, in the case of a few companies it is known that they are 
also active in other industries (e.g. Johnson and Johnson). With respect to this, tables like that cannot be 
used for deeper analysis. This problem is also in correlation with the difficulties in determining the profile 
of global corporations. This table is suitable for giving a review on the largest players and giving 
impressions on the size.  
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companies in the period of 1969-1988 (1996). The investigated interval has been divided 
into four periods. Their division is based on the years when important events had 
considerable effect on the pharmaceutical industry of the United States. Strategic groups 
listed in the table below have been identified. The mentioned examples are either 
companies ranked on the list compiled by Business Week or such corporations which are 
dominant players in the Hungarian pharmaceutical industry (e. g. ICN through the 
privatization of Alkaloida Pharmaceutical Works) or eventually having both features (like 
Ciba Geigy which continues to be active under the name of Novartis since its merger with 
Sandoz in 1987).  
 
  
According to the Table 6.1.7, the strategic groups may be grouped into four types. These 
are the type of research-oriented companies, that of the generic firms, the type of 
companies not carrying out any research activity and that of companies specialized in one 
component diagnostics. It may be seen from the table that companies nowadays 
considered as global companies were ranked into the strategic group of research 
companies (with narrow or wide focus) in the middle of the 1980s. Abott Labs is the only 
exception to this, which forms a separate strategic group in the opinion of the authors. 
Among the generic manufacturers, Zenith has been the member of this strategic group 
since the 1970s. ICN, which is also active in the Central and East European region and is 
involved in the privatization in Hungary, is ranked into the group of companies 
performing limited research activity.  
 
These strategic groups, from the Hungarian pharmaceutical companies’ point of view, call 
the attention to the fact that, although the Hungarian companies are smaller sized, but they 
are facing a choice of fundamental importance on long-term basis. Because of their size, 
the research orientation with narrow focus, manufacturing of generic products and the 
operation with limited research activity may be considered.  
 
Based on the sales of pharmaceutical companies resulted from drugs, Schõn compiled list 
on the top 10 companies, counting their share in the world market and their expenditure on 
R&D in 1990. It should be noted that the table below and the data published by Business 
Week differ from each other. The reason for this may be that Schõn (1999) considered the 
turnover originating exclusively from the sales of pharmaceutical products, which is 
especially in the case of Johnson and Johnson: out of the sales of USD 22.6 billion 
published by Business Week, only USD 8.6 billion resulted from the sales of medicines 
according to the statement by Schõn.  
 
It is worth noting that the market share of the top 10 manufacturers in the world totals to 
35.7% of the whole world market estimated to be USD 300 billion. If a glance is cast at 
R&D expenses, it may be seen that the largest companies spend characteristically more 
than 10% of their sales on R&D. In the case of companies listed in the table, this 
Figureure is 14% on the average.  
 
It is the feature of the pharmaceutical industry that, the international market is fragmented 
the top 10 manufacturers of the world market cover as little as nearly 36% of the total 
market which is mainly rooted in the great variety of pharmaceutical products. In addition, 
it may also be observed that the pharmaceutical companies have a very high market share 
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in a given therapeutic area. On the market of the original products, this share may also 
reach 100%. This is due to the original products launched onto the market that ensures a 
monopolistic position during their patent protection.  
 
Table 6.1.6 Sales and R&D spendings of top ten phamaceutical companies in the world 1997 
Rank Company Country Sales, m 
USD 
market 
shore, % 
R&D 
spending, 
m USD 
R&D as 
% of sales
1. Merck USA 11.3 4.6 1684 11.9
2. Glaxo Wellcome GB 10.9 4.5 1882 14.4
3. Novartis Switzerland 10.5 4.3 1813 18.6
4. Bristol-Myers 
Squibb 
USA 9.0 3.7 1200 12.1
5. Johnson&Johnso
n 
USA 8.6 3.5 1285 16.7
6. Pfizer USA 8.3 3.4 1710 6.0
7. American Home USA 8.1 3.3 1246 16.0
8. SmithKline 
Beecham 
GB 7.2 3.0 Na. na.
9. Hoechst Germany 6.9 2.8 1374 17.0
10. Eli Lilly USA 6.3 2.6 1382 16.2
Based on Schőn (1999) 
 
From the above data, it may be concluded that global companies are really focusing on 
research and the original products. I briefly summarize below what factors determine the 
development of the industry. I sum up the most important factors influencing on the 
pharmaceutical industry based on the Wilson-Henry study (1995) who have summarized 
the most important factors influencing the development of the industry in the book (Want, 
1995) dealing with the radical transformation of the industry.  
 
The Wilson-Henry study (1995) divided the pharmaceutical industry into two large 
groups. These are the groups of research-based companies and generic firms. This 
grouping is less differentiated than that by Bogner-Thomas (1996), but in its logic it 
follows the same approach. The research-oriented companies tightly co-operate with 
biotechnological research companies, universities and other research institutions as well as 
other technological companies. The primary task of the generic firms is to manufacture the 
cheap replication of the products with expired patent protection and to put those onto the 
market. They point out that generic firm do not develop new products and do not carry out 
any research to investigate the effect of the products manufactured by them either (pp 232-
234). Contrary to this, the research-oriented pharmaceutical companies deal not only with 
the development of the new drugs, but they also carry out a research activity focusing on 
improving the life quality of the patients through determining the doses to the different 
treatments. Generally, these companies are large, global corporations. It should be 
emphasized at this point that this judgment on the research activity of the generic firms is 
not correct. The basic research is really not typical of these companies, however, the 
development and especially product development are characteristic. Reformulation of the 
known active ingredient, investigation on the effects of the new version of the medicine 
manufactured this way, give product development tasks to the generic firms. This is also 
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instructive from the Hungarian pharmaceutical companies’ point of view, because generic 
production also requires research activity, in particular in product development. 
 
 
The most important factors of changes taking place in the pharmaceutical industry are as 
follows: great expenses of research and development, pressure to lower the cost level and 
the national governments. The effect of the individual factors is shown in Figure 6.1.5.  
 
Figure 6.1.5. Structure of the biopharmaceutical industry 
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Table 6.1.7 Strategic groups in the US pharmacentical market 
Time-
span 
Strategic groups and examples of its members 
-1969 Medium size limited 
research 
ICN, Marion Labs, 
Zenith 
Medium size moderate 
research 
Bristol-Myers, Eli Lilly, 
Johnson and Johnson, 
Schering-Plough, Squibb
Broud organic 
chemistry focus 
Hoffmann-LaRoche, 
Merck, Smith Kline and 
French 
Early diversification 
Pfizer 
 
1970-
1977. 
Medium size limited 
research 
Bristol-Myers, ICN, 
Johnson and Johnson, 
Shering-Plough 
Traditionaly antibiotics
Abbott,  Ely Lilly, 
Squibb 
Broud organic 
chemistry focus 
Ciba-Geigy, Hoffmann-
LaRoche, Merck, Pfizer, 
Smith Kline and French 
Generic-like firms 
Marion Labs, Zenith 
 
1978-
1980 
Medium size limited 
research 
Glaxo, Johnson and 
Johnson, Shering-Plough 
Traditionaly antibiotics
Beecham, Bristol-Myers, 
Eli Lilly, Pfizer, Squibb, 
Smith Kline and French 
Broud organic 
chemistry focus 
Ciba-Geigy, Hoechst, 
Hoffmann-LaRoche, 
Merck 
Generic-like firms 
ICN, Marion Labs, 
Zenith 
Heavy patenters 
Abbott Labs 
1981-
1984 
Lagging research firms 
ICN, Marion Labs 
Medium sized - 
assertive research 
Bristol-Myers, Glaxo, 
Johnson and Johnson, 
Schering-Plough, Smith 
Kline and French 
Large size-asseritve 
research 
Beecham, Ciba-Geigy, 
Ely Lilly, Hoechst, 
Hoffman-La Roch, 
Merck, Pfizer, Squibb 
Generic firms 
Zenith 
Diagnostics thrust 
Abbott Labs 
1985- Lagging research firms 
ICN, Marion Labs 
Narrow focus research 
firms 
Glaxo, Johnson and 
Johnson 
Broad focus research 
firms 
Bristol-Myers Beecham, 
Ciba-Geigy, Ely Lilly, 
Hoechst, Hoffman-La 
Roch, Merck, Pfizer, 
Squibb 
Generic firms 
Zenith 
Diagnostics thrust 
Abbott Labs 
Source: Based on Bagner-Thomas, 1996,  p. 142-143 
The R&D costs of developing a new medicine in the pharmaceutical industry is estimated 
USD 350 million. This amount was estimated by The Economist (1998b) to be USD 304 
million. The different sources generally indicate the R&D costs between USD 300-400 
million. The Figure of The Economist (1998b) shown below divides the process of the 
development of pharmaceutical products into phases. Considering the time demand of product 
development, it should also be pointed out that the life cycle of pharmaceutical products is 
very long that poses special problems in managing the product mix. Wilson-Henry (1995) 
mentioned the same time demand as The Economist and they both have pointed out that 5000 
molecules having no success fall on one patented compound (molecule) in the United States 
annually. To achieve success in this field, the research-oriented companies strive to co-
operate with universities and scientific institutes, biotechnological companies and 
corporations involved in special technologies. In the framework of the co-operation with the 
academic world, the pharmaceutical industry supports the institutions with financial funds in 
performing clinical and efficacy studies as well as basic research activity. The special 
technological companies have been specialized in developing the individual steps of the drug 
manufacturing process.  
 
The biotechnological companies gain ground in R&D activity. From the 1970s on, R&D 
activity based on the so called biotechnology has been gaining ground against the 
predominance of the earlier chemical researches, and they are more expensive. In the opinion 
of the authors of several analyses, the considerable increase in R&D expenses is attributed to 
this change. These companies play an important role in the innovation of the processes and 
discovering new drugs in the pharmaceutical industry. Because of the considerable expenses 
and high risks, corporations financed by venture capital are active in this field, with which the 
large pharmaceutical companies co-operate in the promising phase of development. 
Companies specialised in genetically engineered technologies are ranked into the group 
which, in addition to the information technology industry, require the largest venture capital 
in the United States (The Economist, 1998b).  
 
 
Figure 6.1.6 Process and costs of drug development 
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Source: The Economics, 1998b. Figures denote the years. 
 
The pressure to lower the cost level also is coming from several outside players. The most 
important are the national governments, insurance companies and consumers. In parallel with 
the continuous increase in the share of the health care expenditure on GDP, there is a 
considerable pressure on the players of the health care to reduce their expenses and the 
pharmaceutical companies are the most frequent targets of this process. The pressure to 
reduce the costs has resulted in the expansion of generic products. It is noted that the generic 
products’ gaining ground also is due to the fact that the active ingredients of the fundamental 
medicines of the widespread diseases has been discovered by the 1980s, their patent 
protection have expired or are very close to expiry. It may be observed that the index of the 
products expressed in DOT-days (dose-on-treatment) is on decrease. It shows that the 
formulations of the active ingredients become more and more effective which is partly 
attributable to the R&D carried out in this field.  
 
The role of the national governments is a determining factor in whole pharmaceutical industry 
and it increases globalization just to the same extent as it decreases it. The national 
governments control the trade of pharmaceutical products on their own markets. There are the 
marketing authorization, tight price control and the list of reimbursed medicines among their 
control tools. Being on the list of reimbursed medicines is generally a key factor regarding the 
market success in countries with a developed health care system, and it is especially 
important for the pharmaceutical companies in the case of original products.  
 
The above factors led to the consolidation of the pharmaceutical industry in the 1990s. This 
partly resulted from the acquisition and mergers within the industry, one part of which was 
horizontal and took place within the industry, while the other part showed a vertical 
integration (e. g. towards marketing channels).  
 
 
6.1.3.2. The European Union and the pharmaceutical industry  
 
In November, 1998, the European Union issued a committee document on the single market 
of pharmaceutical products (EU (1998) (Com98)588 final). The preliminaries to this 
document were the document (COM(98)718) issued in 1994 according to which the decrease 
in global competitiveness of the pharmaceutical industry of the EU was one of the most 
important concerns. In the period elapsed since that time, one of the most important tasks was 
to create the single market as well as a stable and predictable environment. The stable and 
predictable environment was to support the protection of the patients’ health, rapid entry the 
market and therapeutic innovation. In formulating of the principles and regulations of the 
European Union on the pharmaceutical industry, the purpose of creating the single market and 
that of the encouraging of R&D activity are to improve the competitiveness of pharmaceutical 
companies, mainly against the American corporations.  
 
The market of pharmaceuticals is one of the most fragmented markets in the EU at national 
level. The first review on the impacts of the single market was published in July, 1996 (see 
EU (1996)). According to this, several steps were taken to create the single market of the EU. 
One of the issues is the question of prices where the most important expectation is to ensure 
the transparency of price control (89/105/EEC). Only relatively moderate results could be 
achieved in this issue due to the fact that this field is part of the budget policy of the member 
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states (see table 6.8 on the tools of price control applied by the national governments). The 
1992 directives on the „rational use of medicines” (92/26EEC, 92/27/EEC, 92/25/EEC) have 
harmonized the classification of the medicines (prescription drugs, non-prescription drugs), 
advertising of the drugs, information to be provided for patients, and the pharmaceutical 
wholesaling.” Regulations on the intellectual property on pharmaceutical products extended 
patent life for 20 years. This affected the research-oriented manufacturers favorably and 
handicapped the generic firms. The least steps forward have been taken in the application of 
the horizontal tools, e.g. in the issues of product liability, trade marks, public procurements 
and competition policy.  
 
The steps taken to create the single market of the EU pharmaceutical industry have produced 
results in the following fields: Cross-trader sales of drugs have increased. Foreign direct 
investment has been very large, mainly from the part of the US companies which especially 
targeted England and France. There was no change in the number of companies operating in 
the industry however their size has increased. Productivity has been considerably increased in 
the pharmaceutical industry. It is to be mentioned among the achievements that the European 
Medicines Evaluation Agency (EMEA) was established in 1995 and the EU member states 
mutually recognize the authorization system of each other. The Frankfurt Round Table 
discussions, where the interested parties of their pharmaceutical industry represent the 
member states, serve the aim of creating the single market of the European Union.  
 
In accordance with creating the single market, the principle of subsidiarity is emphasized in 
the EU documents. The reason for this is that the pharmaceutical industry is in close 
connection with the health care system of the given country, whose task is to enforce of the 
right of its citizens to health, and it is in correlation with the financial capability of the given 
national economy. Consequently, in addition to the principles and measures serving the 
standardization, the most important requirement is to enforce the principle on transparency. 
The reason for this is that “Member States have exclusive responsibility in the field of the 
health care; they view both the provision of health and its financing as key to social solidarity; 
and they have to meet public expenditure objective, notably for the purpose of European 
Monetary Union.” (EU (1998) p 4) According to the documents, it is a highly important 
aspect that the countries desiring to join should be able to apply the uniform EU principles in 
such a way that it should not be contrary to their national health care system.  
 
At the end of the 1990s, three steps continue to be held extremely important in the 
pharmaceutical industry: completion of the single market; increase the attractiveness of the 
European Union in the field of R&D; improving consumer choices in the medicines of the 
required quality, safety and efficacy at affordable cost. In connection with the pharmaceutical 
industry, the latter is especially the field where a considerable chance is given to the use of 
Internet.  
 
 
Table 6.1.8 Summary of Pricing and Cost Containment Methods 
 United 
Kingdom 
Austria Belgi-um Denmark Finland France Greece The 
Netherlands 
Ireland Germany Italy Portugal Spain Switzer-
land 
Sweden 
Price control on ethicals N Y Y N N Y Y N Y N Y Y Y N N 
Price control on OTCS N Y Y N N N Y N N N N N N N N 
Compulsory pharmaco-
economic data 
N N N N N N N N N N N N N N Y 
Profit control Y N N N N N Y N N N N N Y N N 
Promotional cost control Y N N N N Y N N N N N N Y N N 
Reference pricing N N N Y N N N Y Y Y N Y N Y Y 
Positive list* N Y Y Y Y Y Y Y Y N Y Y Y Y Y 
Negative list Y N N N N Y N Y N Y Y N Y N Y 
Risk sharing N N N N N Y N N N N N N Y N Y 
Co-payment Y Y Y Y Y Y Y N Y Y Y Y Y Y Y 
Prescribing Indgets for 
doctors 
Y N N N N N N N Y Y N N Y N N 
Generic substitution N N N Y Y N N Y N N N N N N N 
Note: Y= applied, N=not applied, * includes lists of medicines „recommended” for reimbursement as well as official positive lists. 
The pharmaceutical industry of the European Union. The pharmaceutical industry of 
EU provides 40% of the world production nearly 490,000 people are employed here, 
among them 71,000 are involved in research and development activity. The 
pharmaceutical industry of the EU has a positive trade balance. The reason for worries on 
EU competitiveness is pharmaceutical industry is that the increase rate in imports of the 
EU is higher than that of exports (see Table 6.1.9).  
 
Table 6.1.9 Pharmaceutical exports and imports of EU, 1995-1998 
 1995 1996 1997 1998 
Export, mEcu/Euro 16.937 18.107 23.205 26.751
Change, % +9.1 +6.9 +28.2 +15.3
Imports, m Ecu/Euro 8.309 9.590 10.799 12.611
Change, % +12.0 +15.4 +12.6 +16.8
Trade balance, m Ecu/Euro 8.628 8.517 12.406 14.140
Source: Based on Eurostat (1999) External and intra-European union Trade Monthey Statistics, 
12. 
 
 
The trading partners of the EU pharmaceutical industry are among the countries also 
having developed pharmaceutical industry, such as the United States of America and 
Switzerland. It means that the intra-industrial trade is at a very high level in this industry. 
The role of the Central-Eastern European region is a significant in the exports of the 
European Union, nearly 9% of the EU-exports are delivered to this region. Considering 
the imports, the situation is highly different from this. The share of 1.6% refers to the fact 
that imports from this region to the EU are not significant in value from the EU’s point of 
view. The high exports and low imports, however, are resulted in considerable trading 
surplus for the EU in this region.  
 
Table 6.1.10 The biggest trading partners of the EU, 1998 
Country Export, 
mEcu/Euro 
Shares in 
exp. %-
ában 
Import, 
mEcu/Euro
Shares in 
inports %-
ában 
Trade 
balance, 
mEcu/Euro
United States 7054 26.4 5507 43.7 +1547
Switzerland 3002 11.2 4613 36.6 -1611
CEEC 2367 8.8 198 1.6 +2169
Japan 1543 5.8 670 5.3 +873
Source: Based on Eurostat (1999) External and intra-European Union Trade Monthly Statistics. 
12.. CEEC – Countries of Central and Eastern Europe 
 
 
One of the greatest challenges to the EU’s pharmaceutical industry is the in the field of the 
research and development. Between 1983 and 1992, R&D expenditure has increased with 
50%. In 1997, ECU 10 million was spent on research and development. The share of 
Europe in the development of new products was 19% in 1997, against the 65% 30 years 
earlier. In the innovation of new active ingredients, the US was with 76%, Japan with 14% 
ahead of Europe, whose share was 10% in 1995 (EU 1996 and EU 1998).  
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The industry of the European Union has become of two levels: one group includes a few 
research-based large corporations; the other group includes several smaller companies. In 
the case of the research-based companies, it could be observed that their activity was 
diversified into the direction of manufacturing generic products and paramedical products 
in the course of the 1990s. On the whole, there was a considerable increase in the 
competition among the companies manufacturing generic products. Among the 
wholesalers, a concentration process could be observed. Such large global companies 
belong to the pharmaceutical industry of the European Union as the English Glaxo-
Wellcome or Bayer AG.  
 
 
6.1.3.3. Pharmaceutical firms of the Central and Eastern Europe and the 
Hungarian pharmaceutical industry  
 
There are much less information available on the pharmaceutical firms in the Central and 
Eastern European region than whether on the pharmaceutical companies in the European 
Union or on the leader corporations of the world. It turned out from the data of the EU that 
the countries in this region are much more important for the market as an exports than in 
respect to imports. The data of 1.6% relating to 1998 refers to the fact that the European 
Union is not the primary target market of the region.  
 
Table 6.1.11 The biggest pharmaceutical companies in the ex-socialist countries, m USD, 
1996-97. 
Company Country Total sales 
revenue 
Pharma sales 
revenue 
Net profit 
  1997 1996 1997 1996 1997 1996 
Pliva Croatia 465 418 221 316 99 84
ICN the shole 
region 
433 n.a. 355 n.a. 70 n.a.
Lek Slovenia 328 281 295 227 23 21
Krka Slovenia 323 311 270 245 32 23
Richter 
Gedeon 
Hungary 279 247 279 247 99 76
Chinoin Hungary 198 149 164 121 47 39
Bryntsalov/ 
Ferane 
Russia 179 340 179 93 n.a. n.a.
Leciva Czech 
Republic 
176 164 176 164 15 10
Slovakofarma Slovakia 159 148 159 148 12 17
Egis Hungary 156 165 156 165 34 38
Source: Schőn (1999) 
 
 
The above table includes data on the 10 largest pharmaceutical companies in the ex-
socialist countries. Data relating to 1996 and 1997 are given in million USD. There are, 
three Hungarian pharmaceutical companies – Richter, Chinoin and Egis – on the list. In 
order to show its scale in the world economy let us see some figures. 10 largest 
pharmaceutical companies in the region amounted to USD 2.2 billion, which was less than 
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1% of the estimated world sales and approximately corresponds to the EU exports to the 
region. The total sales of the top 10 pharmaceutical companies in the region would not be 
sufficient either, to get among the 10 largest global pharmaceutical companies of the 
world. Besides, however, it should be noted that these companies – thus the three 
Hungarian companies in the list – are among the leaders in their own national markets.  
 
In international comparison, Hungary has great traditions in the pharmaceutical industry. 
This can be explained by the early start and development of the domestic pharmaceutical 
industry, which was in accordance with the international trends of that time, and later on 
by their strong position in the Comecon era. The largest Hungarian pharmaceutical 
companies – Chinoin, Egis and Richter - are among the leading companies of the region.  
 
If the data relating to return on sales (total sales/net profit) are investigated in the table 
below, it turns out that the return on sales of the Hungarian companies is the highest in the 
region and these data are far higher than the average. These indices refer to the fact that 
the Hungarian pharmaceutical companies create the forefront of the region in profitability. 
Comparing the return on sales to the values calculated by using the data published in 
Business Week, it turns out that these values also exceed the highest values given in the 
mentioned weekly. The return on sales data made known in the referred weekly were 
between 7.8 and 23.2%, disregarding the data of Eli Lilly showing deficit, in 1997. The 
same data of companies in the region were between 7.0 and 35.0%. This refers to that fact 
that companies of the region, based on this specific index, show the same performance as 
global large companies.  
 
Table 6. 1.12 Performance of the biggest companies in the Central and East European region 
Company Total sales 
revenue 
Net profit Return on sales* 
 1997 1996 1997 1996 1997 1996 
ICN 433 n.a. 70 n.a. 16,2% na 
Lek 328 281 23 21 7,0% 7,5% 
Richter Gedeon 279 247 99 76 35,5% 30,8% 
Krka 323 311 32 23 9,9% 7,4% 
Pliva 465 418 99 84 21,3% 20,1% 
Bryntsalov/Ferane 179 340 n.a. n.a. na na 
Leciva 176 164 15 10 8,5% 6,1% 
Chinoin 198 149 47 39 23,7% 26,2% 
Slovakofarma 159 148 12 17 7,5% 11,5% 
Egis 156 165 34 38 21,8% 23,0% 
Based on Shőn (1999). *Net profit/Total sales revenue. 
 
If the data of the Hungarian pharmaceutical industry are examined in terms of US Dollar, 
it turns out that its production is appr. USD 1 billion, while the exports totals to some 
USD 0.5 billion. In the light of the data of global pharmaceutical companies, these data 
clearly show that the Hungarian pharmaceutical industry is small in global dimensions. 
The position of the pharmaceutical industry in the Hungarian economy is shown by the 
fact that more than 15,000 people are employed here. The reason for my citing these 
 123
provoking figures at the end of this chapter is to underline that an industry, which is small 
on global scale, can be a leading industry in a national economy of small size, for example 
because its jobs provided. An evaluation exclusively based on figures shows the 
oppressive side of globalization especially in the case of small national economy. Besides, 
it warns against investigating exclusively with data expressed in hard currency uprooted 
those from the facts behind the data. The small size of the Hungarian pharmaceutical 
companies, in global dimensions draws the attention to necessity of focusing on such a 
fields where the advantages do not depend on size. Putting in to the language of strategy, 
the segment (niche) strategies may be successful and in the management and operations 
and all economic knowledge should be adapted and applied which are also used by the 
largest players.  
 
Table 6. 1.13 Key figures of the Hungarian pharmaceutical industry in USD and the number 
of employees, 1989-1998 
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 
HuFt/USD 
exchag rates 
59.1 63.2 74.81 79 92.04 105.13 125.7 152.6 186.8 214.5
Pharmaceutical 
production, billions USD 
0.87 0.98 0.93 0.72 0.78 0.8 0.81 0.84 0.93 0.93
Pharma export, billions 
USD 
0.35 0.49 0.38 0.37 0.37 0.39 0.41 0.44 0.54 0.53
Pharmaceutical 
employees, thousands 
22.80 23.43 22.69 20.26 18.52 17.64 17.38 15.69 15.18 15.43
Industrial production 
billions USD 
29.06 30.50 28.67 22.77 22.17 23.55 28.01 28.89 31.93 35.03
Industrial exports, 
billions USD 
7.62 7.28 5.14 5.41 5.35 6.41 8.79 10.20 13.48 16.64
Industrial employees, 
thousands 
1356.4 1282.1 1147.6 997.1 673.4 798.2 763.5 735.4 733.5 750.9
Source: Central Statistical Office (KSH)  Statistical Year books 
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6.2. Factors influencing the competitiveness of the Hungarian 
pharmaceutical industry in the 1990s 
 
In my thesis dealing with the competitiveness of the industries, I have selected the 
pharmaceutical industry to be the subject of the empirical analysis. The reason for this is 
that the pharmaceutical industry could be considered as a flagship industry of the 
Hungarian economy before the changing the political system. Having completed the 
privatization, these companies got into private ownership; their stressed importance in the 
national economy has been reduced. Following the changes in the ownership and due to 
the characteristics of the pharmaceutical industry, this industry can also be investigated 
based on public information. My selecting the pharmaceutical industry has also been 
inspired by Porter (1990) who analyzed, the internationally leading Danish insulin 
manufacturer, Novo Industri (since that Novo-Nordisk), and a case study has also been 
made on this company for educational purposes (Enright, 1992, reg. No. 9-389-148).  
 
The form of this chapter of the thesis is case study. The purpose of this case study is to 
outline the most important trends taken place between 1989-1998, to point out the most 
important economic, business and management factors having influence on the operation 
of the pharmaceutical industry as well as to reveal the motives for the competitiveness of 
the pharmaceutical industry and to give a picture on those. Evaluation of the case study 
may be found in Chapter 6.3.  
 
When preparing this chapter, I relied on public information. The most important sources 
of the information were the papers and analysis published in the Hungarian journals and 
weeklies. Among the data on the pharmaceutical industry, I used the annuals published by 
the Central Statistical Office and National Health Insurance Fund. Where it was necessary, 
I also drew in the laws on the report of the Hungarian annual budget as data source. The 
main source of data for the pharmaceutical industry and pharmaceutical trading companies 
was the Figyelő Top 200 publication which contains the financial data of the 200 largest 
domestic companies ranked on the basis of their annual sales and evaluates the annual 
operation of the first 100 companies. In the case of companies, I also utilized the annual 
reports of Richter and Egis. I used, furthermore, the paper of Katalin Antalóczy who has 
evaluated the operation of the pharmaceutical industry in the 1990s in two long-winded 
studies. One of them was prepared for the “In global competition ” research program 
(Antalóczy, 1997), while the other was a study focusing on the privatization of the 
pharmaceutical industry (Antalóczy, 1999). I also relied on two of my own earlier papers 
on the pharmaceutical industry (Czakó 1997 and 2000). The first was prepared in the 
framework a research investigating the relations of the Hungarian pharmaceutical industry 
to the health care system (consultant Éva Orosz, lead the project of the Market Research 
Co. Ltd.), while the other was prepared on behalf of the Ministry of Economy to deal with 
the growth opportunities of Richter Co. Ltd. to (consultant Károly Balaton). I have also 
reviewed the most important relevant regulations on the industry the source of which was 
the CD-ROMs of the Collection of Hungarian Laws. In addition to the Hungarian laws, I 
have also used the EU guidelines mentioned in the previous section, which can also be 
reached in the Internet (www.europa.eu.int). In the case of companies having their own 
homepage, the information, too, found there were utilized.  
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Time horizon of this study embraces the interval between 1989 and 1999. The year of 
1989 is considered such a year before changing the political system, which could be 
deemed the last untroubled year of the earlier operation. The year of 1999 is discussed in 
connection with the governmental regulations in the first place.  
 
Chapter 6.2 investigates what processes have taken place in the Hungarian pharmaceutical 
industry in the period between 1990-1998. Chapter 6.2.1 positions the pharmaceutical 
industry in the Hungarian industry based on the data published by the Central Statistical 
Office (CSB). The purpose of this investigation is to outline the position of the 
pharmaceutical industry within the Hungarian industry based on statistical data and to 
underline the changes, which may be seen from the data, taken place in the pharmaceutical 
industry. Chapters 6.2.2 and 6.2.3 are a summary on the most important features and 
frameworks which have an influence, on the operation of the pharmaceutical industry. The 
Chapter 6.2.2 describes peculiarities of pharmaceutical products. In the Chapter 6.2.3, the 
principles and practice of the governmental regulations are discussed. My intention is to 
focus on two aspects here: the fields on regulating the industry and through this the factors 
influencing the companies’ behavior to a great extent as well as the size of the market. 
Chapter 6.2.4 deals with the changes occurred in the pharmaceutical industry between 
1989 and 1998. This Chapter is divided into further for subchapters. At the first, I discuss 
the market subsequently marketing issues are discussed. The third subchapter deals with 
the competition within the industry and concentrating on the factors that were driving the 
competition of the market players in the investigated period, then on analyses on the 
performance of the domestic manufacturers is following.  
 
 
6.2.1 Position of the pharmaceutical industry in the Hungarian economy  
 
The pharmaceutical industry is one of the sub-branches of the chemical industry within 
the industry that is kept record by the CSO under the registration number 2423 from the 
year of 1993. The data are based on the account taken on the organizations operating with 
more than 20 employees. The source of the data was the statistical and industry-statistical 
annuals of the Central Statistical Bureau. In the mirror of the statistical data, the 
pharmaceutical industry was characterized through the trends included in the table below 
in the period between 1989 and 1998.  
 
 
According to the statistical data relating to the organizations operating with more than 20 
employees in the period of 1989 to 1998, the share of the pharmaceutical industry in the 
industrial gross production has been diminished from 3% to 2.7%. Considering the 10-
year period, the share in the gross production started to decrease in 1995. Until that time, 
the data show an increasing tendency due to the diminishing average gross industrial 
production. This line of data refers to the fact that the pharmaceutical industry could keep 
its earlier position in the industry in general.  
 
Considering the data on export sales, a diminishing tendency may be seen again. In this 
case, the diminishing is much larger than with the gross production. While the foreign 
sales of the pharmaceutical industry were 6.6% of the export sales of the total industry in 
1989, this figure has been diminished to 2.2% by 1998. This diminishing tendency is 
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characteristic of the pharmaceutical industry from 1995 on. This is in correlation with the 
fact that, in general, the export of the complete industry can be featured by a much larger 
growth rate than that of the pharmaceutical industry. In analytical studies, it has been 
pointed out that the multinational companies settled down in Hungary by inward foreign 
direct investment had a considerable part in it.  
 
Table 6.2.1 Statistical data on the pharmaceutical industry, 1989-1998  
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Gross pharmaceutical 
production. Billion 
HUF 
51.6 61.8 69.9 56.7 71.3 84.0 102.5 128.1 173.9 199.7
Gross industrial 
production. Billion 
HUF 
1717.6 1927.8 2144.4 1798.7 2040.9 2476.1 3521.2 4410.0 5965.2 7514.8
Pharmaceutical as % 
of industrial 
production 
3.0% 3.2% 3.3% 3.2% 3.5% 3.4% 2.9% 2.9% 2.9% 2.7%
Pharmaceutical 
export. Billion HUF. 
29.8 31.4 37.2 26.0 36.9 41.2 48.7 58.2 69.2 79.3
Industrial exports. 
Billion HUF 
450.6 460.4 384.4 427.1 492.6 673.5 1105.4 1557.1 2518.0 3569.7
Pharmaceutical 
exports as % of 
industrial exports 
6.2% 6.8% 9.7% 6.1% 7.5% 6.1% 4.4% 3.70% 2.7% 2.2%
Employees in 
pharmaceutical 
industry. Thousands 
person 
22.8 23.4 22.7 20.3 18.5 17.6 17.4 15.7 15.2 15.4
Employees in 
industry. Thousands 
persons 
1356.4 1282.2 1147.6 997.1 673.4 798.2 763.6 735.4 733.5 750.9
Pharmaceutical 
employees as % of 
industrial employees 
1.7% 1.8% 2.0% 2.0% 2.7% 2.2% 2.3% 2.1% 2.1% 2.1%
Gross pharmaceutical 
wages. Thousands 
HUF 
10.8 16.8 22.6 30.2 40.5 53.7 66.6 85.8 109.3 125.6
Gross industrial 
wages. Thousands 
HUF 
10.7 13.2 16.8 19.6 27.5 33.9 41.2 50.2 61.2 71.5
Pharmaceutical wages 
as % of industrial 
wages 
101% 127% 134% 154% 147% 158% 162% 171% 179% 176%
Source: Hungarian Statistical Office (KSH) yearbooks. Data refer on companies with more than 
20 employees. 
 
If the number of employees in the industry is considered, it may be seen that in this respect 
the pharmaceutical industry not only kept its position as employer, but it could also 
improve it, because it gave work to do to 2.1% of those employed in the industry in 1998 
as against to the share of 1.7% in 1989. 
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Considering the nominal gross wages and salaries, it turns out that the wages and salaries 
of those employed in the pharmaceutical industry have significantly increased compared 
to the industrial nominal gross wages and salaries in the investigated period. At the 
beginning of the investigated period, in 1989, the gross wages and salaries were nearly at 
the same level, which has considerably changed by the end of this period. The gross 
wages and salaries in the pharmaceutical industry are now with 75.6% higher than the 
industrial mean gross wages and salaries. It is presumably in connection with the fact that 
during this period the ratio of the white-collar employees has considerably increased due 
to the circumstance that the number of blue collar staff has been reduced nearly to the 
half, while the number of the white collar staff has increased to a small extent. According 
to the data, the decrease in the number of employees affected the blue-collar staff in the 
pharmaceutical industry at the first place.  
 
Based on the tendencies shown in the development of the gross production, number of 
employees as well as the gross wages and salaries, such an overall picture of the 
pharmaceutical industry comes to light, which shows that; on the whole, the 
pharmaceutical industry could keep its earlier position within the Hungarian industry. It 
holds true of the gross production and especially of the employer status. Diminishing of 
the share in the gross production refers to the fact that the growth rate of the gross 
production of the pharmaceutical industry did not keep space with the growth rate of the 
gross production of the industry. Keeping the position as employer shows that the 
reduction in the staff number was of smaller extent in the pharmaceutical industry than in 
the whole of the industry. The diminishing tendency of the export data poses the problem 
that the competitiveness of the pharmaceutical industry has been reduced as compared to 
that of the whole industry if this issue is examined exclusively on export data. However, if 
the data on the share of the Hungarian export in the world export mentioned in Chapter 5 
are called to the mind – that was 0.32% in 1989 and more than 0.36% in 1997 – the 
pharmaceutical industry should be considered competitive in the approach by Porter 
(1990), because it continues to represent 1.6-2.0% of the total Hungarian export. Based on 
the analysis of the statistical data, it may be concluded that there was no fundamental 
change in the role of the pharmaceutical industry in the industry as compared to the earlier 
situation, however, its competitiveness in export has been diminished compared to the 
whole of the industry. For a deeper interpretation of the above-mentioned data and the 
judgment of the competitiveness of the pharmaceutical industry, it is also necessary to 
review the international and domestic tendencies of the pharmaceutical industry. Before 
this question would be answered, however, the development of the rate of employment, 
per capita productivity and the gross real wages and salaries per head in the 
pharmaceutical industry will be investigated in details.  
 
The more detailed analysis shall be started with the development of the rate of 
employment. As it was mentioned, the pharmaceutical industry kept its employer position 
in the industry in the period between 1989 and 1998. If the chain index on the 
development of the number of employees in the pharmaceutical industry is investigated, it 
may be seen that the number of employees has continuously decreased both in the 
pharmaceutical industry and the industry, and this decrease seems to be stopped at the 
1997 level in 1998. The chain indexes also disclose the fact that the decrease in staff was 
started in the pharmaceutical industry later and the decrease was of smaller rate than in the 
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whole of the industry. The basis indexes on the rate of employment show that in the whole 
of the industry the decrease in employment was much larger than in the pharmaceutical 
industry. The rate of employment has diminished almost to the half; in 1998 only 55.4% 
of employees in 1989 could find work in the industry. The same value was reduced to its 
two-thirds in the pharmaceutical industry, in 1998, 67.7% of the staff in 1989 had job in 
the pharmaceutical industry.  
 
Table 6.2.2 Chain and base indexes of employment in the pharmaceutical industry, 1989-
1998 
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Pharmaceutical 
employees, thousands 
persons 
22.8 23.4 22.7 20.3 18.5 17.6 17.4 15.7 15.2 15.4
Industrial employees. 
Thousands persons 
1356.4 1282.2 1147.6 997.1 673.4 798.2 763.6 735.4 733.5 750.9
Pharmaceutical 
employees as % of 
industrial employees 
1.7% 1.8% 2.0% 2.0% 2.7% 2.2% 2.3% 2.1% 2.1% 2.1%
Pharmaceutical chain 
indices 
100.0% 102.8% 96.8% 89.3% 91.4% 95.3% 98.5% 90.3% 96.7% 101.7%
Industrial chain indices 100.0% 94.5% 89.5% 86.9% 67.5% 118.5% 95.7% 96.3% 99.7% 102.4%
Pharmaceutical 
industry. 1989. 
100.0% 102.8% 99.5% 88.9% 81.2% 77.4% 76.2% 68.8% 66.6% 67.7%
Industry. 1989. 100.0% 94.5% 84.6% 73.5% 49.6% 58.8% 56.3% 54.2% 54.1% 55.4%
Source: KSH yearbooks. Data refer on companies with more than 20 employees.  
 
The gross production value per capita is higher in the pharmaceutical industry than in the 
whole of the industry. However, the difference available in 1989 has significantly been 
reduced during the 10-year period. While in 1989 the gross production value per capita 
was with 78.7% higher in the pharmaceutical industry, the same data was only 29.3% in 
1998. Between the two dates, the decreasing tendency of the difference may be observed, 
however, this decrease was not monotonous. I have also calculated the gross production 
real value per capita. Followed Blahó (1999), the gross production value per head has 
been deflated with the consumer price index. The real productivity indices show an 
increasing tendency. Considering the chain index, it may be seen that in 1992, the 
production value per capita did not reach that in the previous year in the pharmaceutical 
industry, while in the whole of the industry the production value per capita was higher 
every year than in the previous year. Looking back to the table 6.2.1., it may be seen that 
the decrease in export sales was the largest in the pharmaceutical industry this year. In the 
industry, the data of 1993 is mind higher than the previous one, which is justified by the 
sharp decrease the number of employees. According to the statistical data the decrease in 
the number of employees was the largest in the whole of the industry in 1993 and 
following this an increase could be observed. Considering the real productivity basis 
index, it turns out that during the 10-year period the productivity per capita did not 
decrease below the 1989 level, and in the industry from 1991 on, while in the 
pharmaceutical industry from 1993 on, a considerable increase occurred compared to 
1989.  
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Table 6.2.3 Gross production value per capita, 1989-1998 
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Pharmaceutical 
industry, mHuF 
2.263 2.639 3.079 2.800 3.850 4.764 5.897 8.167 11.456 12.941
Industry, mHuF 1.266 1.504 1.869 1.804 3.031 3.102 4.612 5.997 8.132 10.008
Pharmaceutical as % 
of industry  
178.7% 175.5% 164.8% 155.2% 127.0% 153.6% 127.9% 136.2% 140.9% 129.3%
Pharma per capita 
gross production 
value, chain indexes 
100.0% 116.6% 116.7% 90.9% 137.5% 123.7% 123.8% 138.5% 140.3% 113.0%
Industry per capita 
gross production 
value, chain indexes 
100.0% 118.7% 124.3% 96.5% 168.0% 102.4% 148.7% 130.0% 135.6% 123.1%
Consumer Price Index 1.17 1.28 1.35 1.23 1.22 1.18 1.28 1.23 1.18 1.14
Pharma: deflated 
production value per 
capita, m HUF 
1.934 2.048 2.281 2.276 3.143 4.010 4.600 6.607 9.684 11.32
Industry deflated 
production value per 
capita, m HUF 
1.082 1.166 1.384 1.467 2.474 2.611 3.597 4.852 6.874 8.756
Pharma: deflated 
production value per 
capita chain indexes 
100.0% 105.9% 111.4% 99.8% 138.1% 127.6% 114.7% 143.6% 146.6% 116.9%
Industry deflated 
production value per 
capita chain indexes 
100.0% 107.8% 118.7% 106.0% 168.7% 105.5% 137.8% 134.9% 141.7% 127.4%
Pharma: deflated a 
production value per 
capita base indexes 
100.0% 105.9% 117.9% 117.7% 162.5% 207.3% 237.8% 341.6% 500.6% 585.3%
Industry deflated 
production value per 
capita base indexes 
100,0% 107,8% 127,9% 135,5% 228,6% 241,3% 332,4% 448,3% 635,2% 809,1%
 
 
Development of the average gross monthly wages and salaries shows that the difference 
between the gross wages and salaries in the pharmaceutical industry and the industrial 
average gross wages and salaries has considerably increased for the benefit of the 
pharmaceutical industry. The chain indexes deflated by consumer price index show that 
the real wages and salaries have continuously increased both in the industry and the 
pharmaceutical industry. Data on the real wages and salaries in the pharmaceutical 
industry show a more intense growth than the same data on the whole of the industry. A 
more considerable increase in the pharmaceutical industry exceeding the industrial data 
may be especially observed from 1992 on. If the chain indexes on the development of the 
real wages and salaries are compared to the chain indexes of the real production value per 
capita, it may be seen that the rate of increase of the real wages and salaries has regularly 
exceeded the rate of increase of the real productivity in the pharmaceutical industry 
between 1989 and 1992, and following this, with the exception of 1994 and 1998, it 
remained below this. Considering the data relating to the whole of the industry, a tendency 
similar to that of the pharmaceutical industry may be observed between 1989 and 1992, 
when the increase rate of the real wages and salaries has exceeded the rate of increase of 
the gross real production value. Subsequently, with the exception of one year, 1994, the 
increase rate of the real wages and salaries has not, however, reached the growth rate of 
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the production value. These two data series refer to the fact that the correction of the 
wages and salaries earlier considered to be depressed took place between 1989 and 1992, 
then following this the development of the wages and salaries has been adjusted to the 
development of the productivity in its tendency.  
 
Development of the average monthly gross wages and salaries is staggering at the first 
sight; however, a deeper analysis of the reasons is out of the competence of the thesis. I 
call the attention to the fact that the industrial data are the data of companies having more 
than 20 persons on staff, which means that the large companies are dominants in the above 
sample. These companies employ 18% of the Hungarian active workforce. Taking also the 
data of the organizations operating with less than 10 persons into account, the monthly 
average nominal wages and salaries represent a value with 4-5% lower in the industry 
than the data given the above table. This draws the attention to the fact that the 
organizations of larger size pay presumably higher gross wages and salaries than the 
smaller firms.  
 
Table 6.2.4 Gross average monthly wages, 1989-1998  
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Pharma industry 
thousands HUF 
10,8 16,8 22.6 30.2 40.5 53.7 66.6 85.8 109.3 125.6
Indusry, thousands 
HUF 
10.7 13.2 16.8 19.6 27.5 33.9 41.2 50.2 61.2 71.5
Pharma as % of the 
Industry  
101.3% 127.4% 134.4% 153.7% 147.1% 158.2% 161.7% 170.8% 178.5% 175.6%
Consumer Price 
Indes, %  
117.0 128.9 135.0 123.0 122.5 118.8 128.2 123.6 118.3 114.3
Gross deflated 
wages in the pharma 
industry, thousands 
HUF 
9.281 13.019 16.739 24.551 33.058 45.217 51.974 69.397 92.387 109.924
Gross deflated 
wages in the 
industry, thousands 
HUF 
9.165 10.223 12.451 15.970 22.478 28.577 32.148 40.634 51.754 62.585
Chain indexes of 
pharma deflated 
wages 
100.0% 140.3% 128.6% 146.7% 134.6% 136.8% 114.9% 133.5% 133.1% 119.0%
Chain indexes of the 
indusrial deflated 
wages 
100.0% 111.5% 121.8% 128.3% 140.7% 127.1% 112.5% 126.4% 127.4% 120.9%
Base indexes of 
pharma  
100.0% 140.3% 180.4% 264.5% 356.2% 487.2% 560.0% 747.7% 995.4% 1184.4%
Base indexes of 
industry  
100.0% 111.5% 135.9% 174.2% 245.3% 311.8% 350.8% 443.4% 564.7% 682.9%
 
It is also worth comparing the basis index of the real gross wages and salaries with the 
productivity basis index per capita. From this, it turns out that in the whole the real wages 
and salaries have increased in the pharmaceutical industry at a higher rate than the per 
capita real value of the gross production in comparison with 1989. In the pharmaceutical 
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industry, the real value of gross production in 1989 has grown to its 5.8 fold, while the 
real wages and salaries to their 11.8 fold. This statement is not true to the totality of the 
industry. Here, the gross real production value in 1989 has grown to its 8.1 fold, while the 
gross real wages and salaries have increased to 6.8-fold.  
 
Table 6.2.5 White and blue-collars workers in the pharmaceutical industry, 1989-1998 
 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Employees, thousand 
persons, total  
22.90 23.43 22.69 20.26 18.52 17.64 17.38 15.69 15.18 15.43
out of blue collars 16.84 16.89 16.15 14.24 12.67 11.50 10.84 9.53 8.99 8.84
out of white collars  6.23 6.54 6.54 6.02 5.85 6.14 6.53 6.16 6.18 6.59
ratio of blue collars 73.5% 72.1% 71.2% 70.3% 68.4% 65.2% 62.4% 60.7% 59.3% 57.3%
ratio of white collars 27.2% 27.9% 28.8% 29.7% 31.6% 34.8% 37.6% 39.3% 40.7% 42.7%
 
One of the possible explanations of this may be that the composition of those employed in 
the pharmaceutical industry has changed. The ratio of the blue-collar staff to the white-
collar staff was reduced from 2.7:1 in 1989 to 1.3:1 in 1998, i. e. the ratio of the white-
collar employees has considerably increased. This means that the ratio of the white-collar 
employees has grown to 42.7% in comparison to the ratio of 27.2% in 1989. This 
correlation seems to indirectly support the statement that the industry requiring more high-
qualified skills was able to increase the wages and salaries to an extent exceeding the 
average of the totality of the industry.  
 
The statistical data seems to strengthen the statements pertaining that the over-
employment has ceased in the Hungarian industry and in the pharmaceutical industry. 
Data on the pharmaceutical industry have shown that the structure of employment has also 
changed structurally in the sector: the ratio of the white-collar employees has increased to 
the double of the same figure in 1989. When the productivity was investigated, we started 
out from the production value per capital. Our investigations have shown that both in the 
industry and the pharmaceutical industry the real production value has not decreased 
significantly below the value of 1989. In the industry, the increase rate of productivity has 
exceeded the rate of increase of the productivity of the pharmaceutical industry to a great 
extent in which the considerable decrease in the number of those employed had an 
important role. In connection with the gross wages and salaries, it may be established that 
the period between 1989 and1992 could be deemed as the period of correcting the 
depressed wages and salaries, then following this the growth rate of the real wages and 
salaries was in accordance with the rate of increase of the real productivity.  
 
Based on the above analysis to the industry and the pharmaceutical industry, in connection 
with the competitiveness, the following theses can be established.  
The pharmaceutical industry could keep its position as employer in the transforming 
industry. In the pharmaceutical industry, composition of the employees has structurally 
changed for the benefit of the white-collar staff. The gross wages and salaries of those 
employed in the pharmaceutical industry have increased to an extent exceeding the totality 
of the industry which refers to the fact that this industry was able to contribute to the 
increase in the living standards of its employees.  
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6.2.2 Characteristics of the medicines as products  
 
In this subchapter, the characteristics of medicines as products are summarized. My 
intention by that is to underline the features, which fundamentally determine the operation 
of the pharmaceutical industry. At the first, the prescription drugs and non-prescription 
drugs, then the original and generic products are discussed, and finally the special features 
of the price setting are summarized. I hold the summary of the features of the medicines of 
crucial importance, because from this the motivation and interests of the individual 
players of the industry are more transparent.  
 
Medicines are applied in the human organism or on the surface of the human organism to 
prevent, recognize and treat diseases or to maintain, restore, improve or modify 
physiological functions, as the Hungarian Medicine Law (Law XXV, 1998) states. The 
most important classes of the medicines available for the treatment of diseases are 
summarized in the figure 6.2.1. Diseases represent the most motivating needs inciting to 
develop medicines. Grouping of the medicines shown in the figure has been carried out 
based on two aspects. One of the aspects is the patent protection of the product 
(medicine), the other one is whether those are prescription drugs or non-prescription 
drugs. Patent protection classifies the medicines from the manufacturers’ point of view, 
the medical prescription groups the medicines from the patients' access’ point of view.  
 
Medicines intended for human use are products, which are purchased or consumed by the 
ill people upon the advice of competent persons (physicians or pharmacists). This aspect is 
also followed by the European Union as a guideline outlined to serve the creation of the 
single market when the classification applied with the marketing of pharmaceutical 
products was formed. The terms and conditions of the medicine supply are regulated by 
the state. In Hungary, the so-called medicine law, Law XXV, regulates these terms and 
conditions 1998, elaborated taking the relevant guidelines of the EU into consideration. If 
a physician can order a medicine only, it is prescription drug. If no consultation with a 
physician is required to select a pharmaceutical product, then the patient may have access 
to the to medicines non-prescription drug, characteristically as a result of the consultation 
with a pharmacist or the advertisements. Determination of the list of prescription drugs is 
the task of the competent national authority. This list should be published annually. 
Generally, all subsidised medicines are ranked into the group of prescription medicines. 
As a consequence of this, the range of the prescription drugs of the pharma market is more 
traceable than any other product market.  
 
Figure 6.2.1 Main Types of Medicines 
 patent protection 
Doctors prescription 
necessary 
yes: original 
products 
expired: generic 
products 
 
Yes: prescription 
original 
prescription 
 
generic prescription
 
No: OTC, non-
presription 
original 
OTC 
 
generic 
OTC 
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The consumption of pharmaceutical products – and thus the amount of money paid for the 
medicines - does not depend fundamentally on the sovereign decision of the consumer. 
This fact is also important from that point of view that with the sales of the prescription 
medicines not the patients are primarily influenced for the manufacturers but the 
physicians. It is less true for the non-prescription products (over-the-counter, OTC), 
because the opportunity on advertising is also available in our country, but the role of the 
physicians, and especially that of the pharmacists, continue to exist.  
 
Medicines are such confidential products the development of which require considerable 
research and development expenditure and time, thus those are under patent protection. To 
obtain of the patent protection, require a long-lasting research and development process 
leads. The most important phase of which is the verification of the efficacy and safety of 
the product by the manufacturer. (Phases and estimated costs of the development of new 
original medicines are discussed in the subchapter 6.1.) Verification of efficacy and safety 
of a pharmaceutical product is also a precondition of the marketing permission in general. 
From patent protection’s point view, it is worth differentiating to kinds of pharmaceutical 
products: the original and generic products.  
 
The original products are new products under patent protection, while generic products are 
medicines manufactured with the same active ingredient after the patent expiry. Original 
products under patent production get into the market at a much higher price than the 
generic products. The background of this is that nowadays the costs of development of a 
new original product and its introduction to the market are between USD 300-400 million, 
which should be covered by the manufacturer, and this process takes 7-20 years. For the 
recovery of R&D costs invested until launching the original product to the market, the 
manufacturer has 17 years from the date of granting the patent protection, which ensures, 
at the same time, 10-13 years of monopolistic position in the market, in optimal case. In 
the case of domestic import products, the consequence of this process was that the average 
price of the original products per packaging unit was HUF 3068.80 in 1996, as against the 
not new products the price of which was HUF 737.80/box (HVG, 1997).   
 
From the point of view of manufacturing original products, the license products should be 
distinguished, which cover the range of the products manufactured and distributed, 
respectively, based on the manufacturing permission obtained from the patent owner of 
the original products. In Hungary and the developing countries, the group of the so-called 
re-produced products still exists. Products belonging to this group have been developed 
under the patented process system. The essence of this is that the patent protects not the 
active ingredient, like in the product patent system, but the process of manufacturing the 
product from the active ingredient.  
 
The considerable price difference of the original products affects the social insurance 
spending to a large extent, therefore, from the 1980s on there is an international tendency, 
to prefer the generic products, i. e. the so-called generic wave started to gain ground. It 
means that if a cheaper generic product is available, the social insurance systems prefer 
that. This tendency is prevailing in the US market. It is expected in Europe and Japan that 
the share of generic products will increase from the 9% and 7%, respectively, in 1994 to 
14% and 15%, respectively, by 2000 (Antalóczy, 1997).  
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Launching medicines into the market is subject to permission independently from whether 
it is about a prescription drug or non-prescription drug. The conditions on obtaining the 
permission necessary for market the are restrictions of entering the market with respect to 
the fact that the marketing permission should be obtained for each of the products with 
different dose and formulation.  
 
The following feature of pharmaceutical products is the price setting. The most important 
feature of the drugs is that the prices paid by consumers (patients) may considerable differ 
from the prices set by the manufacturers in the case, if the product is subsidized. Patients 
can get pharmaceuticals free of charge, however, somebody should pay their price to the 
manufacturer. The mechanism of the domestic price formation of pharmaceuticals is 
summarized in the figure 6.2.2 based on which the following “prices of the medicines” 
should be mentioned.  
 
Ex-manufacturer price is based on their costs. On the formation of these prices, the 
subsidization system has also an effect in addition to company’s price policy and market 
factors. From their sales’ point of view, the pharmaceutical companies should calculate 
with this price, from governmental point of view this price represents the basis of 
determining the commercial margins. Neither import tax, nor value added taxes are 
imposed on pharmaceutical products in Hungary.  
 
Consumer price is ex-manufacturer increased by the wholesale price- and retail price 
margins (commercial margins). The national authorities regulate the commercial margins. 
If the medicine does not receive subsidization, the consumer price is the same as the 
reimbursement charge. The consumer price is the basis of determining the subsidization.  
 
Figure 6.2.2 Determinants of pharmaceutical prices 
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Charge is the price to be paid by the patient. It is the consumer price reduced by the 
subsidization given by the social insurance (and in the case of private health insurance by 
the private insurance). In the approach of the patients, the reimbursement charge and the 
consumer price are absolutely the same with respect to the fact that the question for them 
is how much they should pay for the medicines.  
 
Reimbursement is an amount determined in the percentage of the consumer price of the 
product or as a fix amount, respectively which are established by the social insurance and 
financed to the account of the Health Insurance Fund. In the price formation process, the 
sum of the subsidy is a cardinal question from the points of view of the National Health 
Insurance Fund (NHIF), manufacturers and distributors. From the NHIF’s point of view, 
the amount of the distributable subsidization (approved in the budget) represents the 
bottleneck. Besides, award of the subsidy is the tool of enforcing public health care and 
social aspects, where the most important aspect is the restored health/well-being due to the 
effect of the medicines. From the manufacturers’ and distributors’ point of view, the issue 
on subsidization is one of the key questions of their market share: the physicians select 
their medicine with higher probability if those go with a lower reimbursement charge for 
the patients.  
 
 
6.2.3 Role of the government in the pharmaceutical industry 
 
The pharmaceutical industry is an industry where as compared to the other industries 
governmental regulations are very important. There are three fundamental reasons for this.  
 
One of the reasons is to prevent patients from making false decisions. This is resulted from 
the fact that the pharmaceuticals are products for the judgment of the quality and efficacy 
of which the patients have not proper knowledge and information. These are the reasons 
for the current governmental regulations on manufacturing; marketing and access are in 
force. There are considerable differences between the developed market economies; the 
most important aspect outlined by the European Union is to ensure the transparency that 
was discussed in the Chapter 6.1.  
 
The next reason is the enforcement of the welfare aspects of the government. The health is 
a basic value that cannot be expressed in terms of money and to which every citizen has 
the right. However, pharmaceuticals necessary for this are market goods the access of 
which depends on the incomes of the citizens. Therefore, for a reason rooted in the 
principle of social justice, a certain range of pharmaceuticals is accessible to those at the 
expanses of the central funds in the market economies whose incomes would not make 
this possible from their own sources. In this field, it is the task of the government to try to 
harmonize the principle of social justice and the governmental expenditure, as well as to 
incite the pharmaceutical companies to put their medicines to the market at the possible 
lowest price. The third reason is the social insurance and, within this the existence and 
coverage of the health insurance. Within the framework of the social insurance system 
formed by traditions and political value selections, citizens can get the pharmaceuticals 
cheaper under regulated conditions. The health insurance belonging to the social insurance 
strives to enforce the principle of insurance the fundamental thesis of which is that the 
health insurance contribution paid in should cover the expenses of health care services. 
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Thus, subsidies on pharmaceuticals are tightly linked to the health care system. The 
private health insurance is a supplement to the compulsory health insurance both in 
Europe and Hungary.  
 
Practical enforcement of the above reasons in the pharmaceutical industry is resulted in 
altering governmental policies and measures based on political value selections. The 
government regulate the professional issues and it controls the price and access to the 
medicines. The pharmaceuticals market behavior of the government is characterized by 
monopsony in countries having compulsory health insurance systems. Regulation 
professional issues are less debated than the control of the prices since it is easier to come 
to compromises in the regulation on professional issues.  
 
The pharmaceutical industry is a dynamic growing industry of the national economy 
because of its R&D intensity. It is a preferred industry in many economies, mainly 
because of its multiplying effect on the innovation and employment. In the recent years 
the life-quality considerations also incites the stressed treatment of this industry (The 5th 
frame program of the EU emphasizes the role of R&D and pharmaceutical industry based 
on this aspect.) Furthermore, pharmaceutical industry is an anticyclical industry, i.e. the 
recessions have less effect on the production and employment here than on the other 
industries of the national economy. The statistical data discussed earlier also referred 
showed to this. This incites the governments of the countries having domestic 
pharmaceutical industry based on other considerations to take steps in order to keep this 
industry. In addition to the governmental policies supporting the domestic production, 
international tendencies clearly show globalization and the operation of companies and 
company alliances passing through the national boundaries and economic integrations. 
Nowadays, the pharmaceutical industry of the developed countries is jointly featured by 
the support and protection of the domestic industry with refined tools and the 
globalization’s gaining ground.  
 
In the Hungarian pharmaceutical industry, the following regulations affecting the 
pharmaceutical industry took place in the period of 1990-1999 in order to establish a 
market-economy conform system.  
 
Control of the subsidization of medicaments. From 1st January 1993, on the National 
Health Insurance Fund and National Pension Fund have been separated in the Hungarian 
social insurance system (Law LXXXIV, 1992). This step targeted to place the social 
insurance on insurance basis where the contributions paid in and the return on the granted 
assets should principally cover the spending of the Fund. The task of National Health 
Insurance Fund (NHIF) is to manage the Health Insurance Fund. The NHIF was under the 
government of an elected body by insured citizens between 1993-1998, since 1998 it has 
been managed under governmental supervision. This a governmental centralization has 
affected the management of both the income and expenditure of the Health Insurance 
Fund. On the income side the collection of the health care contributions was transferred to 
the National Tax and Finance Supervising Authority (APEH), so to say, as taking the 
suggestion of Kornai (1998), and the expenditures have been influenced by a more 
definite attitude keep the budget of pharmaceuticals.  
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Data available on the budget of the Health Insurance Fund between 1994-1998 show that 
exceeded the planned expenditures in each year. According to the data shown in the table 
below, the planned budget was the most exact in 1995 – when the total of the actual 
expenditures exceeded the planned one by 3.4% - while the most critical year was 1998 – 
when the actually sums exceeded the planned amount by 32%. The actual expenditures 
have been increased by the one third of the actual amount of the previous year in each 
year. This growth rate has considerably exceeded the growth of the consumer price index.   
 
Table 6.2.6 Subsidization of medicaments. Targets and actual figurs 1994-1998 
 1994 1995 1996 1997 1998 
Target. billions HUF 50.700 67.702 84.300 85.383 102.580 
Actual. billions HUF 61.572 69.977 97.613 100.876 135.474 
Actual as % of target 121.4 103.4 115.8 118.1 132.0 
Annual growth 100 136.5 139.5 133.4 134.3 
Source: National laws on budgets and reports on social insurance funds. 
 
 
Expenditures of the Health Insurance Fund can be divided into two entries, the provisions 
in kind and financial aids. Subsidization of medicines, financing of preventive provisions 
and the support of the therapeutic appliances belong to the entry of provisions in kind. The 
sickness benefit, child-care and the compensations for indemnification, among others 
belong to the financial aids. If it is investigated what a role the subsidization of 
medicaments had in the expenditures of the Fund, it may be seen that the subsidization of 
pharmaceuticals totaled to an increasing ratio of the expenditures of the Fund and its 
growth rate considerably exceeded the growth rate of the expenditures of the Fund. 
Overdrafts of the budgeted allocations and its growth rate in the expenditures of the Fund 
have led to a more stringent control in the subsidization system of the medicaments.  
 
Table 6.2.7 Subsidization of medicaments as of the Health Insurance Fund 
 1995 1996 1997 1998 
Subsidy on medicaments. Billions HUF 70.777 85.495 100.876 135.475 
Total expenses of the Health Insurance Fund 
(HIF) 
445.175 508.987 555.585 632.194 
Subsidy on medicaments as % of total 
expenses of the HIF 
15.9% 16.8% 18.2% 21.4% 
Subsidy in 1995 value 100.0% 120.8% 142.5% 191.4% 
Expenses of the HIF in 1995 value 100.0% 114.3% 124.8% 142.0% 
Source: National Health Insurnace Fund Administration. Statistical Yearbooks. 1995. 1996. 1997. 
1998. 
 
 
Price control of the medicaments. From 1st March, 1995 on, the price control of the 
medicaments has fundamentally changed (Regulations No: 2/1995 (II.8.) NM and 3/1995 
(II.8.) NM). The purpose of the change was (1) to reduce the amount of money spent on 
the subsidization of pharmaceuticals, (2) to supply the medicine for those in their need and 
(3) to separate the subsidization of medicaments from the welfare. In parallel to this, price 
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liberalizations have also taken place in the pharmaceutical industry. Main changes were as 
follows:  
• Reimbursement rates have been reduced from 95% to 90%, from 80% to 70%, 
from 50% to 40%. 
• A positive list has been introduced: one of the tools for enforcement of the welfare 
aspects in connection with the price regulation. The price increase of the 
medicaments in this list receiving 90% and 100% subsidization has been assumed 
by HIF for one year.  
• The medicines not included in the positive list receive either 40% or 70% rates of 
subsidy.  
• The fixed sum subsidy support continued to be in force: if the direct substitution 
exists among the medicines in both their active ingredient and formulation, then all 
products are given the same subsidization as the sum granted to the cheapest 
medicines.  
 
Price control was transferred to the scope of the government in 1999 (203/1999. (XII.26.) 
Governmental regulation). There was no change in the rates of subsidy but the conditions 
of the subsidy became more stringent. The price increase are assumed by the HIF 
exclusively in the case of the medicaments with 100% subsidy and in case of lowering the 
price of any of the subsidized products, this reduced price will be the basis of all the 
subsidy. Based on the data collected from the national accounting and recipe controlling 
system, the HIF is bound to make a report to the health minister every month.  
 
Enforcement of the welfare aspects. The free of charge access to the medicaments for 
those in the need is ensured by the list on the public health provisions introduced in 1995. 
This step also served as a separation of the welfare issues and insurance considerations in 
the health care system. Through the system of the public health provision card, the 
government desires to provide the medicament, therapeutic appliance, dental technical 
tools and physiotherapeutic provisions free of charge to those in the need of these due to 
their social difficulties (Law III., 1993). The right to have this card is awarded by the local 
governments and they fill in the public health provision cards based on the centrally 
determined aspects. Costs of the public health provision are covered by the central budget 
and social insurance funds, partly through the local governments. The table below shows 
the amounts paid out in the framework of the public health provision. From this it turns 
out that the expenditure increased almost to their four fold between 1994-1998, and this 
growth affected the central budget in the first place that increased nearly to its 5-fold in 
the investigated period. These amounts, however, include the complete allocation of the 
public health provision and affect more than 400,000 patients.  
 
Table 6.2.8. Subsidies for public health provision card owners, millions HUF, 1994-1998 
 1994 1995 1996 1997 1998 
Through local 
governments 
799 1120 1049 1125 1404
Central government 1962 4469 6801 8450 9660.6
Total 2761 5589 7850 9575 11094.6
Source: Lows and reports on state budget and on funds of Hungarian Social Insurance. 
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In the public health provision system, the inhabitants having the right receive 
medicaments free of charge to cover their personal needs, and all the reimbursement 
charge to be paid by the patient will be paid in these cases. According to the HIF’s 
records, it can be principally followed what amount of the subsidy has been used in the 
framework of the public health provision system since physicians should indicate this on 
the recipes of the HIF. The average number of recipes per inhabitant was 9.2 in 1996, 
while the same data per person having public health provision card was 58.1. Total value 
of pharmaceuticals utilized in the public health provision system was HUF 22.566 billion 
70% of which were drugs with 100% subsidization in any way, and the rest of 30% 
resulted from the subsidy on reimbursement charges. As it was mentioned, the budget 
finances these latter costs that corresponds to 7-8% of the subsidization of the 
medicaments.  
 
Table 6.2.9 Subsidy on medicaments for public health card owners, 1994-1998 
 1994 1995 1996 
100 % reimbursed medicaments 8.759 14.263 15.762 
• as % of total medicaments for public 
health card owners 
77.6 71.3 70 
• as % of total subsidy on 
medicaments * 
14.2 20.38 16.1 
Susidized reimbursement. Millions HUF 2.528 5.468 6.804 
• as % of total medicaments for public 
health card owners 
22.4 28.7 30 
Total expenses of medicaments for public 
health card owners 
11.287 19.731 22.566 
• as % of total medicaments for public 
health card owners 
100 100 100 
Source: Gyógyszerészet. June. 1997 and * calculated on the base of table 6.2.6 
 
 
The Houses of Parliament and the government respectively also regulate the 
pharmaceutical industry. The most important fields are as follows:  
 
The Medicine Law was accepted in 1998 (Law XXV., 1998). This law regulates, among 
others, the conditions of putting medicaments into circulation and the prescriptions 
packaging and patient information leaflets. This law has taken the relevant guidelines of 
the EU into consideration.  
 
Manufacturing requirements are regulated by a governmental regulation (37/200. (III.23.) 
in details. Manufacturing of pharmaceuticals is an activity subject to permission; the 
National Institute of Pharmaceutics (OGYI) carries out the supervision. The governmental 
regulation has been accepted owing to the harmonization of the rights in the European 
Union, and the personal and objective conditions of manufacturing pharmaceutical 
products have been determined based on the Good Manufacturing Practice (GMP). In 
connection with this it is noted that due to the export-orientation of the pharmaceutical 
industry the GMP has been in effect with the pharmaceutical companies since 1976. The 
legal conditions of this have been created by the decree of legal force No: 31 in 1976. The 
regulation on the Good Laboratory Practice (GLP) was announced in 1999 (31/1999. 
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(VIII.6.) joint regulation by the EÜM-Ministry of Health Care and FVM-Ministry of 
Agriculture and Regional Development Ministry, the regulation relating to the Good 
Clinical Practice (GCP) was not yet published at the time of preparing this dissertation.  
 
Sales of the medicaments have been regulated in three fields. In the law (LIV, 1994) on 
the foundation and operation of pharmacies, the conditions on the wholesale and retail 
trade of the medicines have been determined. The commercial margin on the 
pharmaceuticals has been controlled since 1992 (22/1992. (VIII.19.) decree by the NM-
Ministry of Welfare, predecessor of EÜM). The regulation of advertising medicaments 
took place in 1997 (24/1997.(VII.14.) decree by the NM).  
 
The most important institutions of the regulation by the government are as follows: the 
Government (as the supervisory board of the Health Insurance Fund, and the final decision 
maker in price setting), the Ministry of Health Care (EÜM) (in professional issues, and in 
setting the commercial margins), National Institute of Pharmaceutics (OGYI) (as the 
issuer of permissions on putting the medicines into circulation, the supervisory authority 
in GMP and GLP issues), National Health Insurance Fund (as the institution conducting 
the price negotiations and managing the budget of the subsidy on medicaments).  
 
The following features characterized the governmental regulation in the period 1989-
1999: The social insurance was transferred to insurance basis from 1993 on. Managing the 
budget of the Health Insurance Fund was centralized and a higher pressure was exerted on 
the price setting of the pharmaceutical industry. With prospect to joining the European 
Union, laws and regulations have been elaborated which regulate the manufacturing and 
distribution of pharmaceuticals based on the guidelines of the EU and OECD countries. 
According to Farkas (1999), the pharmaceutical industry belongs to Hungarian industries, 
which are prepared enough to meet the EU requirements. The institutional frameworks for 
manufacturing and distributing pharmaceuticals have been established and it has 
strengthened.  
 
 
6.2.4.Transition of the pharmaceutical industry  
 
A comprehensive picture on the macroeconomic position of the pharmaceutical industry 
was given in Chapter 6.2.1. In the following, fields of the transition of the pharmaceutical 
industry are discussed. The purpose of this subchapter is to underline the economic as well 
as business and management factors, which had a fundamental influence on the 
competitiveness of the pharmaceutical industry in the period between 1989-1998. As the 
first, the development of the drug consumption and the factors having influence on it are 
discussed. Following this, changes in the marketing are detailed. The subsequent 
subchapter deals with the competitiveness within the industry, and finally, strategies of 
four companies are analyzed.  
 
 
6.2.4.1 Drug consumption  
 
At the first, the size of the domestic pharmaceutical market is discussed in international 
comparison based on the data published by the Central Statistical Office (KSH) and a 
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study performed by the European Union. The EU study referred below (1998) is a 
document was published on the single market in pharmaceuticals (COM(98)588 final) in 
November, 1998. It presents on an overview on pharmaceuticals market in the Eastern-
European countries desiring to join EU.  
 
Based on reports made by the KSH, the size of the domestic pharma market has developed 
according to the table below. According to this table, the domestic sales of drugs totaled to 
1.83-1.95% of the GDP in the period between 1993-1998. Based on the international 
comparison made by the EU (EU 1998), this ratio is lower than the same figures in the 
majority of the EU member states and it corresponds to the same data of Greece and 
Portugal. It is noted that based on the referred comparison the ratio of spending on 
pharmaceuticals calculated, as the percentage of GDP is generally higher in countries 
desiring to join than in the EU member states. In terms of US Dollar, the public sales of 
medicaments corresponds to USD 0.8-0.9 billion. According to the comparison made by 
the EU, in Greece and Portugal having nearly the same size of population as Hungary but 
with the double of the per capita GDP in Hungary, the value of the pharma market in 
terms of US Dollar is USD 1.2 and 1.3 billion respectively.  
 
The largest segment of the pharmaceutical industry, the subsidized drugs, was decreased 
from 77% in 1993 to 65-65% between 1993-1998. According to the referred international 
comparison, the mean value of the European Union was 61.2% around which the member 
states showed a considerable variance. Greece represents the lowest limit with its 16.7% 
value, Luxembourg has the highest limit with 80.2% to which Ireland is very close with its 
78.1% value, while in Portugal the value of 63.2% is close to the EU average. The ratio of 
subsidies to the GDP shows a value close to the EU average.  
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Table 6.2.10 The Hungarian drug sales, 1990-1998 
 1990 1991 1992 1993 1994 1995 1996 1997 1998 
HUF/USD exchange 
rates 
63.2 74.81 79 92.04 105.13 125.7 152.6 186.8 214.5
GDP per capita. USD 3228 3608 3745 4046 4326 4367 4433 4504 4694
GDP per capita. HUF 2079.5 2308.4 2942.7 3548.3 4364.8 5561.9 6893.9 8540.7 9865
Public medicaments 
sales. Billions HUF 
na na na 66.328 81.358 108.666 128.6 156.6 191.2
Reimbursement 
budget. Billions HUF 
25.9 36.7 40.2 51.137 60.885 72.775 84.317 101.733 126.79
Reimbursement as % 
of public 
medicaments sales 
na na na 77.1 74.8 67.0 65.6 65.0 66.3
Total charges. 
Billions HUF 
na na na 15.191 20.473 35.891 44.283 54.899 64.372
Total public 
medicaments sales as 
% of GDP 
na na na 1.87% 1.86% 1.95% 1.87% 1.83% 1.94%
Reimbursement as % 
of GDP 
1.25% 1.59% 1.37% 1.44% 1.39% 1.31% 1.22% 1.19% 1.29%
Charges as % of GDP na na na 0.43% 0.47% 0.65% 0.64% 0.64% 0.65%
Public medicaments 
sales. billions USD 
na na na 0.7 0.8 0.9 0.8 0.8 0.9
Source: KSH Statistical yearbooks 
 
 
The above data show that the size of the Hungarian pharma market corresponds to the 
development state of the Hungarian economy. The size of the Hungarian pharma market is 
small in international comparison; however, the Portuguese and Greek data allow to come 
to the conclusion that the size of the market is in relation to GDP per capita. Through the 
extended social insurance system, the growth of the subsidies determines fundamentally 
the growth of the pharma market. From the table below it turns out that, with the 
exception of 1995, the growth rate of sales of pharmaceuticals changes with the growth 
rate of the GDP together. The growth rate of the segment measured on the reimbursement 
charge exceeded the growth rate of the subsidization and GDP considerably in 1994-1995. 
This period mirrors the changes in the regulation of the drug prices. Following this, the 
growth rate of reimbursement charge is not extremely high.  
 
Table 6.2.11 Annual Growth of per capita GDP and public medicaments sales 
 1993 1994 1995 1996 1997 1998 
Annual Growth of per capita GDP 23.4% 27.8% 0.9% 23.2% 24.4% 19.7%
Annual Growth of public medicaments 
sales 
na 22.7% 33.6% 18.3% 21.8% 22.1%
Annual growth of reimbursement 27.2% 19.1% 19.5% 15.9% 20.7% 24.6%
Annual growth of charges na 34.8% 75.3% 23.4% 24.0% 17.3%
 
 
The domestic consumption of medicines in volume is held high in international 
comparison. It is usually explained by the health state of the Hungarian population held 
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impaired in international comparison, the ageing population and furthermore with the low 
domestic prices of drugs in international comparison. The volume of drugs consumption 
and especially its structure are also in close connection with national health and 
demographic factors. Looking at the distribution of therapeutical groups in the table below 
it can be seen that the sales of medicines is more concentrated according to therapeutical 
groups in Hungary than it is shown by the European data. The listed five therapeutic 
groups represent nearly 75% of sales of pharmaceuticals in Hungary, while this ratio is 
47% with the European data.  
 
Table 6.2.12. Drug sales revenue according to therapeutic groups 
Therapeutic groups Hungary Europe 
Cardiovascular deases 22 19 
Systematic antibiotics 18 14 
Gastrointestinal tract metabolism 14* 8 
Central nervous system 14.3* 9 
Respiratory system 6.1* 7 
Others 25.6 53 
Total 100 100 
Source: Antalóczy. 1997 és * Molnár. 1997 
 
 
From the patients’ point of view, it is important that the medicaments used for the 
treatment of the most frequent types of illnesses should receive the subsidy. This 
expectation is enforced by the Ministry of Health and National Health Insurance Fund 
when forming the subsidization system of medicaments: their striving is that those 
suffering from long-lasting, chronic diseases should receive the allowances. The health 
state of population is resulted from several factors. According to the statistical data, the 
circulatory, cardiovascular diseases are the leaders among the diseases on 100,000 
inhabitants which are followed by the gastrointestinal diseases,  spinal sicknesses and 
diabetes. According the surveys, the medicines consumption in Hungary is not adjusted to 
the diseases: there are illnesses, which are under treated with medicaments, while other 
diseases “over-treated”.  
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Table 6.2.13 Sales of the first 10 drugs in the 1st half of 1996 and 1997 
Drugs Usage Sales at the 1st 
half of 1996 
billion HUF 
Sales at the 
1st half of 
1997 billion 
HUF 
Dose on 
treatment. 
1997 days 
Tensiomin Decrease in blood 
pressure 
2.874 1.3 46
Augmentin Antibiotics 2.295 1.4
Cavinton Stimulating the 
central nervous 
system 
1.461 0.8 49
Insulin Novo Diabetes mellitus 1.379 0.8
Ednyt Decrease in blood 
pressure 
1.270 1.0 39
Nootropil Stimulating the 
central nervous 
system 
1.252
Ceclor Antibiotics 1.168
Nitroderm Vasodilatation 1.134
Nitromint Vasodilatation 1.100 0.7 66
Seropram Anti depressants 1.051 -
Renitec Decrease in blood 
pressure 
- 0.7 30
Centrum 
tabletta 
Vitamins - 0.7 36
Humilin Diabetes mellitus - 0.6
Diflonec Rheum - 0.2
Corinfar Coronary vasodilator - - 40
Eunoctin Sedatives - - 34
Gilemal Diabetes mellitus 29
Total 14.99 8.6
Source: Molná, 1997 and Élő, 1997 
 
From the above table it can be seen that the consumption of blood pressure decreasing 
drugs is considerable both in value and the number of therapeutic doses. It is also clearly 
shown that there was a considerable change in the order of the top 10 best selling products 
in the one-year period while the ratio of the 10 medicines has also decreased in value. This 
refers to the fact that drug consumption becomes fragmented.  
 
Data on the volume of medicine consumption in international comparison, it show that 
consumption measured in boxes. Hungary belongs to the countries consuming the most 
pharmaceuticals. The medicine consumption in boxes shows a decreasing tendency (see 
table 6.2.14). Main reasons for that are as follows. Average price of the medicaments has 
considerably increased in the investigated period, and there was a considerable fall in 
domestic real wages and salaries, especially with that social group which are heavy 
medicine takers.  
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Table 6.2.14 Medicine consumption in volume, 1990-1996, millions boxes 
 1990 1991 1992 1993 1994 1995 1996 1997 
National 324 298.9 264.4 267.3 253.2 231.9 220.7 215.5
Imports 43.1 52.1 51.3 61.1 71.2 74.6 75 83.8
Total 367.1 351 315.7 328.4 324.4 306.5 295.7 299.3
Source: Molnár, 1997 
 
From the table below, it turns out that the drugs consumption per capita is much higher in 
France. The reason for this is that the French data also include the data on homeopathic 
products that are used in large quantity.  
 
Table 6.2.15. Medicine consumption in international comparison 
Country boxes per 
capita 
United Kingdom 14
Czech Republic 17
France 51
The Netherlands 12
Poland 21
Germany 22
Portugal 19
Slovakia 20
Hungary 33
Source: HVG, 1997, based on Pharmafelax data 
 
 
The assortment of medicaments. The liberalization on the Hungarian pharmaceuticals 
market in 1992 has led to a keen competition, which resulted in the intense import of 
pharmaceuticals. The data on pharmaceutical exports and imports show that the medicine 
import calculated at constant prices has increased to more than its 11 fold between 1990 
and 1998. As a consequence of import liberalization, the domestic assortment of 
pharmaceutical products has considerably increased: the number of products, has grown to 
more than the double of the same figure in 1990, while the number of active ingredients 
increased only by 20% in the same period. In the growth of import medicaments, it was an 
important factor that the domestic government did not take any restrictive measures 
against their entering the Hungarian market. In international comparison, the assortment 
considering the number of registered products may be deemed low: based on the data 
recorded in 1995, in Hungary 2890, in Czech 13,000, in Germany 53,000 and in the 
United States of America 100,000 products were marketed. Of these products, more than 
1400 medicaments were subsidised by the National Health Insurance Fund (Kövesi, 
1997), and the number of the registered products was appr. 4000 in Hungary in the first 
half of 2000.  
 
In connection with the assortment, the issue on prices is touched upon which is one of the 
most important factors generating debates both in the negotiations between the medicine 
manufacturers and NHIF and among the medicine manufacturers. Having reviewed the 
assortment consisting of more than 3000 medicaments for human use in 1997, it was 
established in a medical expert’s report that within the range of pharmaceutical products, 
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where the assortment of the domestic medicaments would be sufficient, the share of 
import products was 48% in the value of HUF 141 million which, in the opinion of the 
experts, should be deemed as a superfluous factor deteriorating the trade balance (The 
assortment of medicaments in Hungary … 1997). This was also resulted from the fact that 
the domestic government did not take the advantage of the license on import restrictions 
due to the agreement on association concluded with the European Union: the allocation of 
USD 100 million estimated by 2000 to import pharmaceuticals was exceeded with the 
import of USD 150 million already in 1995 (Antalóczy, 1997). Assortment of 
pharmaceutical products has been happily increased, but their expenses, too, at the same 
time.  
 
Considering the domestic average medicine price of a box, it turns out from the table 
below that the average per box price in HUF shows an increasing tendency. There is a 
considerable difference in the average prices of domestic and import medicines, the price 
of import medicines was 3-4 times higher than that of the domestic medicines in the 
investigated period. In the period between 1990-1998, the price of the medicaments has 
considerably increased, the price of the domestic medicines has grown to its 8 fold, while 
that of import products has increased to more than its 6 fold.  
 
The price increase in 1995 was extremely high in the case of both the domestic and import 
medicaments. It can be explained by the new system of the subsidization of medicaments 
introduced from 1st March 1995. It was forecasted that the new system of the subsidization 
of medicaments would be resulted in a more than 50% increase of the spending of the 
inhabitants on medicines. In creating the positive list, the active ingredient was taken as 
the basis: if a given active ingredient was entered in the positive list, then every 
pharmaceutical product containing the same active ingredient was entered in the basic list, 
independently from its formulation, origin, manufacturer and retail price. Finally, the 
subsidization system has contributed that the inhabitants became aware of the prices of 
pharmaceuticals, but this was not resulted in the radical decrease of the subsidy budget. 
The effect of the new subsidization system exerted on the price increase appeared already 
in April 1995, which was also resulted in the increase of the subsidization budget with the 
medicines entered in the positive list.  
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 Table 6.2.16 Average prices per box. 1990-1998 HUF/box 
 1990 1991 1992 1993 1994 1995 1996 1997 1998 
National. HUF/box 43.4 62.1 76.0 89.5 116.2 164.4 210.9 256.0 299.0
Import. HUF/box 176.4 195.1 208.9 222.5 249.2 678.5 805.5 888.0 1026.0
National as % of 
import 
24.6% 31.8% 36.3% 40.2% 46.6% 24.2% 26.1% 28.8% 29.1%
Import  value index, 
% 
100.0 110.6 118.4 126.1 141.2 384.4 456.4 503.2 581.4
National value index, 
% 
100.0 143.0 174.7 205.8 267.3 378.0 484.9 588.6 687.5
Import price annual 
growth  
na 10.6% 7.1% 6.5% 12.0% 172.2% 18.7% 10.2% 15.5%
National price annual 
growth 
na 43.0% 22.2% 17.8% 29.9% 41.4% 28.3% 21.4% 16.8%
Source: Molnár, 1997 and Bogsch,.2000 
 
 
Tables on the volumes and prices of consumption shows that the considerable increase in 
the average per box prices from 1994 to 1995 resulted in decline of the consumption of the 
medicaments in the same year. This shows that price sensitivity can be observed in 
consumption.  
 
In international experiences, introduction of a national recipe controlling system might 
reduce the consumption of prescription medicines with 15-18%. Implementation of the 
national recipe controlling system has also taken place in Hungary accompanied with 
heated debates and rescheduling of many years. The high ratio of the prescription 
medicines shows that the drugs consumption is directly in the hands of the physician 
community, and thus the recipe controlling system also targets the changes in the habits of 
the physicians in prescribing the medicines. Therefore, the implementation of the recipe 
controlling system has generated both the antipathy and resistance of the physician 
community: their interests have suffered damages to a great extent due to the fact that 
their freedom in prescribing medicines has become more limited and thus restrictions were 
imposed on their role in the marketing of the medicaments.   
 
As it was underlined when the features of pharmaceuticals were discussed, physicians and 
pharmacists (or the employees in the pharmacy) influence the medicine consumption of 
the patients. The physicians have a major role in making decision on what a medicine – in 
respect of its active ingredient content and reimbursement charge – they order for their 
patients as prescription medicine. As it was noted by Gulácsi-Matejka (1999), “it is true 
all over the world that a mortal combat is going on for the “pen” of physicians ordering 
the medicines between the manufacturers and the financing agencies. This question is 
raised in an especially sharp way in Hungary, because one of the roots of the financing 
problems of the medicine spending is the over-consumption of the medicaments” (p 315). 
Thus, the need of patients should be judged from a double aspect: from the aspect of the 
effect of the medicament and the aspect of the patient’s financial ability. The physicians 
exclusively on the recipes determined by the NHIF can order the prescription and the 
reimbursed medicines. The role of the pharmacies becomes more and more important in 
the non-prescription (OTC) segment. In this case, the employees of pharmacies consider 
the situation from a double aspect, like the physicians, when they offer medicaments to the 
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patients. From the pharmaceutical industry’s point of view, setting up and managing the 
medical representative system have a very important role.  
 
When patients make their (consumer) decision, they have to trust the judgment of 
physicians and pharmacists respectively, and as a final decision making factor, the price to 
be paid for the medicaments plays a role in their decision. There is a tendency that the 
price to be paid and the available and discretional income are compared to each other. 
Surveys show that a part of the population could not take out the prescription medicines 
receiving support either (Kövessi 1997). However, there are no data available on how this 
phenomenon affects the complete pharmaceuticals consumption and how it relates to the 
reimbursement system.  
 
 
6.2.4.2. Distribution: wholesaling and retailing of pharmaceuticals  
 
It is the feature of the selling process of pharmaceuticals that it is under governmental 
regulations. The European practice’s feature is that “ … European drug distribution 
remains a non-harmonized and relatively in efficient two-tier operation: a highly 
consolidated wholesaling industry (with the combined sales of the top three Firms 
accounting to 75% of the Dutch, France, German and UK market) deals with an extremely 
fragmented pharmacy retail sector. / … / So far, mail order for ethical drugs occurs only 
on a small scales in the Netherlands and Scandinavia; the EU is considering clearing mail 
order for the OTC market. Relaxing distribution may cause wholesalers to move forward 
into the pharmacy sector and as compile patient information as a stepping stone towards 
managed care”. (Boscheck, 1996. p. 636). For the pharmaceutical industry retailing – 
similarly to every other product markets – has a key importance: the pharmacy owners can 
obtain such an information basis on pharmaceuticals consumption territory, which put 
them into a very advantageous bargaining position. According to those cited, this is why it 
means a milestone on the long-term how much the pharmacies can be integrated backward 
to wholesalers and forward to patients and what possibilities the governmental regulations 
grant them. As in all field of commerce, the electronic commerce represents one of the 
greatest opportunities and challenge here.  
 
The domestic wholesaling and retailing have been separated from each other, 
pharmaceuticals can get to the consumers exclusively through the wholesalers and 
retailers. In Hungary, both the conditions on performing distributor activity in the pharma 
market (involvement in the commerce of pharmaceuticals) and the margins on the 
distribution are regulated. According to the medicine law, the provision of inhabitants 
with medicaments can be performed only by pharmacies meeting determined 
requirements, and the pharmacies are allowed to procure the marketed medicaments only 
from organizations holding pharmaceutical wholesaling license.  
 
In the period between 1990-1996, the privatization affected the retailing in the pharma 
market most. The first step in the transition of the drug distribution channels was the 
change that from 1990 on it became possible to operate private pharmacies. The 
privatization process of the pharmacies was rather long and associated with debates, the 
privatization ideas having been formed since 1992 were resulted in closing the 
privatization of the pharmacies practically by 1997. The professional aspects (pharmacies 
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cannot get into private ownership without a pharmacist owner), insurance of the access by 
the inhabitants (pharmacies should continue to operate as pharmacies), the property right 
of the pharmacies (pharmacy centers versus self-governments) were three factors, in some 
cases conflicting with each other, which made the privatization process full of temper. As 
it turns out from the table below, not only the ownership has also changed between 1990-
1998, and the public pharmacies have got into private property, but the number of 
pharmacies has increased by 25% at the same time. During this period, the number of 
pharmacists working in pharmacies has increased with 25% that is in relation with the 
regulations on privatization and pharmacy operation.  
 
Table 6.2.17 Number and ownership of pharmacies, 1990-1998  
 1990 1991 1992 1993 1994 1995 1996 1997 1998 
State owned 1449 1455 1479 1457 1463 1075 388 0 0
Private 30 113 259 372 473 919 1613 1965 1972
In hospitals .. .. .. .. 27 30 35 38 38
Total 1479 1568 1738 1829 1963 2024 2036 2003 2010
Employed 
pharmacists 
3390 3549 3392 3265 3306 3422 4104 4389 4789
Source: Statistical Office(KSH) yearbooks 
 
 
In the same period, the operation of the pharmacies (see Law LIV, 1994, on the 
establishment of pharmacies and the individual rules on their operation), and the size of 
margins were regulated in a comprehensive way. The Minister of Health regulates in a 
decree the conditions on the distribution of pharmaceutical products and the maximum 
commercial margin allowed to be set. The regulation of the conditions on the distribution 
of medicaments can be justified with the special features of pharmaceuticals: proper 
professional and technical conditions should be available in commerce, especially in 
respect to retailing which are more stringent than in retailing other products. The 
professional conditions, rooms, necessary tools and opening hours belong to this. The 
Hungarian Chamber of Pharmacists and the National Public Health Center (ÁNTSZ) 
control fulfillment of these conditions. These mean retailing that, there are considerable 
barriers to entry.  
 
There is a special segment in drug the retailing, the institute pharmacies. They provide 
direct patient care and pharma provision in kind to their patients and ethical drugs. All the 
hospitals belong to this segment, which provide medicaments in kind to patients during 
their hospital treatment owing to the existing health insurance practice, which is 
practically subsidized in 100% by the NHIF. The following table shows the pharma sales 
of the public pharmacies and the institute (clinical) pharmacies and their distribution of 
sales in 1996. As it turns out from the table below, the public pharmacies sell the majority 
of pharmaceutical products that is more than 80%.  
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Table 6.2.18 Sales in public and hospital pharmacies, 1996. 
 Pharmacies Hospitals Pharmacies Hospitals 
  % 
Number of Pharmaceuticals 2467 2761 89.3 100
Sales on ex manufactures 
prices. HUF billions 
88.8 18.4 82.3 17.7
Sales on boxes. million boxes 269.5 26.2 91.1 8.9
Source: Molnár, 1997 
Note: Number of pharmaceuticals taken as 100 % in hospital sales. since they comprise the public 
drugs as well. 
 
In the public pharmacies, a wider range of products can be marketed than in the 
wholesaling of the medicaments that is between certain limits the pharmacies rest upon 
more activities than the wholesalers. It is allowed for them e.g. to sell medical and 
healthcare products, hygienic products, and self-medication products. The more stringent 
governmental regulation in 1999 also affected the operation of the pharmacies. Contrary 
to the previous practice, the NHIF does not make any prepayment to procure the 
reimbursed pharmaceuticals, but the amount of reimbursements is transferred based on the 
actual sales afterwards. This may lead to temporary financing problems with the 
pharmacies, which, together with the burdens due to the repayment of the privatization 
credits, may cause serious cash flow problems (HVG, 1999).  
 
Pharmaceutical wholesaling can be pursued only the permission issued by the National 
Institute of Pharmaceutics (OGY). In the wholesaling, too, the privatization was one of the 
most important processes in the period between 1989-1998. The pharmaceutical 
wholesalers were established by the privatization of the earlier pharmacy centers. In 
addition to the wholesalers, the distributors (sales representatives) and the pharmaceutical 
manufacturers are also entitled to perform wholesaling with their own products.  
 
Table: 6.2.19.Sales of pharma wholesalers, million HUF, 1995-1998 
 1995 1996 1997 1998 
Hungaropharma 41158 43701 51396 57713
Pharmafontana 6512 23658 12817 19943
Phoenix Pharma na 9311 17254 27533
Humantrade na 9372 12790 16860
Medimpex na na na 18813
Bellis Rt. na na na 11891
Total 47670 86042 94257 152753
As % of the public pharma sales 43.9% 66.9% 60.2% 79.9%
Source: Figyelõ Top 200 and KSH Statistical yearbooks 
 
In the summary made public by the HVG in October 1999, eighty-four organizations were 
mentioned as the holder of the pharmaceutical wholesaler license with reference to the 
data of the Association of the Hungarian Pharmaceutical Wholesalers, of which 14-15 
were held active. Considering the data and information made known in the Top200 
publication of the Figyelő, inspite of this rather large number, the pharmaceutical 
wholesaling sector has become concentrated by 1998. According to the above table, the 
largest pharmaceutical wholesalers marketed the increasing ratio of public pharma sales. 
 156
The ratio of the six largest companies ranked by their annual sales has increased to nearly 
80% by 1998. The following featured the individual companies.  
 
The largest pharmaceutical wholesaler company, Hungaropharma Pharmaceutical 
Wholesaler Co. Ltd., was founded in 1993 and was in the property of the state (State 
Privatization Holding Co. Ltd.) at the end of 1998. In 1998, the company had a market 
share of 30% in the pharmaceutical wholesale trade corresponding to the annual turn over 
of HUF 57.7 billion. This company marketed the widest product range covering 4900 
pharmaceuticals in 1998. This company is now before privatization.  
 
Phoenix Pharma Pharmaceutical Trading Co. Ltd. was the second largest pharmaceutical 
wholesaler company. The company was established through the privatization of the 
Pharmacy Center of County Pest in 1995. Its owner is the Phoenix AG through the 
Beteiligung GmbH, which is the market leader pharmaceutical wholesaler in Germany, 
and with its sales of more than DEM 10 billion it is the second largest pharmaceutical 
wholesaler in Europe. The sales of HUF 27.5 billion in 1998 represented a 17.2% market 
share, which was an increase as compared to the same data in 1997, and due to this 
achievement this company came up from the third place to the second in Hungary. The 
company has further strengthened its position, because the Beteiligung GmbH also 
acquired the Westpharma Company, which had stakes in pharmacies, in 1999.  
 
The third largest company in the pharmaceutical wholesale sector was the 
Pharmaphontana Pharmaceutical Co. Ltd. in 1998. The company started its operation in 
1995, then the local-government of the capital sold its shores to Naturland Co. Ltd. in 
1997. In addition to the pharmaceutical wholesaling, the company has traded in, of 
Fitotéka (self-medication) products and persuaded export and import of pharmaceuticals. 
In 1998, the company achieved a sales revenue of HUF 19.9 billion that corresponded to 
an appr. 14% market share, which is as much as to say that the company lost its second 
place on the list of wholesalers. Since that time, the company has declared itself insolvent 
and has been liquidated.  
 
Medimpex Pharmaceutical Wholesaler Co. Ltd. got onto the Top200 list of the Figyelő as 
a new player, as the fourth largest firm in the market, in 1998. The company started its 
operation in 1997, it deals exclusively with domestic pharmaceutical wholesaling. The 
owners of the company are Gedeon Richter Co. Ltd. and Egis ltd. Before 1998, the 
enterprise was the foreign trade company of the pharmaceutical industry. Medimpex has a 
13% market share with its sales of HUF 18.8 billion.  
 
The further two pharmaceutical wholesalers got on the Top200 list of the Figyelő in 1998 
were Humantrade Pharmaceutical Wholesaler Ltd. with its sales of HUF 16.8 billion and 
Belis Co. Ltd. with its turn over of HUF 11.8 billion.  
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Table: 6.2.20. Owners` equity of pharma wholesalers, HUF million, 1995-1998  
 1995 1996 1997 1998 
Hungaropharma 11239 10318 11422 11485
Pharmafontana 5469 5804 3921 398
Phoenix Pharma na 702 -1 971
Humantrade na 528 549 1606
Medimpex na na na 1886
Bellis Rt. na na na 1291
Source:  Figyelő Top200 
 
Among wholesales, there were two, which did not make any profit before taxation in 
1998. These were Phoenix Pharma Co. Ltd. and Pharmaphontana Co. Ltd. Considering the 
development of the owners` equity, which is the basis of further growth opportunities, it 
turns out that Pharmaphontana Co. Ltd. should face a serious challenge, because in 1998 it 
closed its second year with loss and its owners` equity was reduced from HUH 3.9 billion 
to HUF 308 million. The development of the owners` refers to danger in the case of 
Phoenix Pharma Co. Ltd., however, with respect to its owner, which is the market leader 
wholesaling company in Germany, this enterprise will supposedly be a player on the 
market on the long-term. The data and example of Phoenix Pharma Co. Ltd. and 
Pharmaphontana Co. Ltd. refer to the phenomenon that the accounting data can be 
interpreted and compared only in the case, when owners are also investigated. Further 
changes are expected to occur in the pharmaceutical wholesaling sector, because the 
privatization of Hungaropharma Co. Ltd. has not been completed yet.  
 
Regulation of commercial margins is in relation to the price regulation of 
pharmaceutical products and through this it incites the pharmacies to operate with 
foreseeable consumer prices and to keep a proper assortment of the pharmaceuticals on 
the stock. The ex-manufacturer prices are the basis of determining the margins. In the 
period lasting till 30th June, 1999, the following margins were in force: in the case of 
pharmaceutical raw materials, the wholesale margin can be 20% of the ex-manufacturer 
price, while in the case of finished packed products, the margin can be, between the 
maximum of 16% and the minimum of 7%, of ex-manufacturer decreasing in parallel to 
the increase in the prices. Consequently, in the case of cheaper medicaments the margin of 
the pharmaceutical wholesaler is larger, while it is smaller with the more expensive 
products. This margin formulation method is also in force for the pharmaceutical retail 
dealers, where the maximum margin is 30% and the minimum one is 16%. From 1st July 
1999 on, the wholesale margins were reduced to 5% as minimal key and to the maximum 
of 12%. There was no change in the retail margins (22/1992(VIII.19.)WM decree).  
 
The changes in the regulations implemented in 1999 refer to the fact that the government 
held the wholesale margins high, while in retailing it ceased the practice of refinancing. 
Beside governmental regulations, the electronic commerce represents further opportunities 
in this field both in the B2B (business-to-business) and B2C (business-to-customer, i.e. 
between companies commerce however, in this latter case only in the segments of the 
OTC products.  
 
Domestic distribution of pharmaceuticals is regulated both from the entry the sectors and 
from the size of the commercial margins. Among the processes taken place between 1989-
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1999, the privatization was of key importance and the wholesaling sector is still before 
further changes. The intention of the government to manage drug budget was also asserted 
in the distribution, because the wholesale margins have been reduced as well as the 
practice of prefinancing has been ceased in retailing. The pharmaceutical wholesaling 
trade and retailing have appeared as a distribution channel at the end of the 1990s, which 
do not have a considerable bargaining power over the Pharmaceutical industry. In the field 
of the wholesaling trade, a heated competition can be observed among the wholesalers 
traders that is also increased by the situation that the pharmaceutical manufacturers and 
distributors, too, are allowed to pursue wholesaling activity. The reason for having 
discussed the issue on distribution in details was that the transition of the wholesaling and 
retailing has taken place in parallel to the privatization of the pharmaceutical companies in 
the first half of the 1990s and as it could be seen, the privatization of the wholesale sector 
has not been finished yet.  
 
 
6.2.4.3 Competition in the pharmaceutical industry  
 
In international comparison, Hungary has a considerable tradition in the domestic 
manufacturing of pharmaceuticals. This can be explained with the early start of the 
domestic pharmaceutical industry in accordance with the international tendencies on the 
one hand, and with the COMECON period on the other hand. From the 1950s on, the 
Hungarian pharmaceutical industry has been basically consisted of the following six 
companies: Alkaloida (currently ICN Hungary), Biogal, Chinoin, Egis, Human, Richter. 
Further on, the denomination of domestic manufacturer/company covers these companies. 
Pharmavit Co. Ltd., too, the success company of the 1990s, may be listed here, which was 
acquired by the Bristol Myers Squibb.  
 
Table: 6.2.21 Market shares in 1990-1998. % 
 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Alkaloida 5.3 4.8 4.5 3.9 3.1 2.7 2.7 2.5 2.1
Biogal 18 17.4 14 11.2 8.4 7.1 6.2 6 5.1
Chinoin 16 14.5 13.1 10.3 8.4 8 8.1 7.5 6.5
Egis 17.7 18.5 15.1 13.1 12.4 12.4 11.3 10.2 9.2
Human 2.1 2 2.8 1.8 1.1 1.1 1.5 1.5 1.7
Richter 14.5 13.1 11 9.2 8.8 9.4 9.8 10.7 10.2
Other 
Domestic 
0.1 0.3 1.5 3.6 4.5 4.1 4.2 4.4 4.2
Domestic, 
total 
73.7 70.7 62 53 46.6 44.8 43.8 42.7 39
Import 26.3 29.3 38 47 53.4 55.2 56.2 57.3 61
Total 100 100 100 100 100 100 100 100 100
Source: Antalóczy. 1999. 
 
In the period between 1990-1998, the market share of the domestic companies has 
considerably decreased. As it turns out from the above table, the domestic manufacturers’ 
market share of 73.7% in 1990 lowered to 39%, and in parallel to this the role of the 
subsidiaries of non-domestic companies rose from 26.3% to 61%. On market shares of the 
foreign companies, only incomplete public information are available. The reason for this 
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may be that the majority of these companies distribute mainly the products of their mother 
companies; they do not carry out any production in Hungary. Among the domestic 
players, there are also subsidiaries of well-know multinational companies such as 
Novartis, Hoffman La Roche or Merck Sharpe and Dohme.  
 
As it turns out from the table below, the pharmaceutical industry exported the increasing 
share of its production in the period between 1990-1998. The export of the pharmaceutical 
industry amounted to nearly 2% of the total domestic export during this period. 
Considering the ratio of the production for the domestic and foreign markets, it may be 
seen that 50% of the production in Hungary was exported in 1990 and this ratio was kept 
by the industry: in 1994, 49.9% of the production, while in 1995, 51% of the production 
was delivered to foreign markets, then this ratio increased to 60% by 1998. These data 
show that the pharmaceutical industry has been export-oriented.  
 
Table: 6.2.22 Pharma sales by markets 
 1990. 1991. 1992. 1993. 1994. 1995. 1996. 1997 1998 
Export. 
HUF billion 
31.347 28.754 28.934 33.774 41.157 51.722 66.626 100.234 113.658
Domestic. 
HUF billion 
30.981 37.186 26.046 36.943 41.183 48.732 58.153 69.166 79.319
Total 62.328 65.940 54.980 70.717 82.340 100.454 124.779 169.400 192.977
Az export as 
% of total 
50.29% 43.61% 52.63% 47.76% 49.98% 51.49% 53.40% 59.17% 58.90%
Source: KSH Industry statistics. Data comprise both finished drugs and substances 
 
The data and the cited researches underline that it seems to be an important question from 
the aspect of the export capability of the Hungarian pharmaceutical industry how the 
domestic sales position of the domestic manufacturers develops. Preference of the 
products of the domestic pharmaceutical manufacturers by the domestic health care 
against the products with the same active ingredient may be a factor improving the 
efficiency of the national economy through transmissions at macroeconomic level: relying 
on domestic resources, with cheaper resources, using cheaper products, both the health 
care budget and the trade balance, can save considerable amounts. In their study, Bartlett-
Goshal (2000) mention Ranbaxy, a pharmaceutical company in India, as such a successful 
example, which was also able to grow as a late starter. Not calling in doubt the 
international successes of the company and the professional competence of the 
management of the company, it should be mentioned that with this instance the authors 
forgot about the fact that the World Trade Organization (WTO) gave time to the Indian 
pharmaceutical industry till 2005 to change over to the product patent system. Based on 
process patent system, until that time the domestic companies may have advantage over 
the foreign competitor on the Indian market which means that they can produce and 
market original products of their competitors as reproduced products to the domestic 
market without consequences.  
 
Fundamental changes have taken place in the Hungarian pharmaceutical industry in the 
1990s. The most important changes can be summarized as follows:  
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The responsibility of the domestic manufacturers for producing good ceased which, in 
itself, allows a much larger ground to improve the rational operations of the domestic 
manufacturers. In 1994, the change over from the process patent system to the product 
patent system took place that required the reconsideration of R&D activity with the 
domestic manufacturers. Concurrently to this, the reimbursement system and the 
distribution system have been transformed: the systems have become more transparent on 
the one hand, and market economy conditions have been created on the other hand in the 
pharmaceutical industry.  
 
Traditional markets have become uncertain and smaller: As consequence of the collapse 
of COMECON, the traditional big market of the Hungarian manufacturers have become 
uncertain and smaller. According to the data of Thököly (1994), the ruble account export 
in 1989 represented nearly 50% of the total export of the pharmaceutical industry. The 
export of HUF 14.8 billion in 1989 was reduced to its half in 1991 and its value of HUF 
13.1 billion did not reach the 1989 level in nominal value in 1993 either. The collapse of 
COMECON affected the domestic pharmaceutical manufacturers, while the pharma 
import has been liberalized practically to a full extent that resulted in a sharp competition 
for the domestic manufacturers on their home market.  
 
As a consequence of import liberalization, the number of products distributed on the 
domestic market has considerably increased that is the assortment of the pharmaceuticals 
has become wider. Import liberalization went with the change that the net exporter 
industry until that time has become a net importer industry in the Hungarian encoring. 
From the table below it turns out that the trade balance of the industry shows a 
considerable deficit. HUF 20.433 billion suffices in 1990 became a deficit of HUF 48.203 
billion by 1998. Export grew to more than to its double between 1990 and 1998, while the 
import increased to more than its 11 fold in this period. The patent system changed in 
1994, as a consequence of which the pharmaceutical industry changed over from the 
process patent system to the product patent system. The change over to the product patent 
system also meant among others that instead of the earlier license agreements the license 
holders started to distribute their products by their own.  
 
Table: 6.2.23 Trade balance of pharmaceuticals, 1990-1998 
 1990 1991 1992 1993 1994 1995 1996 1997 1998 
Export, million 
HUF 
31347 37186 23435 22991 28312 36078 47253 70384 72964
Import, million 
HUF 
10914 22423 23537 30243 47317 55982 70766 90657 121172
Balance 20433 14763 -102 -7252 -19005 -19904 -23513 -20273 -48208
Export base 
indexes, 
1990=100 
100,0% 118,6% 74,8% 73,3% 90,3% 115,1% 150,7% 224,5% 232,8%
Import base 
indexes, 
1990=100 
100,0% 205,5% 215,7% 277,1% 433,5% 512,9% 648,4% 830,6% 1110,2
%
Notes: Data for 1990 and 1991 taken from industrial Statistics, from 1992 onwards SITC statistics 
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As it was earlier mentioned, the share of inland manufacturers reduced from the 73.9% in 
1990 to 39% in 1998. The market share of the two largest domestic manufacturers, Egis 
and Richter, seems to be stabilized at about 10%. If the market shares are considered in 
volume, the loss of the share of the domestic manufacturers was smaller and took place at 
a lower rate. As it turns out from the table below, the share of the domestic manufacturers 
in the volume is 68%, which is more than the double of the same figure of imported 
pharmaceuticals.  
 
Table 6.2.24 Domestic and import consumption indexes 
 1990 1991 1992 1993 1994 1995 1996 1997* 1998*
Domestic boxes. m boxes 324 298.9 264.4 267.3 253.2 238.2 220.7 215.5 na
Import boxes. m boxes 43.1 52.1 51.3 61.1 71.2 68.2 74.9 83.8 na
Total 367 352.2 305.7 328.5 324.4 306.5 295.7 299.3 na
Domestic as % of Total 88% 85% 86% 81% 78% 78% 75% 72% 68%
Import as % of Total 12% 15% 17% 19% 22% 22% 25% 28% 32%
Source: Molnár (1997). 17 and * Bogsch (2000) and IMS 
 
The privatization of the domestic pharmaceutical industry has practically finished. The 
privatization should be deemed as successful. The domestic manufacturers have got 
additional capital and professional knowledge from their new owners. The most important 
milestones of privatization are shown in the table below. The table shows that the majority 
of the domestic pharmaceutical companies have got into the property of professional 
investors. The only exception to this is Richter Co. Ltd. where the dominant owners of the 
company are financial investors.  
 
Table 6.2.25 Privatization of domestic manufacturers at the end of 1998 
Manufacture
r 
Date of Date of 
Privatization 
Major Owners and their stake 
Alkaloida October 1, 1991 August 30, 1996 ICN Pharmaceuticals Inc., USA, 
67,1 % 
Biogal January 1, 1990 November 5, 1995 Teva, Israel, 97,8 % 
Chinoin January 1, 1990 February 24, 1991 Sanofi, France, 99 % 
Egis January 1, 1992 December, 1993  Servier, France, 51 % 
Human Julius 1, 1992 December, 1993 Novopharm, Canada 55,5 % 
Richter November 1, 1992 October, 1995 Financial inventors 56,9 % 
Source: Antalóczy, 1999. 
 
In her study summarizing the experiences with privatization, Antalóczy (1999) has 
pointed out that the government had no professional conception on the privatization of the 
pharmaceutical industry; the most important purpose was to conduct the privatization. 
Their management and the potential future owners formed the fate of the individual 
companies.  
 
The subsidiaries of the multinational (global) companies started their operation in 
Hungary. From their mother companies’ point of view, the majority of the foreign 
subsidiaries are to be deemed as sales force most important task of which is to distribute 
the products of their mother companies. This may also be concluded from the fact that 
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while the import of pharmaceutical products has considerably grown, the increase in 
domestic production and export was not so spectacular at all.  
 
Table 6.2.26. Top ten companies at ex-manufactures prices, million HUF, 1995-1998. 
 1995 1996 1997 1998 
Richter Gedeon 6951 9544 12264 15192 
Egis 9283 11005 11803 13511 
Novartis (Ciba+Sandoz) 6634 7302 8259 10676 
Chinoin (Sanofi) 5436 7168 7824 9406 
Biogal (Teva) 5734 6478 7054 8373 
Eli Lilly 2276 2767 3825 4852 
Merck Sharp Dohme 989 1637 2801 4802 
Pfizer 1384 2127 3200 4524 
Bristol Myers 
(Pharmavit) 
1738 2359 3319 3922 
Schering Plough 1645 2467 3035 3879 
Sources: IMS. 
 
The above table shows the order of the 10 largest companies according to their sales to the 
Hungarian pharmacies. From this table it turns out that two domestic companies, Richter 
and Egis, are on the top. Novartis is behind them, but before the third largest domestic 
manufacturer, Chinoin. Among the 10 largest companies, five are local subsidiaries of 
multinational companies focusing on sales. The other five are such companies – Richter, 
Egis, Chinoin, Biogal, Bristol Myers Squibb – which may be considered as 
pharmaceutical manufacturers in Hungary.  
 
The new entrants into the Hungarian market have introduced a very aggressive marketing 
practice not yet applied so far. They have made it routine as the first that the most 
important target points of the manufacturers and distributors to be influenced in order to 
stimulate their sales are the physicians and pharmacists. As in the case of the physicians 
and pharmacists, it is about a very strong professional marketing, it is very difficult to 
draw the line between the ethical and not ethical promotion of sales which is regulated by 
the rule 24/1997.(VIII.14.)NM in accordance with the law on the advertising of 
pharmaceutical products, accepted in 1997. This decree prescribes that only those with 
qualification of physician, dentist or pharmacist are allowed to perform medical 
representative tasks and the data of these persons should be reported to the National 
Institute of Pharmacy. When the new players entered, they recruited their staff from the 
underpaid physicians and pharmacists speaking foreign languages. According to the 
information available on the medical representatives (HVG 1997), Richter employed 70, 
Egis nearly 100 and SmithKline Beecham appr. 50 medical representatives, while the 
majority of the players had 5-15 persons with this task in 1997.  
 
Among the foreign companies, data are available on Novartis. Novartis Hungary Ltd., is 
the third largest competitor on the market, it is before Chinoin in the order. The legal 
predecessor of Novartis, CIBA Hungary Ltd., started its operation in June, 1991 and 
continues its operation under the name of Novartis Hungary Ltd. after the merger of the 
mother companies in 1997.  
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The Swiss mother company of Novartis Hungary Ltd. is Novartis, which is the second 
most valuable company in Switzerland. Its sales totalled to USD 20.4 billion in 1998. 
Based on its market price, the Swiss mother company was the 11th most valuable company 
in the world on the Global Top 1000 list of Business Week in 1998, and it the 29th in 1999 
(Business Week, 12th July, 1999).  
 
Novartis Hungary Ltd. has a Hungarian language website (www.novartis.hu). From the 
information in the website, it turns out that the company has two large divisions: the 
health care products division and agricultural products division. Within the health care 
products, the distribution of the prescription medicines, non-prescription medicines and 
generic products are managed separately from each other. The company has its own 
medical representative network through which information are provided on their products 
to physicians, hospitals and pharmacies. It is emphasized on the website that the task of 
their own filing and registering department is to ensure the rapid entry of their products to 
the market. About the operational results of the company, the Figyelő Top200 publications 
provide information - there are no data relating to this in the company’s website – because 
the company ranks into the 200 largest domestic companies based on its sales.  
 
Table 6.2.27 Key figures of Novartis Hungary* million HUF, 1995-1998 
 1995 1996 1997 1998 
Sales 8536 10898 16085 20953 
Pharma sales. %** na 67.0 45.4 50.9 
Export 366 315 307 573 
Number of employes 193 198 233 228 
Owners Equity 560 322 494 295 
Profit before taxes -223 -233 -186 na 
Source: Figyelő Top 200 
Notes: * until 1996 data are on CIBA Hungarian company, ** based on the previous table 
 
 
According to the above data, the company has dynamically increased its sales, but it 
operated with loss between 1995-1997. Its sales revenue from pharmaceuticals contributed 
to the total sales with 67% in 1996 and with 50.9% in 1998. It may be presumably 
attributed to the financial loss that the owners'` equity of the company decreased between 
1995 and 1998. The Hungarian subsidiary contributed with USD 97.7 million – counted at 
the average exchange rate - to the sales of the mother company in 1998, which represented 
0.48% in the total sales of Novartis. These data in themselves – not taking the mother 
company into consideration – are very difficult to be interpreted. The Hungarian sales of 
Novartis amounting to hardly 0.5% of the total sales of the company refer to the fact that 
the Hungarian subsidiary is not substantial from the Novartis’ point of view. Based on the 
results before taxation, the Hungarian subsidiary cannot be evaluated, because the losses 
may be resulted from the initial expenditure undertaken in order to get the desired market 
share. Comparing Novartis Hungary Ltd. to the other Hungarian market players, I 
underline that it employs appr. 10% of the staff which is employed by Chinoin taking 
nearly the same position in the Hungarian market, and the amount of its owners` equity is 
1-2% of that of Chinoin. This comparison refers to the fact that the main direction of the 
Novartis’ activity is the sales.  
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The domestic pharmaceutical manufacturers were shocked by the liberalization of the 
pharma market from one day to the other (practically from 1993 on), the change over to 
the product patent system (from July, 1994 on) and losing the certain “socialist” markets 
due to the collapse of COMECON (in 1991). As a result of the adjustment to these 
challenges, the domestic manufacturers organize their production and operation fitted to 
the market economic conditions featured by sharp competition. Next to the import 
competition in their home market a sharp competition in their export markets, also 
stimulate them. As a result of the changes occurred in the first half of the 1990s, the 
domestic manufacturers, are evaluated by the rules of the market economy, their products 
are in competition with products of the multinational companies both in the domestic and 
foreign markets. They are also expected  that they should sell their products at low prices 
in Hungary in order to enforce social values through this. This is enhanced by the fact that 
in the public opinion they are still “the” pharmaceutical companies. Changes and the 
market competition spurred the domestic pharmaceutical manufacturers to a cost-oriented 
behavior. Import competition made, the domestic manufacturers change their marketing 
activity, packaging their products and rationalization of their production. In the latter, it 
also took part that the responsibility for producing goods of the domestic manufacturers 
has ceased and the privatization has been started and finished. The new owners expect the 
profit usual in the pharmaceutical industry internationally, which means a very high 
pressure on the profitable operation.  
 
With the local subsidiaries of the foreign manufacturers, the factors having effect on the 
costs develop in another way. The basis of pricing is the free on border (FOB) price on 
which the mother company has a decisive effect. It should be seen at this point that these 
prices reflects the relationship of the developed market economy and are adjusted to those. 
These prices, converted into Hungarian Forints, are much higher in many cases from the 
beginning than the prices of the pharmaceuticals with the same efficacy manufactured in 
Hungary. The local subsidiaries involved in the distribution in Hungary have also some 
influence on the prices, but their most important task is to generate a market (demand) for 
the products at the set prices. Their most important tools in this are the sales promotion 
and the communication policy. Because of the price formulation and the cost conditions 
behind, the prices of import pharmaceuticals have a considerable effect on the budget of 
the subsidization of medicaments with the disease groups where no medicine with proper 
therapeutic effect, manufactured in Hungary is available.  
 
One of the largest long-term challenges for the domestic pharmaceutical producers is the 
R&D. Discontinuance of the process patent system practically existing till the middle of 
1994, jointly with the privatization and import liberalization, have seriously raised the 
question on what the intellectual capacity and provision with equipment of the domestic 
research and development is sufficient for. In addition to this issue, the institutional 
background of R&D of the industry has also been questioned due to the changes occurred 
in the ownership. Before the transition, in the 1970s and 80s, the domestic pharmaceutical 
industry could deem several successful original Hungarian products as its own (Hollósi, 
1998). In the meantime, R&D strategies of the pharmaceutical industry have also changed: 
innovation of the leader molecule and the pre-clinical studies require 3.5 years and USD 
205 million, while the clinical studies 7.5-8.5 years and USD 99 million on the average 
(Based on The Economist, 1998 and Hollósi 1998). The developments in 1990s show that 
the chemical synthesis and discovering new molecules continue to be the strong point of 
 165
the Hungarian pharmaceutical producers. In the phase of the clinical studies of R&D, 
however, it seems that the pharmaceutical companies can accompany the selected leading 
molecules until receiving the permissions neither by themselves, nor relying on the 
domestic R&D basis. In R&D, the domestic and international research co-operations seem 
to be inevitably necessary just like concluding strategic alliances for the clinical studies 
and launch into the market (see Szilbereky, 1998 and Schõn, 1998).  
 
The pharmaceutical industry, which was always important from national economy’s point 
of view, could keep this position, especially in respect to export and R&D, in the 1990s. 
In two fields, the incumbent pharmaceutical producers have dominant position 
independently from their ownership structure. These fields are domestic production and 
export. Investigating the domestic pharmaceutical industry in international context, it may 
be seen that three Hungarian companies, Richter, Egis and Chinoin, are among the ten 
largest companies in the region, and based on the data Richter has a good chance to 
become the leading pharmaceutical company in the region. The key question seems to be 
in this issue what results the company can reach in the field of R&D.  
 
As a result of the discussed changes, the Hungarian market has become a multiplayer 
market in the early 1990s. According to a paper published in 1997 (Molnár, 1997., p. 16-
17.), 188 companies in all were active on the domestic pharma market in the first half of 
1997 of which as little as 23 companies gave work to more than 20 persons according to 
the records of the Central Statistical Office (KSH). The nearly 75% market share of the 
domestic pharmaceutical manufacturers, in terms of value, in 1990 was reduced below 
40%. Considering the number of boxes sold, the first three Hungarian manufacturers 
(Egis, Richter and Chinoin) cover 55.2% of the market, which corresponds to a 29.2% 
market share in the value of sales. In the pharmaceuticals production and their export, 
however, the domestic producers continue to be in leading position, because these 
companies produce 90% of the domestic production and the same percentage of the export 
independently from their ownership structure.  
 
 
6.2.4.4 Competitiveness of three domestic pharmaceutical producers  
 
In this chapter, I analyze the performance and competitiveness of three leading Hungarian 
producers also reputed in the region. These companies are Richter, Chinoin, and Egis. The 
shares of Richter and Egis are quoted the Budapest Stock Exchange, thus further public 
information may be obtained regarding their operation.  
 
Table 6.2.28 Shares of the three manufactures in industry sales revenue, 1994-1998 
 1994 1995 1996 1997 1998 
Richter 26.54% 27.54% 30.09% 31.03% 28.68%
Chinoin 22.04% 22.08% 23.60% 22.16% 20.80%
Egis 18.58% 19.72% 19.78% 14.85% 16.48%
Total 67.17% 69.34% 73.46% 68.04% 65.96%
Source: Figyelő Top 200 and KSH 
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Glancing at the above table showing the concentration of the domestic production, it may 
be seen that the threl pharmaceutical producers play a leading role both in domestic 
production, where their share was 65.96% and in export, where their share was 73.77% in 
1998. To paraphrase, it can be said that if business is up for the large pharmaceutical 
producers, then business is also up for the Pharmaceuticals export.  
 
Table 6.2.29 Shares of the three manufacturers in the Hungarian pharma export, 1994-1998. 
 1994 1995 1996 1997 1998 
Richter 35.88% 36.20% 38.13% 36.63% 33.03%
Chinoin 27.83% 27.15% 28.31% 24.91% 24.27%
Egis 16.40% 19.72% 19.78% 14.85% 16.48%
Total 80.11% 83.07% 86.22% 76.39% 73.77%
Source: Figyelő Top 200 and KSH 
 
The data on employment in the table below show that the three domestic manufacturers 
could jointly keep their position as employer in the pharmaceutical industry: 65% of the 
employees find their jobs here. Behind the overall picture, considering the sequence, there 
is no change, but considering the ratios, there is: the share of Chinoin and Egis has slightly 
decreased, while that of Richter has increased.  
 
Table 6.2.30 Shares of the three manufacturers in the Pharmaceuticals industry employees. 
1994-1998 
 1994 1995 1996 1997 1998 
Richter 27.15% 26.96% 29.81% 30.68% 30.67%
Chinoin 16.71% 16.15% 16.85% 16.61% 15.90%
Egis 20.81% 19.10% 18.61% 18.55% 18.10%
Total 64.67% 62.21% 65.27% 66.02% 64.67%
Note: Number of company annual employees / Total employees in the pharmaceutical industry 
 
Before analyzing the profitability, the companies are briefly introduced according to the 
same structure. Firstly the privatization is mentioned which determines the basic 
opportunities in each company. Following this, their position in the domestic market, and 
finally their results in the external markets are discussed. This latter gives a picture on the 
international competitiveness of each producer. 
 
 
Gedeon Richter Co. Ltd. 
 
Gedeon Richter Co. Ltd. is one of the oldest companies of the pharmaceutical industry in 
Hungary. It has been operating since 1901. The company was named after Gedeon Richter 
who was the founder of the company. It was reorganized into a company limited by shares 
in November 1990, after the change in the political system. With respect to the fact that 
the company was oriented to the earlier socialist markets, after the collapse of 
COMECON it had serious problems in sales, which was also shown in the profitability. 
Thus the company closed the year of 1992 with a loss of HUF 1.463 billion. As it turns 
out from the table below, the share of Richter was the largest in the Ruble account export 
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among the domestic pharmaceutical producers, thus the collapse of COMECON affected 
this company to the greatest extent.  
 
Table 6.2.31 Shares in the Ruble export in 1989.and 1992-1993. 
 Alkaloida Biogal Chinoin Egis Reanal Richter Other Total HUF 
Billion. 
1989. 5.90% 6.20% 20.10% 19.00% 1.50% 46.50% 0.80% 100% 14.8
1992. 0.86% 7.58% 18.50% 26.47% na 45.66% 0.93% 100% 9.3
1993. 2.81% 5.03% 14.12% 20.97% 0.31% 56.70% 0.05% 100% 13.1
Source: Tököly (1994) 
 
The year of 1992 resulted in a promising change in the life of the company. A new general 
manager, Erik Bogsch, and a new management was appointed, the main task of which was 
to prepare the privatization. Instead of debt consolidation, Richter asked, as an external 
aid, to receive tax holiday (Antalóczy, 1999, attachments No: 20 and 18) and elaborated a 
plan to improve the efficiency of the company. The elaborated corporate strategy outlined 
the necessity of focusing and increase of efficiency. The elements of improving the 
achievements of the company were as follows: improvement of financial management 
(more stringent credit policy, more efficient information system), decrease in the staff, 
clarification of the product portfolio and in parallel to this, obtaining new licenses, taking 
the sales on the ex-Soviet markets under self-control, and creating a marketing 
organization as a response to the increasing competition in the home market. The results 
of these changes could already be seen in 1993, because the company became profitable 
again in 1993.  
 
Table 6.2.32 The Richter R&D spendings as % of its sales, 1993-1997 
 1993 1994 1995 1996 1997 
Percentage 8.3 7.0 6.1 5.7 5.5 
Source: Antalóczy. 1999.. p.71. 
 
The new strategy also treated the investments and R&D expenditure with special 
emphases. As a result of the new strategy, the company became suitable for privatization.  
 
The company was privatized by and public offerings financial investors through the stock 
exchange. The ownership structure of Richter was as follows in May, 2000: foreign 
institutional and private investors 61.97%, State Property and Privatization Holding Co. 
27.11%, management and employees 0.1%, other domestic institutional and private 
investors 9.53%, own shares 1.29%. 71.5% of the shares are outstanding.  
 
Approximately 60% of sales revenue came from medicines in three therapeutic areas 
(central nervous system, cardiovascular system, gynecology). There are two leading 
products, Cavinton having effect on the central nervous system, which is an original 
product, as well as Ednyt, a reproduced blood pressure decreasing agent. In addition to the 
finished products, manufacturing of active ingredients is also part of the product policy of 
the company. In the product portfolio, the ratio of the reproduced and generic products 
represents nearly two-thirds.  
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Distribution of sales according to geographical relations shows that the share of the 
Hungarian market is appr. one-third. Due to the impairment of the CIS market in 1998, 
there was a change in the export markets. The nearly one-third ratio of the CIS market was 
reduced and in parallels to this the share of the Polish and US market increased.  
 
Table: 6.2.33 Performance of Richter after its privatization 
 1994 1995 1996 1997 1998 
Sales, HUF 
million 
21854 27664 37541 52568 55345
Export, HUF 
million 
14767 18723 25403 36714 37540
Number of 
employees 
4789 4684 4680 4657 4732
Owners' equity, 
HUF million 
27275 33057 42783 72449 85073
Operating profit, 
HUF million 
5170 7191 9964 16569 13277
Earnings before 
taxes, HUF million 
4294 7749 12240 19492 16824
Source: Figyelő Top200  
 
According to the Top200 publications of Figyelő, Richter was among the 10 largest 
Hungarian companies based on its sales and the number of employees in the second half 
of the 1990s. The year of 1998 resulted in a breakage in the annual increase rate of the 
company due to the impairment on the CIS market, where Richter was the largest foreign 
supplier with its 10% market share. In addition to the CIS market, the Polish and 
Romanian markets are also important external markets for the company. In Romania, the 
company acquired the majority share in the S. C. Armadica company. Richter is active due 
to its a distribution network on the CIS market, where it continues to hold a dominant 
position. (Source: Figyelő Top200. and www.richter.hu)  
 
 
Chinoin Co. Ltd.  
 
Chinoin Co. Ltd., too, is a player with a well-established name in the Hungarian 
pharmaceutical industry, it has been operated under the name of Chinoin since 1912. 
Among the pharmaceutical companies, the privatization of Chinoin took place in 1991 as 
the first. Following the privatization, measures affecting the efficiency of the company 
were introduced which were carried out in parallel to the integration of the company into 
the organization of Sanofi, the new owner.  
 
The owner of Chinoin, the French Sanofi, is considered a new player in the international 
pharmaceutical industry, it was founded in 1973 and since 1980 it has been listed on the 
Paris stock exchange. Sanofi the owner of Chinoin, got on the list of the top 15 foreign 
direct investors in Hungary in 1998, because Sanofi invested USD 220 million in total in 
the Chinoin till the end of 1998.  
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Following the privatization, measures affecting the efficiency of the company were 
introduced in the field of financial management, human resource management as well as 
in the field of the rationalization of the operation and product portfolio. In the field of 
R&D activity, the chemical research basis gave the main attractiveness of Chinoin, which 
was rationalized, to a great extent. R&D costs on sales have been increased, it were 6% in 
1990, which was the year of privatization, 8% in 1992, 10% in 1995 (Antalóczy, 1999), 
9% in 1997, 10% in 1998 according to the Top200 publications of Figyelő which means 
that the company has increased its R&D activity.  
 
The largest reconstruction has been carried out in the marketing. Chinoin has been 
integrated into the marketing organization of Sanofi, their products are sold by the 
marketing channels of Sanofi in the foreign markets. There was a change on the top of the 
company in 1998, because Philippe Besse replaced György Miklós, who was nominated 
concurrently to the privatization, in the post of the CEO.  
 
Table: 6.2.34 Performance of Chinoin after its privatization 
 1994 1995 1996 1997 1998 
Sales, HUF million 18147 22177 29442 37533 40131
Export, HUF million 11456 14042 18862 24965 27580
Number of employees 2948 2807 2645 2521 2454
Owners' equity, HUF 
million 
17761 20535 20718 26454 27162
Operating profit, HUF 
million 
3934 5307 6185 8935 8138
Earnings before taxes, 
HUF million 
4028 6364 8296 8984 7482
Source: Figyelő Top200  
 
Chinoin is one of the dominant players in the market of the non-prescription products. In 
addition to pharmaceutical products, Chinoin is also a key player in the market of the plant 
protection agents. Among its export markets, those in the surrounding countries are the 
largest ones.  
 
 
Egis Co. Ltd.  
 
Egis was created through the merger of the Swiss owned Wander Co. Ltd. and other 
smaller nationalized private pharmaceutical companies in the course of the nationalization 
in 1948.  
 
Egis has been privatized in two phases. In the first phase, the company was introduced to 
the stock exchange and financial investors (EBRD as a dominant owner) were drawn into, 
then in the second phase, in December 1995, professional investor was drawn into through 
selling the shares of financial investors to a professional investor (to NatWest through 
acquiring the shares of EBRD and State Privatization Agency). The ownership structure of 
the company was as follows in May, 2000: Servier 50.91%, foreign institutional and 
private investors 43.25%, domestic institutional and private investors 5.76%, management 
and staff 0.08%. 49.01% of the shares of the company were outstanding.  
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The management of the company has played an active role in the preparation and 
conducting of the privatization from the beginning to the end and since that time its role 
has also been decisive. The CEO of the company is Dr. István Orbán who assumes the 
presidency of the Hungarian Pharmaceutical Manufacturers Association at the same time. 
The main strategic purpose of the company squared with Servier is that Egis should also 
become an internationally competitive generic firm (Antalóczy, 1999, p. 70).  
 
The French Servier was established in 1954. In the 1990s, the company formulated two 
strategic objectives: expansion in the East-European region and rapid expansion in the 
market of generic products (Antalóczy, 1992., p. 62). Egis seems to have met both 
strategic objectives. It is the 27th pharmaceutical company in the world at present; it 
earned a sales of FFR 10 billion in 1998, 70% of which resulted from international sales. 
Servier defines itself as a research-based pharmaceutical company. It spent FFR 2.2 
billion on 240 that corresponded to 22% of its annual sales, in 1998. The research-oriented 
nature of Servier has also been shown in its sales distribution 81% of its total sales 
resulted from 8 products of the company. The company operates in 130 countries with 70 
subsidiaries; it has subsidiaries, in addition to Hungary, in Poland and Russia in the East-
European region, as well. (Source: www.servier.fr.) 
 
Considerable changes occurred in three fields of the operation of the company. In R&D, 
the ratio of original product researches was reduced, the development activity for generic 
products increased, thus so-to-say creating a division of labor between Servier and Egis.  
 
Table: 6.2.35 The Egis R&D spendings as % of its sales. 1993-1997 
 1993 1994 1995 1996 1997 
Percentage 7.2 8.8 8.6 8.7 7.7 
Sources: Antalóczy. 1999. p.71. 
 
Adjusted to the new profile, the field of marketing also underwent a considerable 
development. The earlier insufficient development of the marketing is featured by the fact 
that it was the only area where a professional from the mother company was appointed. 
The third field was the change in the market orientation where the aim is to protect the 
sustainable market positions in the domestic market and to strengthen the market positions 
in the target segments in East-Europe and in the western markets.  
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Table: 6.2.36 Performance of Egis after its privatization 
 1994 1995 1996 1997 1998 
Sales, HUF 
million 
15302 19813 24687 25159 31810
Export, HUF 
million 
6751 8856 11068 15234 16744
Number of 
employees 
3671 3319 2921 2816 2793
Owners' equity, 
HUF million 
18603 22876 27863 33973 39739
Operating profit, 
HUF million 
3015 4035 5011 5561 4726
Earnings before 
taxes, HUF million 
2546 4905 5618 6274 5381
Source: Figyelõ Top 200 
 
Nearly 80% of sales of the company come from selling finished pharmaceutical products 
and appr. 20% from the sales of active ingredients. In the product portfolio, the ratio of 
generic products was 73%, that of the license products was 25% and the share of the Egis’ 
own pharmaceuticals was 2% in 1998. In its exports, the greater emphasis was on the 
Central-East-European regions in the 1990s. Beside Servier, Egis acquired an ownership 
share in the Polish company, Anpharm in 1997 and it operates with its own subsidiaries in 
the US, Czech, Slovak and English markets. The distribution of sales according to 
geographical relations shows that the major market of the company continues to be the 
Hungarian market, however, its market share lowered below 50% in 1997. Among the 
export markets, beside the CIS and Central-East-European region the share of West-
Europe, North-America and Japan have been increased since 1997.  
 
 
Conclusions on the adjustment of companies 
 
In the privatization of the three companies, the management had influence on the way of 
privatization and the selection of the new owners. There was no change in the person of 
the number one manager of Richter and Egis following the privatization either. The 
management of these companies was active in the Hungarian pharmaceutical industry 
earlier, too, and they had a considerable part in the increase of the efficiency of their 
companies.  
 
Attractive ness of the companies was given by the international success of their original 
products in the 1980s and their chemical research basis.. The original products were 
attractive especially in the case of Richter and Chinoin. The research basis and R&D 
activity as far as the privatization proved to be important in the field of the development of 
generic products in companies with professional inventors. Professional investors matched 
the, R&D activity of the acquired companies with R&D activity of their own. The 
research for original products is a key issue for Richter with respect to the fact that the 
major owners of the company are financial investors.  
 
In the course of the privatization, two factors impelled the companies to restructure their 
operation:  of COMECON and the import competition in their home market. Both areas 
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stimulated companies to create their marketing operation missing until that time, 
especially in the field of sales force and sales promotion. The professional owners 
provided the most amount of support to their subsidiaries in these fields. Beside the 
creation of their medical representative networks, Richter and Egis also hold wholesaling 
trader subsidiary.  
 
Among the companies, Richter has the greatest freedom in its strategy formulation 
because its ownership structure. It goes on its own individual way: it has kept its 
bridgeheads in the eastern markets and strives to strengthen its positions there. The 
company operates as a potential leading pharmaceutical company in the region and the 
success of this is fundamentally influenced by the success of R&D activity.  
 
It seems that the three companies pursue three different strategies. Beside the generic and 
non-prescription medicines, Chinoin has been diversified into the manufacture of plant 
protection agents still in the 1970s, where it is a leading player in the Hungarian market. 
Egis has moved toward the manufacturing of generic products and as a company like that 
it is one of the most important subsidiaries of its owner (mother company) in the region. 
In international comparison, Richter is a small pharmaceutical producer, which should 
carry out a highly focused research activity so that it could also be successful on its own 
on the long-term.  
 
After the introduction of companies, I analyze the profitability of companies based on data 
available from the pharmaceutical industry and companies. If the data in the table below 
are considered, it turns out that the decrease in the number of employees was the most 
remarkable with Egis, where the staff was decreased with 24% as against 1994, the same 
data is 17% with Chinoin, while in the case of Richter it is as little as 2% it can be 
explained by the fact that with Egis a considerable outsourcing has taken place. 
Consequently, it is worth underlining at this point that Richter could reach the 
improvement in its results practically with the same number of employees.  
 
Table: 6.2.37.Growth of employment, 1994-1998. 
 Chain indexes Changes to 
 1995 1996 1997 1998 1994 
Industry average 98.52% 90.29% 96.74% 101.67% -12.7%
Richter 97.81% 99.91% 99.51% 101.61% -1.2%
Chinoin  95.22% 94.23% 95.31% 97.34% -16.8%
Egis  90.41% 88.01% 96.41% 99.18% -23.9%
 
The table below shows the development of sales per capits. It may be seen that the per 
capita sales grew as compared to 1994 with the Egis to the greatest extent, to its 2.7 fold, 
but as it may observed in the previous table, the decrease of employment affected the most 
people with this company.  
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Table: 6.2.38. Sales revenue per capita HUF billion, 1994-1998 
 1994 1995 1996 1997 1998 On 1994 
price 
Pharmaceutical average 4.668 5.781 7.953 11.162 12.507 267.9%
Richter 4.563 5.906 8.022 11.288 11.696 256.3%
Chinoin 6.156 7.901 11.131 14.888 16.353 265.7%
Egis 4.168 5.970 8.452 8.934 11.389 273.2%
 
If the data of the individual companies are compared to the sales per capita in the 
pharmaceutical industry, then Chinoin may be considered to be the most efficient 
company. With this company, the per capita sales were 30% higher than the average of the 
pharmaceutical industry every year.  
 
Table: 6.2.39 Sales revenu per capita as % of pharmaceutical industry, 1994-1998 
 1994 1995 1996 1997 1998 
Richter 97.75% 102.17% 100.86% 101.13% 93.52%
Chinoin 131.86% 136.67% 139.96% 133.39% 130.76%
Egis 89.29% 103.26% 106.27% 80.04% 91.07%
 
I also analyse the profitability of companies by calculating the return on sales and return 
on equity ratios. According to the ratio of earnings before taxes/sales, Richter was the 
most profitable domestic manufacturer from 1996, with an index exceeding 30% in all the 
three years.  
 
Table: 6.2.40 Return on sales. 1994-1998 
 1994 1995 1996 1997 1998 
Richter 19.65% 28.01% 32.60% 37.08% 30.40% 
Chinoin 22.20% 28.70% 28.18% 23.94% 18.64% 
Egis 16.64% 24.76% 22.76% 24.94% 16.92% 
Note: ROS=Earnings before taxes/Sales 
 
Return on equity shows a picture on the profitability from the owners’ point of view. I 
have investigated the profitability on equity as compared to the operational profit and the 
profit before taxes. From the operational profit’s point of view, the basic activity and 
operation of companies have a special emphasis, while the profit before taxes put the 
operational efficiency of the total company in the limelight.  
 
Table  6.2.41 Return on equity 1, 1994-1998 
 1994 1995 1996 1997 1998 
Richter 18.96% 21.75% 23.29% 22.87% 15.61% 
Chinoin 22.15% 25.84% 29.85% 33.78% 29.96% 
Egis 16.21% 17.64% 17.98% 16.37% 11.89% 
Note: ROE = Operating profit/Owners' equity 
 
In respect of the operational profit on equity, Chinoin showed the best results with a value 
of nearly 30%  between 1996 and 1998. Investigating the profit on equity before taxes. it 
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may be seen that the data of companies are regularly higher than the data calculated on the 
basis of the operational profit.  
 
Table 6.2.42 Return on equity 2, 1994-1998 
 1994 1995 1996 1997 1998 
Richter 15.74% 23.44% 28.61% 26.90% 19.78% 
Chinoin 22.68% 30.99% 40.04% 33.96% 27.55% 
Egis 13.69% 21.44% 20.16% 18.47% 13.54% 
Note: ROE = Earnins before taxes/Owners' equity 
 
From the tables on financial performance of the largest domestic manufacturers, the 
following conclusions may be drawn: The three largest companies, Richter, Chinoin and 
Egis have continuously increased both their production and export between 1994 and 
1998. Increase in their operational efficiency is marked by the fact that the value of the 
operational profit has increased to more than the double with all the three companies.  
 
Figyelő Top200 published a comparative analysis on the comparison of efficiency of 
individual industries of companies got to the Top200 list and the industries of the USA 
and Great Britain with the aid of CA-IB at first in 1997 and never since that time. The data 
are shown in the table below. From the data, it is worth investigating the operational 
margin, margin before taxex and ratio on the earnings before taxes on equity.  
 
Table 6.2.43 Pharmaceutical financial ratios, 1997 
 Sales per 
capita. HUF 
million 
Operating 
margin %* 
Pretax margin. 
%. ** 
ROE. % *** 
Richter Rt. 12.3 29.1 35.9 27.7 
Chinoin Rt. 14.9 23.8 23.9 34.0 
Egis Rt. 10.4 19.1 21.5 18.5 
Pharmavit Rt. 28.3 13.3 10.8 30.8 
ICN 
Magyarország 
Rt. 
6.3 12.0 6.3 9.0 
Humán Rt. 11.8 6.5 8.3 11.3 
Top200 14.1 17.3 17.8 21.9 
USA 49.9 24.8 23.0 52.2 
Nagy-Britannia 45.6 27.6 26.7 109.6 
Soruce: Figyelő Top200 (1998.)  
Notes: * Operating margin =Operating profit/Sales, ** Pretax margin = Earnings before 
taxes/Sales, *** ROE = Easning before taxes/Owners' equity 
 
 
Investigating the ratios on the operational margin compared to data of the pharmaceutical 
industry of the USA and Great Britain belonging to the leading pharmaceutical industry of 
the world, it turns out that Richter produced a value above the average value of there in 
this field, while the Chinoin’s value was slightly below, and that of the other companies 
was well below these data. Considering the operational margin, Richter also exceeded 
both the US and English average, while Chinoin exceeded the US average, but was below 
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the English average value. In this respect, the ratio of Egis is closer to the international 
data. Considering the ratio of return on equity, the picture is less flattering, because the 
performance of all domestic companies was below the US average, which is amazingly 
high, 52.2%, not speaking about the English data which was 109.6% in 1997. The ratios of 
the operational margin and the margin before taxation suggest that the three largest 
domestic companies, Richter, Chinoin and Egis, perform around the international average 
or above it, respectively.  
 
In the chapter 6.1, I compared the return on sales of the three domestic producers to that of 
global companies found on the list of the Business Week and the largest companies in the 
region. Those data showed that based on these ratios the domestic producers are among 
the best ones. Beside the data flattering in the international comparison, however, we 
should not forget about the size of the domestic companies. As I have referred to it, the 
total production value of the domestic pharmaceutical companies did not reach USD 1 
billion in 1997.  
 
Finally, I speak about the performance of Richter and Egis on the stock exchange. As I 
discussed it in the above, the two pharmaceutical producers are the leading players of the 
Hungarian pharmaceutical industry; their operational efficiency has been considerably 
improved in the 1990s. In international comparison, however, these are small companies; 
their annual sales are only a few hundred million USD. Is it possible at all and how is it 
possible to summarize the international competitiveness of these companies? To answer 
this question, I decided for investigating the development of the capitalization of Richter 
and Egis on the stock exchange. Both companies are listed on the stock exchange, and 
their data may be traced back until 1995. The stock exchange capitalization of both 
companies shows that the capital market appreciates the achievements of these two 
companies.  
 
Figure 6.2.3 Market capitalization of Richter and Egis, 1995-1999 
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 176
 
Bibliography for Chapter 6.2 
A magyar gyógyszerválaszték összetétele és az abban rejlő megtakarítási lehetőségek 
(Assortment of the drugs in Hungary and savings opportunities), Sajtó háttéranyag, 
Budapest, 1997. október 20. 
Antalóczy Katalin (1997) A magyar gyógyszeripar versenyképessége - adatok, 
hipotézisek, töprengések (Competitiveness of the Hungarian Pharmaceutical Industry - 
Data, Hyphotheses and Meditation), műhelytanulmány, Versenyben a világgal kutatási 
program, BKE Vállalatgazdaságtan tanszék, Budapest, 1997. március 
Antalóczy Katalin (1999) Privatizáció a gyógyszeriparban (Privatization in the 
Pharmaceutical industry), ÁPV Rt., Budapest 
Bartlett, Christopher - Ghostal, Sumantra (2000) Going Global: Lessons from the Late 
Movers, Harvard Business Review, March-April, pp. 132-142. 
Bencze Gyula (1995) Van-e gyógyszer a hazai gyógyszeripar bajaira? (Is there any 
remedy for the problems of the pharmecentical industry)?  Magyar Tudomány, 5. szám., 
pp.568-574 
Blahó András (1999) Labour Productivity and Competitiveness of Central European 
Transition Economies: 1990-1998, kézirat, BKE Világgazdaságtan tanszék 
Bogner, William C. – Thomas, Howard (1996) Drugs to Market. Creating Value and 
Advantage in the Pharmaceutical Industry, Pergamon, Elsevier Science Ltd. 
Bogsch Erik (2000) A magyar gyógyszeripar helyzete (On the Hungarian Pharmaceutical 
industry), Egészségügyi Gazdasági Szemle, vol. 38, No.2., pp. 165-174. 
Boschek, Ralf (1996) Health Care Reform and the Restructuring of the Pharmaceutical 
Industry, Long Range Planning, vol. 29, no.5, pp.629-642 
Central Europe Best Companies, Business Week Special Report, June 30, 1997, pp.20-27 
Cool, Karl - Röller, Lars – Hardrik -  Leclux, Benoit (1999) The Relative Impact of Actual 
and Potential Rivalry on Firm Profitability in the Pharmaceutical Industry, Stategic 
Management Journal, vol. 20., pp. 1-14. 
Czakó Erzsébet (2000) A Richter Rt. növekedési lehtőségeiről (On the growth 
opportunity, of Richter), kézirat, BKE Vállalatgazdaságtan tanszék 
Czakó Erzsébet (1997) A gyógyszerügy gazdasági kérdései és a hazai helyzet jellemzői, 
1990-1996., háttértanulmány A magyar egészségügy gazdasági viszonyai c (Economic 
busines of the Hungarian pharma business). GKI Gazdaságkutató Rt. koordinálta kutatás 
keretében 
Csontos László - Kornai János - Tóth István György (1996) Az állampolgár, az adók és a 
jóléti rendszer fogalma (The citizen, taxes and the welfare system), Századvég, Új folyam 
2. szám, pp.3-28 
Egészségügyi Finanszírozás. Klinikai eset (Financing the health care).(1997) Figyelő, 
november 13., pp.24-25. 
Egis Rt. éves beszámolói (EGIS Annual Reports), 1995-1999. 
 177
Élő Anita (1997) Gyógyszer-top-10. Mindent beveszünk ? (Pharma top 10) , Magyar 
Nemzet, 1997. október 15. 
EU (2000) Pharmaceuticals and Public Health in the EU: Proposals to the High Level of 
Committee on Health for Policies and Actions in the Framework of the Treaty of 
Amsterdam,  
EU Report of the Working Group on “Pharmaceuticals and Public Health” of the High 
Level Committee on Health, Brussels 28 March, 2000., p.36 
Enright, Michael J. (1992) Novo Industri, esettanulmány, Harvard Business School, Reg. 
No. 9-389-148. 
Fahy, John – Hooley, Graham – Cox, Tony – Berács, József – Fonfara, Krzysztof – Snoj, 
Boris (2000) The Development and Impact of Marketing Capabilities in Central Europe, 
Journal of International Business Studies, 1st quaarter, pp.63-81 
Farkas György dr. (1999) A magyar EU-integráció és a csatlakozás közlekedése 
alkalmazkodási sajátosságok a vállalkozói szférában, Miniszterelnöki hivatal Integrációs 
Stratégiai Munkacsoportja, Budapest 
Figyelő TOP200 , Figyelő Különszám, 1997-1999. évi kiadások 
Fuchs, Victor R. (1996) Economics, Values, and Health Care Reform, The American 
Economic Review, vol. 86, no. 1., pp. 1-24 
Global 1000. The World`s Most Valueable Companies, July 12, 1999 and July 13, 1998 
Grant, Robet M. (1998) Contemporary Strategy Analisys. Concepts, Techniques, 
Application, 3rd  ed., Blackweel Publi phers Ltd. 
Gulácsi László-Matejka Zsuzsa (1999) Gyógyszerek hatékonyságának a vizsgálata: 
Magyarország, Ausztrália, Kanada, in. Gulácsi (szerk.) (1999) Klinikai kiválóság, 
Technológiaelemzés az egészségügyben (Analysis the efficiency of drugs: Hungary and 
Canada), Springer Orvosi kiadó Kft, Bp,. pp. 311-333. 
Hamecz István – Kánai Károly – Arányi Péter (1998) Gyógyszerkutatás a Chinoinban, 
(Pharma R&D)  Magyar Tudomány, 9. szám, pp.1091-1094 
Hollósi Miklós (1998) Gondolatok a hazai gyógyszerkutatásról egy ankét kapcsán, (On 
the Hungarian pharmaceutical R&D) Magyar Tudomány, 11. szám, pp.1345-1348 
HVG (1997) Gyógyszercsaták, HVG melléklet (Drug-battles. Survey), Heti 
Világgazdaság 1997. szeptember 13, pp.63-78 
HVG (1999) Medicina (Medicines. Survey), HVG melléklet, Heti Világgazdaság, 1999. 
október 30. 
Kornai János (1998) Az egészségügy reformja (On the reform of the health care system), 
Közgazdasági és Jogi Könyvkiadó, Budapest 
Kövesi Ervin (1997) A hazai gyógyszerellátás helyzete nemzetközi összehasonlításban 
(Pharma supply in Hungary in international comparison), Egészségügyi Gazdasági 
Szemle, vol..35, no.3., pp.275-283 
KSH Statisztikai és Iparstatisztikai évkönyvek (Central Statistical Office Statistical 
yearbooks), 1989-1988., KSH Budapest 
 178
Laborgyakorlat. A gyógyszerkutatás dossziéja (Survey on the pharma R&D). Figyelő, 
1995. november 16., pp.14-20. 
Lengyel András (2000) A Richter Gedeon Rt. vállalati stratégiája – egy sikertörténet 
képlete, évfolyamdolgozat (Strategy of the Richter. Formula of a success story), BKÁE 
Vállalatgazdaságtan tanszék, április 
Losoncz Miklós (1996) A gyógyszeripar és az Európai Unió (The Hungarian pharma 
industry and the EU), Ipargazdasági Szemle, 4. szám, pp.28-45. 
Molnár Károlyné, dr (1997) A gyógyszerforgalom alakulása 1997. I. Félévében (Drug 
sales in 1997), MOTESZ Magazin, 1997/5., pp.15-18. 
Molnár Zsolt (1996) Richter Gedeon Rt. Előnye a hátránya, Figyelő, 1996. április 11., 
pp.24-25. 
Országos Egészségbiztosítási Pénztár évkönyvei (Statistical yearbook of the NHIF), 1995, 
1996, 1997, 1998, Budapest 
Regős Zsuzsa (1997) Gyógyszertámogatási rendszer. Nem veszik be., (Reimbursement 
system of the medicaments) Figyelő, november 13., pp23-24. 
Richter Gedeon Rt. éves beszámolói és éves jelentései, 1994-1999. (Annual Reports of 
Richter) 
Richter Gedeon Rt. részvénykibocsátási tájékoztatói 1994., 1995., 1996. (Prospectuses of 
Richter) 
Schőn István (1998) A gyógyszerkutatás új irányai és hazai lehetőségei, Magyar 
Tudomány, 9. szám, pp.1077-1081 (Opportunities of the Hungarian pharma R&D) 
Schőn István (1999) Mi lesz veled, hazai gyógyszerkutatás? (The future of the Hungarian 
pharma R&D), Magyar Tudomány, 6. szám, pp.704-710 
Stigler, George J. (1989) [1975] A közgazdászok hagyományos elmélete az állam 
gazdasági feladatairól (Traditional views on the role of state in the economics), in. Stigler, 
George J.: Piac és állami szabályozás. Válogatott tanulmányok (szerk.: Kertesi Gábor), 
Közgazdasági és Jogi Könyvkiadó, Budapest, pp.313-324 
Széchenyi Terv, www.gm.hu (Széchenyi development plan for the Hungarian economy) 
Szépvölgyi János (1999) Vegyipar – ezredfordulós pillanatfelvétel (Review on the 
chemical industry), Magyar Tudomány, 6. szám, pp.666-681 
Szilbereky Jenő (1998) Tanulságok és tapasztalatok a gyógyszer-K+F-ben. A Bimoclomol 
példája (Lessons and experiences in the Hungarian pharma R&D. The examples of 
Bimoclomol), Magyar Tudomány, 9. szám, pp.1095-1103 
The Economist (1998) A Survey of the Pharmaceutical Industry, February 21st
Tökölyi Imre (1994) A magyar gyógyszeripar pénzügyi állapota és export-finanszírozási 
lehetőségei, doktori értekezés (Financial evaluation, of the Hungarian pharma industry 
and opportunities for export financing), BKE Budapest, július 
Yeon, Ph-Lin- Roth, Kendell (1999) An Empirical Analosis of Sustained Advantage in the 
U.S. Pharmaceutical Industry: Impact of Firm Resonce and Capalicities, Strategic 
Management Goarnd, vol. 20., pp. 637-653. 
Vállalati stratégiák: A gyógyszeripar fájdalmai. Figyelő, 1997. június 5., pp. 47 
 179
Vállalati stratégiák: A gyógyszeripar öngyógyítása. Figyelő, 1997. február 20., p 39. 
Want, Jerome H.(1995) Radical Change and the Business Change Cycle, in. Want, Jerome 
H.: Managing Radical Change. Beyond Survival in New Business Age, John Wiley and 
Sons Inc., pp.1-118. 
Wernerfelt, Briger (1984) A Resource-Based View of the Firm, Strategic Management 
Journal, vol. 5., pp. 171-180 
Wilson, Robert N. – Henry, Sarah E. (1995) The Pharmaceutical Industry: What`s Driving 
Change?, in Want, Jerome H.: Managing Radical Change. Beyond Survival in New 
Business Age, Johng Wiley and Sons Inc., pp.231-250. 
 
Laws and decrees Törvények, rendeletek, forrás: Magyar Törvénytár CD-ROM-jai: 
A társadalombiztosítás pénzügyi alapjainak költségvetéséről és végrehajtásának mérlegei 
(Balances of the national insurunce budgets) 
1976. évi 31. törvényerejű rendelet a gyógyszeripari termékek előállításárát érintő 
felügyelet kölcsönös elismerése tárgyában (Decree on pharma production) 
1992. évi LXXXIV. törvény a társadalombiztosítás pénzügyi alapjairól és azok 1993. évi 
költségvetéséről (Law on the social insurance funds and their budgets) 
1991. évi XI. törvény az Állami Népegészségügyi és Tisztiorvosi Szolgálatról (Law on 
Public Health) 
1993. évi III. törvény a szociális igazgatásról és szociális ellátásokról (Law on the Welfare 
System and social insurance provisions and benefits) 
1994. évi LIV törvény a gyógyszertárak létesítéséről és működésük egyes szabályairól 
(Law on starting and running pharmacies) 
1994. évi VII. törvény egyes iparjogvédelmi és szerzői jogszabályok módosításáról (Law 
on the patents) 
1997. évi LVIII. törvény a gazdasági reklámtevékenységről (Law on advertisments) 
1997. évi LXXXIII. törvény a kötelező egészségbiztosítási ellátásról (Law on the 
universal basic helath provisions) 
1998. évi XXV. törvény az emberi felhasználásra kerülő gyógyszerekről (Law on the 
Medicine) 
13/1987(VIII.19.) EÜM rendelet a gyógyszerkészítmények törzskönyvezéséről és a 
törzskönyve bejegyzett gyógyszerkészítmények forgalombahozataláról (Decree on 
registering) 
15/1997(VI.20.) NM rendelet a gyógyszertárak működési, szolgálati és nyilvántartási 
rendjéről (Decre on operations of pharmacies) 
2/1995(II.8.) NM rendelet a társadalombiztosítási támogatással rendelhető 
gyógyszerekről, és ezeknek a társadalombiztosítási támogatás alapjául elfogadott árhoz 
nyújtott  társadalombiztosítási támogatásról (Decree on reimbursing of pharmaceuticals) 
3/1995 (II.8.) NM rendelet a gyógyszerek rendeléséről és kiadásáról (Decree on drug 
prescription) 
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21/1997(III.19.) Országgyűlési határozat az Egészségbiztosítási Önkormányzat és az 
Országos Egészségbiztosítási Pénztár Működéséről (Decree on the Helath and Pension 
Funds) 
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gyógyászati ellátások árához nyújtott támogatásáról (Decreee on subsities on drugs, 
medical devices and health care provisions) 
22/1992(VIII.19.) NM rendelet a gyógyszerek kereskedelmi árréséről (Decree on the 
commercial margins of drugs) 
24/1997(VIII.14.) NM rendelet az embergyógyászatban használatos gyógyszerek, ill. 
gyógyszernek nem minősülő gyógyhatású készítmények reklámozásáról és ismertetéséről 
(Decree on drug ads) 
25/1997(VIII.22.) NM rendelet a társadalombiztosítási támogatás nélkül forgalmazott 
gyógyszerekről (Decree on sales of non-subsidized drugs) 
3/1995(II.8.) NM rendelet a gyógyszerek rendeléséről (Decree on prescription) 
56/1996(XII.27) NM rendelet A gyógyszer kereskedelmi árrések módosítása (Decree on 
drug commercial margins) 
8/1994(IV.22) NM rendelet a társadalombiztosítási támogatással rendelhető gyógyszerek 
árához nyújtott társadalombiztosítási támogatás igénybevételének és elszámolásának 
szabályairól (Decree on access and accountancy on drug subsidies) 
9/1982(VII.21.) EÜM rendelet az Országos Gyógyszerészeti Intézetről (Decree on OGYI) 
91/1993(VI.9.) Kormány rendelet az Országos Nyugdíjbiztosítási Főigazgatóság és az 
Országos Egészségbiztosítási Pénztár, valamint igazgatási szerveik létrehozásáról és ezzel 
összefüggő egyéb intézkedésekről (Decree on setting the Pension and Health Funds) 
Ideiglenes megállapodás a kereskedelemről és a kereskedelemmel kapcsolatos ügyekről 
egyrészt a Magyar Köztársaság másrészt a Európai Gazdasági Közösség és az Európai 
Szén- és Acélközösség között - hatálybalépett: 1992. 03.01-jén (Agreement on trade and 
related issues betucen the Hungarian Republic and EU) 
203/1999. (XII.26) Kormányrendelet a kötelező egészségbiztosítás ellátásairól szóló 1997. 
Évi LXXXIII. Törvény végrehajtásáról rendelkező 217/1997 (XII.1.) Kormányrendelet 
módosításáról (Decree on universal basic health care provisions) 
37/2000 (III.23.) Kormány rendelet az emberi felhasználásra kerülő gyógyszerek 
gyártásának személyi és tárgyi feltételeiről (Decree on drug manufacturing, MRP) 
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6.3. Modifications of competitiveness of the pharmaceutical industry 
 
In the 6.2 Chapter I described and analyzed the changes, which took place in the 
Hungarian pharmaceutical industry. In this chapter I summarize the competitiveness of the 
pharmaceutical industry with two different approaches. One of the approaches, adequate 
to what was said in Chapter 5., is the Porter diamond model, the other one is the approach 
trying to catch more dimensions of competitiveness which can be found in my Ph.D. 
thesis. At the end of the 5.4 Chapter I made the following hypotheses concerning the 
pharmaceutical industry: 
1.  The pharmaceutical industry is a global industry. The Hungarian pharmaceutical 
industry faced up to the fact within its own markets during the 1990s. With the 
appearance of globalization the competitiveness of the pharmaceutical industry 
was not declined. 
2. The opportunities of the export-oriented pharmaceutical industry. The 
characteristics of global industries, forces of global competition, and the strategies 
of global enterprises influence the pharmaceutical industry’s opportunities. 
3. The pharmaceutical industry belongs to the industry portfolio of the Hungarian 
economy, which promotes both the competitiveness, and achievements of the 
national economy due to on its competitiveness in the national and foreign 
markets. Besides export-orientation, R+D demand contributes to the 
pharmaceutical industry’s being a progressive industry in the national economy. 
Statements about the above hypotheses are summarized in 6.3.3 sub-chapter. 
 
 
6.3.1. Competitiveness of the pharmaceutical industry on the basis of Porter’s 
diamond 
 
First, I summarize the determinants of the Hungarian pharmaceutical industry’s 
competitiveness between 1988 and 1998 on the basis of the Porter (1990) diamond model. 
This model turns the attention to determinants, which influenced the international 
competitiveness of enterprises located in Hungary. 
 
Factor conditions 
1. The Hungarian pharmaceutical industry has remarkable, nearly hundred-year-old 
traditions. These traditions could be found at all of the three closely investigated 
pharmaceutical companies. 
2. Keeping in mind the value chain of pharmaceutical companies, the international 
success is influenced by two basic activities: research and development, and 
marketing. 
• Traditions and strengths are in chemical research. There is a disadvantage 
in connection with R&D that is in the eagerly growing biological research 
there are no traditions, and there are few well-trained professionals. The 
experience accumulated in reproductive research meant an advantage for 
the companies in the development of generic products. Before the 
privatization the companies entered on the international market with 
successful drugs, which was an attracting factor for professional investors 
in the coarse of privatization. 
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•  Marketing fell far behind all of the other factors before the political 
changes. The greatest leap forward has happened in this field since then. 
The companies created and operated their sales networks, and their home 
experience is an advantage in their international markets also. We should 
mention the former COMECON market connections, because Hungarian 
pharmaceutical companies had experiences and local knowledge on the 
former COMECON markets first of all. The obtained experiences and 
connections gave advantages for the companies in the former socialistic 
markets when they reorganized and stabilized their trade relations after the 
collapse of COMECON. These advantages have been or are still being 
realized in the privatization, and by the making use of the present 
international sales opportunities. It seems that besides the home market, 
these markets can contribute most to the growth of the companies. 
However, it carries a considerable risk, which makes the pharmaceutical 
companies careful, especially after the 1997 crisis of CIC countries. As a 
consequence, in the case of Richter and Egis the developed countries’ 
markets (EU and USA) are gaining a more important role in their sales. 
3. In connection with the value chain we should also emphasize technology. The 
exporting Hungarian pharmaceutical companies followed the GMP directions from 
the middle of the 1970s. The 1999 legal regulation brought a slight support in 
competitiveness from the economic diplomacy, because the regulation made the 
existing practice legal, and made it even more acceptable from the side of foreign 
governments and international organizations. 
4. There was a shift in the whole of the pharmaceutical industry towards a more 
qualified work force. We do not have detailed data, but it is probable that it was 
mostly caused by strengthening the sales activity, and less caused by the boom of 
R+D activity. 
5. The opening up the stock exchange and the operation of capital market made a 
good opportunity for the companies to gain resources also through the stock 
exchange. (It was a significant factor especially in the case of two companies, Egis 
and Richter, during their privatization.) The efficiency indices of the companies 
show that companies can meet the expected efficiency terms.  
 
Demand conditions 
1. The Hungarian consumption of medicines corresponds to the country’s 
development in international comparison, in the forming of which the government 
has a decisive role by influencing the size and structure of demand. The beginning 
of the 1990s was characterized by flood of the imported drugs, which led to the 
use-up of approved medicine subsidies. At the end of the 1990s the Hungarian 
government put more and more pressure on the pharmaceutical companies through 
the subsidization system to reduce prices and provide proper drugs. 
2. The government has the biggest influence on shaping the size of demand through 
the subsidization system. From the side of the government we can see the intention 
to comply with the budget. It strengthens the home market competition. 
3. In the marketing channels of drugs there was also privatization, but because of 
margin regulation the governmental influence remained significant, and the 
government’s budgetary considerations also touches this segment. It would mean a 
challenge for the pharmacies to finance their operation. In wholesale trade it would 
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influence the outcome of the privatization and consolidation process. The 
marketing channels of drugs operate like distribution channels, as for the 
pharmaceutical industry. Its influence on pharmaceutical companies is not 
noteworthy. 
4. Keeping in mind the size of the home market, the prospects of the pharmaceutical 
companies’ traditional East European markets, especially political risks and GDP 
growth, considerably determine and influence the home manufacturers growth 
prospects. 
 
Firm strategy, context and rivalry 
1. The increased imports increased competitiveness significantly in the national 
market, and the field of competition was marketing, and within it sales. 
2. The privatization created new ownership structure in the Hungarian 
pharmaceutical industry. Most of the national manufacturers became the property 
of professional investors, and to some extent these manufacturers integrated into 
the parent company. A few financial investors also has stake. The transformation 
of ownership structure significantly contributed to the improvement of 
competitiveness. 
3. The management played an important role in managing the privatization too, and 
preserved their freedom in shaping strategies of national manufactures. In our 
opinion the success of privatization depended to a great extent on the management 
of pharmaceutical companies that could push the companies onto the way, which 
could found their operations in market economy. 
 
Related and supporting industries 
1. The institutional system of Hungarian pharmaceutical research was disintegrated. 
We cannot talk about any operating cluster in this field. 
2. Concerning Richter and Egis, cooperation could be seen in one field that is in 
wholesale trade. Medimpex was restructured, which managed the former 
pharmaceutical wholesale trade. Concerning the present legal regulation, the 
integration towards pharmaceutical wholesale trade can increase the 
competitiveness of home manufacturers even more. 
 
The role of the government 
1. The role of the government as the owner in pharmaceutical industry practically 
ceased by 1996. This led to a situation in which the government could only 
contribute to the increase of competitiveness of national pharmaceutical 
manufacturers by creating a stimulating. 
2. The government backed up the operation of privatized companies by tax brakes. 
Tax brakes were given even for both professional and non-professional investors. 
Tax brakes are over after 2000 that could contribute to the consolidation of the 
pharmaceutical enterprises’ market position. By Antalóczy’s case study (1997, 
p.44) the three investigated companies, Richter, Chinoin and Egis received and 
still enjoy the same company tax breaks. 
3. The government with its international, EU conform regulation went partly after, 
partly to meet the practice of the pharmaceutical enterprises. Concerning 
regulation pharmaceutical industry is mature joining the EU. 
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4. The role of the government is decisive by forming the system of subsidization of 
drugs. Managing the subsidization funds became central at the end of the 1990s 
and it heated up the competition among enterprises. Enforcing the government’s 
price sensitivity could contribute to the Hungarian drug preference with the same 
compound against imported drugs. The government could be encouraged not just 
by managing the subsidization funds but by the improvement of pharmaceutical 
products’ trade balance as well. 
5. Among the intentions of the government there is the emphasized role of clusters 
and R+D, which is mentioned many times (e.g. Széchenyi Plan). But in this field 
rather wishful thinking than action programs can be found. By Porter’s (1998) 
logic, clusters could be created only by organizing them around an enterprise or a 
product group. Certain segments of the pharmaceutical industry offer an 
opportunity to take a step ahead in this field. 
 
Chances 
1. The most important phenomenon, which could not be influenced by enterprises, 
was the build-up of market economy between 1989 and 1998. Its first and most 
radical result was brought by the collapse of COMECON, which influenced one 
third of the Hungarian pharmaceutical companies’ markets. 
2. We should mention among in the opportunities of joining the EU, which started 
with a significant legal harmonization. From the point of view of pharmaceutical 
industry, joining the EU does not promise notable market increase, but it could 
mean an opportunity to join EU research programs and projects. 
 
On the basis of the above summary I sketch the connections existing among Porter’s 
diamonds’ certain elements on figure 6.3.1. As it turns out I emphasized four 
determinants: the government, firm strategy, structure and rivalry, and demand conditions. 
 
 
Figure 6.3.1. Determinants of the competitiveness of the Hungarian pharmaceutical industry 
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The most important one from those four is the government’s role, considering that it 
greatly influenced the rivalry (e.g. import liberalization, subsidization system), strategies 
(e.g. changes ownership structure) during the creation of market economy. By setting drug 
prices  the government has a big influence on demand. Here we can notice the role of a 
price sensitive buyer in the steps of government, at least in price regulation past few years. 
 
The firm strategy, context and rivalry determinant underwent the most remarkable 
changes in the period of 1989-1999. The industry import generated competition and 
privatization played a prevailing role in that.  
 
The demand conditions depend on the national competition and enterprise strategies (with 
which products and segments, on which geographical markets the manufacturers 
compete). The demand is influenced the most by the drug subsidies, which, as a whole, is 
favorable for lower priced medicines. 
 
We take two factors out of the chances. The first is the collapse of COMECON, and the 
other is joining the EU. This determinant has influenced the demand conditions, 
competition, and the behavior of the government. 
 
 
6.3.2 Competitiveness of pharmaceutical industry by a multilevel approach 
 
In the following I summarize the most important statements about the competitiveness of 
pharmaceutical industry by a multilevel approach outlined in the Chapter 5.3.2. 
 
The level of products 
The Hungarian pharmaceutical industry is competitive first of all in its prices of products 
with the same compound. The product portfolios of enterprises seem to be dominated by 
generic, licensed, and reproductive products, and there are less original products. The 
original drugs for endemic diseases can mean an advantage for the companies in 
competition in countries with similar circumstances. The companies developed much in 
adopting marketing and sales methods. The international standards on products’ 
manufacturing and sales indicate that the national manufactures can be competitive 
especially on their prices. 
 
Competitiveness at company level 
We on analyzed some financial data in the case study. They showed that the investigated 
enterprises performed well even in international comparison, and they met their owners’ 
requirements. 
Changes in the Hungarian economy and in international markets demanded significant 
adjustment from the companies. With additional capital investment during the 
privatization the companies created the basis of their own restructuring and further 
development. The management of home manufacturers could manage and direct the 
processes at the companies. The proportion of highly qualified employees has grown at 
the companies. 
 
Competitiveness at industry level 
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The Hungarian pharmaceutical industry has not just survived after the privatization, but 
from many points of view maintained its earlier position in the national economy. It was 
described by statistics of KSH (Central Statistical Office). Three of the former seven 
important players are still considered to be top players in the Hungarian pharmaceutical 
industry and market. The analysis on gross income showed that the industry contributed to 
the increase of its employees’ living standards. In the significant import competition the 
companies’ share was declined is the home market, but data show a stabilization of the 
leading companies’ share products.  
 
 
Competitiveness from the government’s point of view: competitiveness national economy 
level 
At the beginning of the 1990s the government played an important role in conducting the 
privatization. As Antalóczy (1999) showed, there were quite a few characteristic 
professional ideas upon privatization. At first, Chinoin Ltd. and Humán Ltd. were 
privatized in the pharmaceutical industry. They became property of professional investors. 
In both cases the management had a word in choosing a professional investor. The 
privatization of Egis took place in two phases, first by initial public offering, then by 
inviting professional investors. Richter is the only example of a privatization done purely 
through public offerings. The management played an active role, in choosing both the 
forms and management of privatization. 
 
As a whole, privatization could be said to be successful, in which the management of the 
involved companies played an important role. The direct government policy to influence 
competitiveness of the pharmaceutical industry seems to have come to an end. 
 
From the governmental point of view it is not of minor importance if such an industry 
employing more than 15 thousand people survives, and it can pay gross wages above the 
industrial average. Bogsch (2000) called the attention to the fact that the pharmaceutical 
industry as an employer contributed to fulfilling governmental objectives with reasonable 
budgetary payments. 
 
In the 1990s the government influenced the competitiveness of pharmaceutical companies 
by the legal environment of the drug market, production and sales. The import 
liberalization was said to be extreme by several analysts and national pharmaceutical 
manufactures. The import liberalization meant such a competitive constraint which, in our 
opinion, accelerated the adaptation and consolidation of their market conform operations. 
The government tries to provide basic drugs with managing the approved budget. It is a 
generating rivalry among pharmaceutical companies.  At the end of the 1990s from the 
governmental point of view the dominant issue was complying with the budgetary limits. 
This heated up competition among the distributors as well. The question of drug prices is 
also a political question, one of the means of social justice. In this field establishing NHS 
treatment system and NHS treatment list was a step ahead by the government in order to 
separate the insurance principle and social security considerations. 
 
As the overall institutional reforms of the health care system have not yet happened, the 
pharmaceutical industry means such a sub-system where the governmental policy, which 
is intended to show successful actions, could show spectacular solutions. 
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6.3.3 Is the Hungarian pharmaceutical industry competitive? 
 
I have summarized the competitiveness of the pharmaceutical industry by Porter (1998a) 
and on the basis of the multilevel competitiveness approach. 
 
I meant those companies by the Hungarian pharmaceutical industry, which manufacture 
products in Hungary and contribute to the Hungarian pharmaceutical industry’s 
production and so also to the GDP and pharmaceutical industry’s exports. Now in 2000 
nearly 200 pharmaceutical enterprises operate in Hungary. The tenth of that number, that 
is nearly twenty companies, employ more than 20 employees according to the statistics of 
KSH (Central Statistical Office). These companies employ more than 15,000 employees 
altogether, and they provides the Hungarian pharmaceutical industry’s production and 
exports. Among those twenty companies that also operated before 1980, the national 
pharmaceutical manufactures play a prevailing role. These are the following: Alkaloida 
(today called ICN Hungary), Biogal (today a Teva interest), Chinoin (the owner is the 
French Sanofi), Egis (the dominant owner is the Servier), Human Rt. (the owner is Teva 
as a result of Novopharm’s acquisition), Richter (international and national financial 
institutions and the private investors’ property), and Pharmavit (its owner is the Bristol 
Myers Squibb). So I take those companies as Hungarian in the global pharmaceutical 
industry that manufacture drugs, give jobs, and contribute to Hungarian export. The 
detailed analysis covered the three biggest home manufacturers, keeping in mind their size 
as follows, Richter, Chinoin, and Egis. These companies provided two thirds of the 
Hungarian pharmaceutical production, and employed nearly one third of the 
pharmaceutical employees. In the following the name of national companies and 
manufacturers covers the above listed seven enterprises. 
 
In the following, I summarize the most important theses concerning my hypotheses. 
 
The pharmaceutical industry is a global industry. The Hungarian pharmaceutical 
industry was confronted with this fact in the 1990s. With the appearance of 
globalization the competitiveness of the pharmaceutical industry was not declined. 
• The Hungarian pharmaceutical industry was confronted most indirectly with 
globalization through import liberalization. Import liberalization was realized 
through the sale of multinational and global subsidiaries. This brought significant 
pressure on the development of the national manufacturers’ marketing and sales 
methods. 
• The nature of global industry influenced the ownership structure of the Hungarian 
drug manufactures. There are leading professional and financial investors among 
shareholders of them. 
• We can take the legislation of international principles and rules on manufacturing 
and distribution as part of globalization. In this field the Hungarian manufacturers 
were much more prepared than in marketing and distribution. 
• The competitiveness of the Hungarian pharmaceutical industry was investigated by 
the performance of the pharmaceutical industry and the companies’ adjustment 
ability. Analyses on performance compared the Hungarian pharmaceutical 
manufacturers’ performance to Hungarian industrial average, to the result of global 
corporations, and to the leading companies in the region. On the basis of these data 
I prove that: 
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a) The pharmaceutical industry preserved its position in the Hungarian 
industry as an employer, and it is still an export-oriented industry. 
b) The analysis of on company performance I found that the performance of 
the leading Hungarian players was better than, or around the best global 
corporations’ performance.  
 
The formerly export-oriented Hungarian industry operates in global. The 
characteristics of global industries, forces of the global competition, and the strategic 
alternatives and moves of global enterprises should be known by small players as well. 
• Global pharmaceutical corporations, as I showed it in Chapter 6.1, determine the 
operation of the pharmaceutical industry. This has influence on the behavior of 
professional investors in Hungarian privatization. I showed that the Egis was fitted 
in to the strategy of its dominant owner, the Servier’s, on generics and in the 
region of in East Europe. In the case of Chinoin we do not have data on 
privatization intentions, but the implemented policy and measures show that 
Chinoin fits into its parent company’s operations, and it works as its regional 
enterprise. 
• The companies gained such knowledge and skills during the process patent, 
reproduction that gave an advantage in developing and manufacturing of generics. 
Their retained market position on East European markets brought a formerly not-
known and not managed geographical segment for their the parent companies in. 
• The experience and local knowledge of the Hungarian pharmaceutical 
manufacturers on former socialistic markets is advantageous in the competition for 
being leading players in markets that are considered too risky by the global 
players. This is especially true about Richter’s CIC market positions. 
 
The pharmaceutical industry belongs to industry-portfolio of the Hungarian, which 
promotes both the competitiveness and performance of the national economy due to its 
competitiveness in national and foreign markets. 
By the analysis based on KSH (Central Statistical Office) data on industry and the 
pharmaceutical industry we could settle the following theses in connection with 
competitiveness upon the Hungarian pharmaceutical industry. 
• The pharmaceutical industry preserved its position as an employer in a 
transforming industry. The composition of employees in the pharmaceutical 
industry structurally changed to the white collars’ advantage. The gross wage of 
pharmaceutical employees grew quicker than the industrial average, which shows 
that the industry could contribute to the growth of its employees’ living standard. 
Because of this we could take the pharmaceutical industry as an industry, which 
contributed to the improvement of the Hungarian economy’s competitiveness in 
the period between 1989 and 1998. 
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